Epidemiology of Streptococcus pneumoniae in northern Tanzania. by Batt, S.L.
Epidemiology of Streptococcus pneumoniae in
Northern Tanzania
By
Sarah Louise Batt (BSc.)
A thesis submitted to the University College 
London in fulfilment of the requirement for the 
degree of Doctor of Philosophy
Department of Medical Microbiology 
Royal Free and University College Medical School 
University College London 
Royal Free Campus 
Rowland Hill Street 
London NW3 2PF
UMI Number: U602449
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602449
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
To achieve representative bacterial surveillance it is important to have effective 
transport and storage media. In this thesis two transport media, STGG and SGG were 
evaluated and shown to be suitable for optimal transport and storage o f S. 
pneumoniae. These media will be particularly useful for field studies in developing 
countries.
A previously published serotyping technique based on amplification by PCR and 
RFLP of the first two genes of the capsulation locus, cpsA and cpsB, was evaluated 
and modified for use directly on clinical specimens. This method did not produce 
serotype specific data from a single PCR reaction so an alternative method was 
devised. PCR amplification of the whole capsulation locus (~20kbp) was adopted 
followed by restriction digestion to produce different patterns. It was shown that the 
patterns obtained were capable o f discrimination to the serotype level. This technique 
is fully portable.
In conjunction with a study to evaluate azithromycin distribution for the community 
wide treatment o f trachoma, the impact o f azithromycin on macrolide resistance in S. 
pneumoniae was assessed. No increase in macrolide resistance was found among 
pneumococcal isolates. Significant association was found between resistance to 
penicillin and co-trimoxazole, both commonly used antibiotics. Co-colonisation was 
found by isolates o f different serotypes in a few carriers. Carriage was not found to 
last for more than a few months and familial transmission was not found to be an 
important mechanism of transmission in this population.
The population structure of the penicillin non-susceptible pneumococci (PNSP) was 
studied using penicillin binding protein PCRs and RFLP. The results showed many 
different PBP genotypes suggesting that the population is polymictic and that there 
has been recent recombination of PBP genes. Pneumococcal penicillin resistance is 
thought to be evolving in this community independently of international clones.
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1.1 General Introduction
Streptococcus pneumoniae was first described in 1881 and remains one of the most 
important pathogens for man today, with the death rate in the United States being 
greater than for any other bacterial pathogen (Rubinstein & Rubinovitch 1994). 
Respiratory disease has overtaken diarrhoeal disease as the major cause o f death in 
developing countries (Obaro 2000b) with pneumonia claiming the lives of between 
three and five million children each year (Adegbola & Obaro 2000; Greenwood 
1999;Obaro 2000a;0baro 2000b). Worldwide mortality due to S. pneumoniae 
infections annually reaches one million and causes around 9% o f all child deaths (Obaro 
2000b;Tomasz A 2000). The problem is being exacerbated by the global spread of 
antibiotic resistant organisms which result in treatment failures and thus an increasing 
mortality rate (Appelbaum 2000;Neu 1992).
1.1.1 History of Streptococcus pneumoniae'. Isolation and Nomenclature
S. pneumoniae was first isolated in 1881 by Louis Pasteur (France) and George M. 
Sternberg (USA), who were working independently. Both scientists recovered the 
organism from rabbits which they had injected with saliva; Pasteur used saliva from a 
child who had died from rabies and Sternberg used his own. The organism was named 
Microbe septicemique de la salive by Pasteur (Pasteur L 1881). Three months later 
Sternberg confirmed Pasteur’s findings in his published description of Micrococcus 
pasteuri (Sternberg G M 1881). In 1886 the organism was named pneumococcus by 
Fraenkel, “pneumo” because of its role in pneumonia and “coccus” from coccoid 
meaning round, owing to its shape observed through the light microscope, a name still 
used today (Fraenkel A 1886). It was renamed Diplococcus pneumoniae in 1920 due to 
the appearance of paired organisms in clinical specimens. In 1972 the current name 
Streptococcus pneumoniae was assigned, and the organism transferred to the genus 
Streptococcus, owing to its characteristic chain formation in liquid broth (Deibel R H & 
1974).
Since its isolation S. pneumoniae has been one of the most extensively studied 
organisms, which has led to many important discoveries in medical and related fields. 
Gram, while working on his staining method, described coccoidal organisms (which 
retained alanine dye) that had been isolated from the alveoli of patients who had died of 
pneumonia (Gram C 1884). At the time he did not recognise the significance o f other 
organisms that did not retain the dye, but his work led to the technique which bears his
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name. S. pneumoniae was the model organism used by scientists working on non 0 -  
lactamase drug resistance, which led to the discovery of penicillin binding proteins and 
the understanding of the mode of action of penicillin (Tipper & Strominger 1965). The 
role o f the bacterial capsule in resistance to phagocytosis was elucidated by Avery and 
Dubos (Avery OT & Dubos 1931), who observed that injection of an enzyme which 
could remove the capsule was protective to mice that had been challenged with a lethal 
dose o f pneumococci. After Mendel had already laid down the foundation for genetic 
inheritance during his work on sweet peas in the monastery garden and Griffith’s 
observation of capsule transformation, Avery, MacCloed and McCarthy published a 
cornerstone paper describing DNA as the “transforming” principle using S. pneumoniae 
as the model organism (Avery OT, Macleod, & MaCarty M 1944). Until then genetic 
properties were thought to be proteinaceous in nature, but ultra-centrifugation 
experiments separated the “transforming principle” from proteins and demonstrated it to 
be composed of nucleic, not amino, acids. Avery and co-workers chemically purified 
the “transforming principle” and were able to destroy it only with preparations 
containing depolymerase for deoxyribonucleic acid leading them to conclude that the 
active principle is a nucleic acid of the deoxyribo type, this was later confirmed with 
electrophoresis and spectroscopy. They were surprised that the pure transforming 
principle had such biological specificity in inducing transformation in amounts ranging 
from 0.02 to O.OOpg, yet had little or no serological reactivity and that the induced 
substance was biologically distinct; being a polysaccharide. This work was the 
foundation o f molecular biology and was followed by an explosion o f knowledge about 
DNA, genes, inheritence and techniques for their study. The history o f S. pneumoniae 
is reviewed in the following papers (Austrian 1981a;Robinson et al. 2001;Watson & 
Musher 1999).
1.2 The Organism
S. pneumoniae are bullet or lanceolate shaped, alpha-haemolytic Gram positive cocci 
(AlonsoDeVelasco et al. 1995). The structural components o f the organism are 
discussed alongside relative pathogenicity in section 1.2.2.
1.2.1 Culture and identification
S. pneumoniae is a fastidious organism which means it dies rapidly during prolonged 
culture and inappropriate storage. It requires blood or serum for growth and is typically 
sub-cultured on blood agar. Growth is enhanced in an atmosphere of 5% carbon
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dioxide. Nutrient broth, e.g. brain heart infusion, can also be used for liquid cultures. 
Oxolinic acid or gentamicin can be incorporated into solid media for isolation of 
pneumococci from clinical specimens such as swabs or when sub-culturing from blood 
cultures. Whole blood is used to supplement solid agar as the organism is a-haemolytic 
(partially haemolytic), and a green zone can be seen around colonies. Identification is 
done on the basis of a-haemolysis and draughtsman (dipped centre) morphology. 
Incubation in a carbon dioxide rich atmosphere enhances haemolysis, making 
identification easier. Optochin discs, bile solubility, agglutination with anti-capsular 
pneumococcal antibodies and API® bacterial identification system strips are used to 
positively identify a pneumococcus from other streptococci (Givon-Lavi et al. 
1999;Whatmore et al. 2000). S. pneumoniae are virtually universally susceptible to 
optochin (ethylhydrocuprein hydrochloride; EHC), and resistant mutants are rare. 
Impregnated discs are placed on inoculated agar, around which a zone of no-growth will 
be seen. Bile (10% deoxycholic acid) dissolves colonies on solid media (by stimulating 
autolysin, see section 1.3.3.3.b), or will clear a suspension o f cells, incubated for 30 
minutes at 35 - 37°C. Anti-capsular pneumococcal antibodies or omni-serum (which is 
a mixture o f all specific antibodies) can be used in slide agglutination or Quellung 
reactions (see serotyping in main methods section 2.4.3). The API® system 
(Biomerieux, France) consists of plastic strips of 20 wells containing dehydrated 
biochemical substrates which are inoculated with a heavy suspension o f the organism 
and incubated for 48 hours. Isolates are identified by biochemical characteristics that 
are indicated by colour changes and interpreted using the manufacturer’s numerical 
schemes. More recently many PCR techniques have been designed to target unique 
pneumococcal genes e.g. lytA (Gillespie et al. 1994) and pneumolysin (Virolainen et al. 
1994) which can also be used for identification. These obviate culture of specimens and 
are useful for patients who have already begun antimicrobial therapy where cultures 
may not yield any living organisms.
1.2.2 Structure and pathogenicity of S. pneumoniae
The overall structure of the pneumococcal cell is summarised in figure 1.1.
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Figure 1.1: Structure of the pneumococcal cell, illustrating the cell wall, capsule and the major virulence proteins.
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1.2.2.1 Cytoplasm and cell membrane
The central region of the cell has low electron density and is packed with fibrils and the 
bacterial chromosome. The cytoplasm contains large numbers o f ribosomes and 
polysomes1 distributed evenly throughout. There are a high number of intracellular 
membranous organelles of unknown function referred to as mesosomes or chondrioids 
(Tomasz A, Jamiesson JD, & Ottolenghi E 1964). The plasma membrane is 
asymmetrical with the outer layer being wider. There are numerous bridges or 
invaginations that connect the plasma membrane to the cell wall (Tomasz A 2002).
1.2.2.2 Cell wall
External to the plasma membrane is the cell wall that is composed o f peptidoglycan, 
teichoic acid and lipoteichoic acid see figure 1.2. Peptidoglycan is a complex protein 
structure that provides the mechanical strength for the cell. The carbohydrates teichoic 
acid (TA) and lipoteichoic acid (LTA) are embedded into the peptidoglycan. The 
weight ratio o f peptidoglycan : TA/LTA is 1:1. Pneumococci are able to undergo phase 
switching between phenotypes best suited to colonisation (transparent) and invasion 
(opaque) of the host. Phase switching allows the bacteria to up- or down- regulate cell 
wall components and is discussed in greater detail in section 1.3.2.a. S. pneumoniae has 
a single equatorial located growth zone, the septum, into which new cell wall material is 
deposited, and a new growth cycle can be engaged before complete separation has taken 
place thus leading to the appearance o f pairs or chains o f cells depending on the growth 
conditions (Tomasz A 2000). The cell wall is a potent inducer o f inflammation, and 
challenge with cell wall components can re-create many of the symptoms of pneumonia, 
otitis media and meningitis in experimental models (Tomasz & Saukkonen 
1989;Tuomanen et al. 1985).
1 Polyribosome or polysome is a structure formed of mRNA carrying ribosomes that are situated at 
intervals along its length
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Figure 1.2: Components of the cell wall of Streptococcus pneumoniae (Tomasz A & 
Werner F. 2000).
1.2.2.3 Peptidoglycan
The relationship between the components of the cell wall was clarified in 1970 by 
Tomasz and Mosser (Mosser & Tomasz 1970). Peptidoglycan, also called murein 
(from the Latin word murus meaning wall), makes up part of the Gram negative and 
Gram positive cell walls. It is composed of a backbone of N-acetyl-muramic acid and 
N-acetyl-glucosamine linked by p(l -4) glycosidic bonds and each muramic acid moiety 
forms an amide bond with a D-amino acid containing peptide, thus forming the
repeating muropeptide subunit. Peptidoglycan is species specific and pneumococcal
peptidoglycan is characterised by highly conserved structures synthesised from 18 
different muropeptides or stem peptides (Severin & Tomasz 1996). There are four 
classes of stem peptides; oligomeric, trimeric, dimeric and monomeric. The structures 
have been resolved using reverse-phase High Performance Liquid Chromatography 
(HPLC) and isolates of different serotypes grown under standard conditions all produce 
a species-unique structure, examples of peptide precursors are shown in figure 1.3 
(Severin & Tomasz 1996).
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Figure 1.3: Structures of 12 stem peptides that make up the side chains of
peptidoglycan in S. pneumoniae, N.B. they all have an alanine terminal residue (Severin 
& Tomasz 1996).
Chains formed of repeating muropeptide units are cross-linked via the terminal alanine 
residues of the peptide moiety, a reaction that is catalysed by transpeptidase enzymes, 
which are also called penicillin binding proteins (PBPs) as they are the binding site for 
penicillin. This cross-linking forms sheets and layers of around 20 sheets make up the 
Gram positive peptidoglycan tertiary structure. Peptidoglycan variants occur when 
isolates become resistant to penicillin because the PBPs responsible for cross-linking 
alanine-alanine are remodelled to avoid penicillin binding (Garcia-Bustos & Tomasz 
1990;Severin & Tomasz 1996). The biological price for the remodelling of these 
proteins is that the altered peptide structure has more side chains and monomeric stem 
peptides are incorporated. There are differences between laboratory-generated mutants 
and naturally occurring ones, and the mechanism of this phenomenon is not fully 
understood (Severin & Tomasz 1996).
1.2.2.4 Lipoteichoic and teichoic acids
Teichoic acids (from the Greek word teichos meaning city walls) are polymers of 
galactose, glucose and ribitol linked by phosphodiester bridges. Pneumococci are 
unique among Gram positive bacteria in that their teichoic and lipoteichoic acids have 
identical repeat units (Fischer W 2000). In the 1930s, before LTA and TA had been
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defined, TA was described as C polysaccharide (Tillet WS, Goebe WF, & Avery OT 
1930). Thirteen years later LTA was described by Goebel et al. and named 
lipocarbohydrate or the Forssman antigen (F antigen) due to its fatty acid content and 
immunogenicity (Goebel WF et al. 1943). In 1980 the complete structure o f the LTA 
was solved (Behr T et al. 1992;Jennings, Lugowski, & Young 1980). LTAs are 
synthesised from lipid precursors whereas TAs are synthesised from nucleotide- 
activated precursors. LTA and TA are important as they contain phosphorylcholine to 
which many surface proteins anchor themselves e.g. pneumococcal surface protein A 
(PspA), autolysin (LytA) and choline binding protein A (CbpA) (Jedrzejas 2001). The 
structure of the pneumococcal lipoteichoic and techoic acid are shown in figure 1.4.
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Figure 1.4: Structure of pneumococcal teichoic acid and lipoteichoic acid from 
laboratory strain R6 (Tomasz A & Werner F. 2000).
1.2.2.4.a Teichoic acid
Teichoic acid is a major cell wall component and is covalently linked to peptidoglycan 
through the muramic acid residue (Brundish & Baddiley 1967;Poxton, Tarelli, & 
Baddiley 1978). It is uniformly distributed on both the inside and outside of the cell 
wall and the thickness is strain dependant. Phosphorylcholine is a component of TA and
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if  choline is substituted by ethanolamine physiological defects occur e.g. inability to 
undergo genetic transformation and resistance to autolysin preventing cell division. 
Choline is required for cell surface located proteins to bind (Garcia et al. 1988), the first 
of which to be discovered was autolysin (Holtje & Tomasz 1975), such proteins are 
described in section 1.2.3.1.
TA is shielded by capsular polysaccharide and so it is inaccessible to antibodies but it 
can activate the alternate complement pathway via the phosphorylcholine portion o f the 
molecule (Fischer W 2000). Removal o f this antigen diminishes complement activation 
by cell wall components (Tomasz & Saukkonen 1989). This interaction with 
complement is crucial to the inflammatory response in the alveoli, meninges and middle 
ear. Treatment with penicillin results in a rapid increase in inflammatory responses 
(Schmidt, Froula, & Tauber 1993). TA contributes to increased pathogenicity and 
adverse prognosis, especially in meningitis, has been correlated with detectible TA in 
serum (Gillespie et al. 1995).
Antibody to C-polysaccharide appears in the bloodstream in the early years o f life but is 
unable to protect against pneumococcal infection following colonisation, or pneumonia 
following bronchitis, or bacteraemia following pneumonia (Fischer W 2000). Antibody 
to phosphorylcholine is not opsonic, but may provide protection by reducing the impact 
of circulating C-polysaccharide (McNamara, Ward, & Kohler 1984).
1.2.2.4.b Lipoteichoic acid
Lipoteichoic acid (LTA, formerly the Forssman antigen) is uniformly distributed on the 
surface of the plasma membrane. The molecule contains a glycolipid anchor and is 
hydrophobically attached to the outer layer of the membrane. Forssman antigens are 
defined by their ability to induce rabbits to form haemolytic antibodies against sheep 
red blood cells and have been reported for many bacteria (Fischer W 2000). LTAs are 
common to bacilli, lactococci, listeria, staphylococci and some streptococci but 
pneumococcal LTA is different in composition. The polysaccharide part is located on 
the surface and the lipid moiety is anchored in the membrane. Lipid makes up 5.7% of 
the molecular weight o f the antigen, into which 15% of the organisms’ choline is 
incorporated (Fischer W 2000). LTA is a major inhibitor of autolysin and a regulator of 
the murein hydrolase activity. During the stationary phase autolysis releases LTA, the
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loss of which leads to unrestrained activity of autolysin leading to cell lysis and death 
(Fischer W 2000).
1.2.2.5 The capsule
Virulent strains of S. pneumoniae are surrounded by a serotype specific polysaccharide 
capsule which is a highly hydrated shell surrounding the bacterium, illustrated in figure
1.5. There are over 90 immunologically and chemically different serotypes of 
pneumococcal polysaccharide. The role of the capsule is to control the passage of 
molecules and ions to the cell envelope, adhere to biological and inorganic surfaces and 
to form bio-films and micro-colonies, in addition to shielding the bacteria from the 
immune system in a serotype specific manner (Tomasz 1999). Phenotypic variation can 
occur between encapsulated or smooth cells and spontaneous rough or acapsular cells. 
The thickness of the capsule is also up- or down-regulated during phase variation (Kim 
& Weiser 1998). The capsule is not stained by Gram preparations, although it can be 
seen as a halo surrounding the cell. The multiplicity of different capsular types, 
determining different levels of immune response, has meant that S. pneumoniae remains 
a significant cause of morbidity and mortality in humans (Scott et al. 1996). Specific 
anti-capsular antibodies are used for serotyping and will be described in more in 
sections 2.5 and 4.1.1.
Capsule
Pneumococcal
cellSeptum
Figure 1.5: Chain of an encapsulated strain of pneumococci shown by electron
microscopy (Tomasz A 2002).
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1.2.2.5.a Historical background of the understanding of the capsule
Soon after the early descriptions of the role of pneumococcus in disease Klemperer and 
Klemperer demonstrated that rabbits injected with heat killed pneumococci or with 
filtrates from broth cultures containing “factors that were protective to the rabbit”, were 
able to survive against challenge with the same clinical isolate but not necessarily 
another. Furthermore, that rabbits were protected from infection by injection with 
serum from an animal previously immunised with the same serotype (Klemperer & 
Klemperer 1891). In 1902 Neufeld observed that adding specific anti-serum to a 
suspension of pneumococci resulted in macroscopic agglutination and microscopically 
visible swelling of the external capsule (quellung in his native German) which formed 
the basis o f the Neufeld test or Quellung reaction (Neufeld 1902). In 1910 Neufeld and 
Handel published a paper describing the typing of pneumococci on the basis of whether 
they killed mice previously immunised with types referred to as type I and type II. This 
formed the foundation for the serological typing system used today (Neufeld & Handel 
1910). A biological classification system for pneumococci was published in 1913 by 
Dochez and Gillespie that was based on the survival of mice which had been previously 
immunised (Dochez A.R. & Gillespie L.J 1913). In 1917 Dochez and Avery described 
a type specific soluble substance in the blood and urine from humans and rabbits 
(Dochez A.R. & Avery 1917). In 1922 Griffith published a report on the distribution of 
pneumococcal types and went on, in 1928, to be the first to describe the phenomenon of 
capsular switching in vivo (Griffith F 1928). It was Avery and co-workers whose 
observations first formed the link between pathogenic bacteria and carbohydrates and 
they determined the soluble substance which they previously described, to be capsular 
polysaccharide (Dochez A.R. & Avery 1917). This was the first known example of an 
immunogenic substance being carbohydrate, as it was thought that only proteins were 
immunogenic. Vaccines including whole cell preparations were designed as early as 
1914 (Wright et al. 1914) but interest in the capsule decreased after the introduction of 
antibiotics (Heidelberger M. & Avery 1923), discussed further in section 1.6.1. In the 
1960s it became clear that despite the widespread use of antibiotics, the mortality due to 
S. pneumoniae remained high, and interest in the capsule and vaccines was rekindled. 
The first comprehensive study of capsular polysaccharide structures was made in 1964 
(How, Brimacombe, & Stacey 1964) and reviewed in 1976 (Larm & Lindberg 1976). 
Many of the early structures have been updated using modem techniques such as mass 
spectrometry (MS) and Nuclear Magnetic Resonance Spectrometry (NMR). However, 
the serotype 3 structure was elucidated in 1941 and has been unaltered since (Reeves &
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Goebel 1941). It was only in the 1990s that focus switched to molecular 
characterisation o f the capsular polysaccharide synthesis determinants. Griffith was 
first to observe capsular switching in vivo and the idea that the genes required to build 
the capsule were linked together on the chromosome was first suggested by Griffith and 
Avery, reviewed in (Austrian 1981a). Further genetic and biochemical studies are 
described in section 6.1.
1.2.2.5.b The importance of capsular serotypes
The capsular serotype of S. pneumoniae is an important sub-classification o f the species 
because the immune response is serotype specific. The polysaccharide capsule protects 
against opsonization by the host and therefore is important in determining susceptibility 
to invasive disease, along with other epidemiological factors such as age and geographic 
location (Scott, Hall, Dagan, Dixon, Eykyn, Fenoll, Hortal, Jette, Jorgensen, Lamothe, 
Latorre, Macfarlane, Shlaes, Smart, & Taunay 1996). All fresh isolates from patients 
with pneumococcal infection are encapsulated, and spontaneous non-encapsulated 
strains are completely a-virulent (Morona, Morona, & Paton 1999).
The capsular polysaccharide (CPS) is considered to be the “sine qua non” of 
pneumococcal virulence and pneumococci devoid of the capsule are completely 
avirulent (Austrian 1981a). Although CPS is non-toxic it is considered the main 
virulence factor because it shields teichoic acids, preventing activation of the alternate 
complement pathway and interaction with C3b and receptors on phagocytic cells. Most 
pneumococcal polysaccharides are negatively charged because they possess negatively 
charged entities; acidic components such D-glucuronic acid e.g. serotypes 1, 2, 3, 5, 8, 
9A and 9V or phosphodiester bonds e.g. serotypes 6A, 6B, 11A, 15F, 19F and 19A and 
23F. The CPS is strongly anti-phagocytic in hosts with no specific immunity. 
Interruption of phagocytosis is achieved by neutralisation of the phagosome preventing 
intracellular degradation due to the pneumococcal cell’s high polar charge and 
hydrophilic properties at physiological pH (Musher 1992).
Polysaccharides are T cell independent antigens that interact with B cells directly to 
initiate predominantly IgG2 antibody production and specific antibodies to CPS are 
highly protective and result in rapid clearance (AlonsoDeVelasco, Verheul, Verhoef, & 
Snippe 1995;Morona et al. 2000). Antibodies bound to capsules interfere with their 
charge and hydrophobicity and are required for opsonization, although under certain
36
Introduction
conditions polymorphonuclear leukocytes and alveolar macrophages can use an opsonin 
independent mechanism of phagocytosis. Polysaccharides are able to activate the 
alternative pathway by interacting with complement, C3b, which is important as the 
complement receptor (CR2) on the B cells of infants is under-developed 
(AlonsoDeVelasco, Verheul, Verhoef, & Snippe 1995).
Composition and quantity (thickness) are also important determinants o f the 
invasiveness o f the strain. Serotype 3, which is the most virulent strain in adults, 
serotype 8 and sometimes serotype 19 have a thick, mucoid capsule and are all invasive 
strains. Conversely, serotype 37 has a thick mucoid capsule yet is rarely associated 
with disease, which highlights the importance of other virulence factors (Tomasz A 
2000).
The pneumococcus is capable of capsular transformation, which allows evasion of the 
immune response in an already immune host by switching serotypes. Some serotypes 
are poorly immunogenic, such as serotype 3 which frequently causes invasive disease in 
adults, and serotype 14 which is predominantly isolated from children (Scott, Hall, 
Dagan, Dixon, Eykyn, Fenoll, Hortal, Jette, Jorgensen, Lamothe, Latorre, Macfarlane, 
Shlaes, Smart, & Taunay 1996).
The capsule is synthesised rapidly during the logarithmic growth phase. It is the 
outermost and thickest layer and consists of repeating units of oligosaccharides making 
up high molecular weight polymers, the chemical composition being serotype specific 
(AlonsoDeVelasco, Verheul, Verhoef, & Snippe 1995). Capsular polysaccharides 
include neutral sugars like ribitol or arabinitol, acidic components like D-glucuronic 
acid (types 1, 2, 3, 5, 8, 9A and 9V) or phosphodiester bonds (types 6A, 6B, 11 A, 15F, 
19F, 19A and 23F). The structures of serotypes 3, 4, 5, 6A, 6B, 7F and 7A are 
illustrated in figures 1.6 and 1.7.
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Figure 1.6: The structures of serotypes 3 - 7A (Kamerling 2000).
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Figure 1.7: Schematic representation of the structures of the primary structure of the 
carbohydrate chain (Kamerling 2000).
1.2.2.5.C Nomenclature
There are over 90 serotypes of S. pneumoniae and two systems of nomenclature have 
been devised for classification (Henrichsen J 1995). Originally pneumococci were 
assigned serotypes in order of recognition of new capsular types, a system now called 
the American system. However, after serotype specific encapsulation was fully 
understood, the typing system was revised to become what is now known as the Danish 
system. The Danish system, used in this document, is the most widely used, and
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perhaps the more useful as it groups together closely related serotypes on the basis of 
their chemical composition. Hence, group 6 contains subgroups 6A and 6B as they 
have the same composition but different structures in their rhamnosyl-ribitol bonds, 6A 
has a l-»3  bond and 6B has a l-»4  bond (Robbins et al. 1983). Serotype 14 has no 
subtypes. The first type in each group is assigned F, e.g. 19F and 23F and thereafter 
they are assigned letters in alphabetical order e.g. 19A, 19B, 19C etc with the exception 
of group 9 which has 9V, 9N and group 6 in which there is no 6F.
1.2.2.5.d Capsule synthesis and genetics
A complex synthetic pathway is required for capsule production including synthesis of 
component monosaccharides, activation of each to a nucleotide precursor, sequential 
transfer o f each sugar to the repeating oligosaccharide, polymerisation and transfer and 
attachment to the cell surface (Morona et al. 1999). Serotype 3 is the simplest o f the 
capsules, consisting of only glucose and glucuronic acid, which is derived from glucose 
via UDP-glucose dehydrogenase (UDP-GlcDH) (Arrecubieta, Lopez, & Garcia 1994). 
Classical experiments performed by Austrian et al. in 1959 demonstrated that the genes 
required for capsule production were closely linked (Austrian et al. 1959;Austrian 
198la;Johnston, Jr. 1981). Since then many investigations have confirmed this and 
demonstrated type specific genes to be flanked by homologous genes at either end, dexB 
(downstream) and aliA (upstream) (Morona, Morona, & Paton 1997). The genes 
relating to capsule synthesis are described in more detail in the introduction to chapter 
four.
1.2.2.5.e Capsular transformation
S. pneumoniae are able to undergo genetic transformation because they are naturally 
competent. Competence is defined as the capacity of the bacteria to absorb DNA 
molecules from their environment and become genetically transformed (Tomasz A & 
Hotchkiss R 1964). S. pneumoniae are capable of taking up DNA from other 
pneumococci or from related streptococcal species. Competence for transformation is 
controlled by competence (com) genes, competence and uptake o f DNA is described in 
section 1.2.2.7 (Chen & Morrison 1987). Capsular transformation takes place through a 
cassette-type homologous recombination mechanism. This means that all o f the 
capsular genes are transferred together, and insertion o f the genes into the correct 
location is directed by conserved genes at either ends o f the locus (Austrian 
1981a;Morona, Morona, & Paton 1997). This generally results in the loss o f the ability
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to express the original polysaccharide, however, the type specific genes are not replaced 
(Dillard et al. 1995;Dillard, Vandersea, & Yother 1995).
1.2.2.5.f Elucidation of capsular transformation
Capsular transformation in S. pneumoniae is the best example of experimentally 
inducible specific changes that can be successfully reproduced in vitro. Pioneering 
work by Griffith laid the foundations for future work on transformation, the significance 
of which really began to come to light following the elucidation of the structure and role 
of DNA. Griffith injected mice subcutaneously with a small amount o f non­
encapsulated or rough (R) cells of serotype 2 together with a large inoculum o f heat 
killed serotype 3 fully encapsulated and virulent or smooth (S) cells. He found that the 
mice frequently succumbed to infection, yet the R strain was avirulent (and therefore 
incapable of causing disease) and the heated S cells were not viable (and also incapable 
of causing disease). This provided convincing evidence that the R forms had newly 
acquired the virulent capsule from the type III organisms (Griffith F 1928).
Following this Dawson and Sia, in 1931, successfully accomplished transformation in 
vitro by growing non-encapsulated R cells in fluid medium containing anti-R serum and 
heat killed encapsulated S cells. They showed that transformation could be induced in 
vitro as well as in vivo depending on the serotype of the cells (Dawson & Sia 1931).
1.2.2.5.g Binary encapsulation
Binary encapsulated strains possess two sets of serotype specific capsular 
polysaccharide genes for different serotypes. Stable binary strains can produce both and 
hence contain a second set of type specific genes at a site unlinked to the recipient’s 
type specific genes. Unstable binary strains were shown to frequently lose the donor 
type-specific genes, which were usually linked to the recipient type specific genes 
(Munoz et al. 1997).
1.2.2.6 Competence
In culture pneumococcal competence develops under certain growth conditions; rich 
medium containing calcium and serum or albumin and starting pH 7.0 -  7.2. Lower pH 
prevents development o f competence and higher pH induces multiple waves of 
competence over a broader range of cell densities, rarely reaching a peak. The initial 
pH of the medium affects both the timing and occurrence o f competence (Chen &
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Morrison 1987). Using micropore filters to separate cells in two cultures and by 
dialysis Tomasz and Hotchkiss in 1964 demonstrated that competence is mediated by a 
macromolecular cell product, probably a protein. This is now known to be the 
competence factor, encoded by the comC gene, and is a small peptide capable of 
inducing expression of other genes encoding transformation related proteins (Tomasz A 
& Hotchkiss R 1964).
Natural transformation among streptococcal species provides a mechanism for genetic 
recombination resembling sex in higher organisms. The oral streptococci are normally 
non-pathogenic residents of the human micro-flora and there is substantial evidence that 
they provide a DNA reservoir for other organisms as they make their way through the 
mouth, the principle entry point for a wide variety of bacteria. Interspecies genetic 
exchange is an important evolutionary mechanism in S. pneumoniae as it allows rapid 
acquisition of novel function between related species (Cvitkovitch 2001). A pre­
requisite is the presence of streptococcal donor DNA and release of DNA from a sub- 
fraction o f the population induced at the onset of competence. The majority o f cells 
induced for competence take up DNA as recipients while the rest act as donors. It is not 
known exactly how DNA is released but it is now known that it is not just through the 
lysis o f cells dying from natural causes.
1.2.2.7 Competence inducing mechanism
Competence in S. pneumoniae is controlled by the com locus which codes for genes 
comA, comB, comC, comD and comE. ComC codes for a competence stimulating 
peptide (CSP). CSP is released through the comAB membrane channel, which is 
responsible for controlling CSP release. The CSP, once released extra-cellularly, acts 
back on the bacterium at a critical concentration via the comDE complex (encoded by 
comD and E genes) (Campbell, Choi, & Masure 1998;Steinmoen, Knutsen, & 
Havarstein 2002). ComDE is a transmembrane histidine kinase receptor; CSP binds to 
comD (Whatmore, Barcus, & Dowson 1999). The histidine kinase phosphorylates a 
response regulator that activates synthesis of a SigH like protein. The new a  factor 
enables expression of a set of proteins transcribed from a novel promotor (Lacks & 
Greenberg 2001). ComD can be mutated, Asp299Asn, so that that the histidine kinase 
is constitutively on.
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1.2.3 Protein antigens: adhesins, virulence factors and toxins
Although the capsule is considered the main virulence factor, there are a number o f cell 
wall located proteins that contribute to virulence and the disease process, either by 
concealing the bacterial surface from the host defence system or by directly interacting 
with host tissue to facilitate binding or toxicity (Jedrzejas 2001). These proteins have 
been the focus of much investigation as vaccine candidates and some proteins e.g. 
pneumococcal surface protein A (PspA), pneumolysin (Ply) or autolysin (LytA), have 
shown significant promise (McDaniel et al. 1987), for more details see section 1.6.3. 
Figure 1.7 summarises the pneumococcal proteins that have been characterised.
1.2.3.1 Choline binding proteins
1.2.3.1.a Pneumococcal surface adhesin A - PsaA
PsaA was detected using monoclonal antibodies and has attracted attention in recent 
years as a candidate in protein vaccine design. It is a 37kDa surface lipoprotein 
essential for pneumococcal virulence and has considerable sequence homology to 
putative lipoprotein adhesins of S. sanguis and S. parasanguis (Sampson et al. 1994). 
PsaA is part o f an operon which includes three open reading frames: ORF1, PsaA 
(ORF2) and ORF3, and the intact operon is essential for full virulence. ORF1 is a 
putative ATP-binding protein, from sequence homology with the ORF upstream of 
PsaA counterparts in other organisms. The precise function of PsaA is unknown but 
mutants with defects in PsaA are deficient in the ability to bind alveolar cells (Paton, 
Berry, & Lock 2000). However, recent work has suggested that PsaA is a permease, 
involved in regulating, but not itself responsible, for adherence (Dintilhac & Claverys
1997).
1.2.3.1.b Pneumococcal surface protein A - PspA
PspA is found on the surface of every strain discovered to date and varies with respect 
to expression o f antigen determinants and molecular weight. It is a 67-99 kDa surface 
protein with four distinct domains: an N-terminal highly charged a-helical domain 
which exhibits variability due to accumulation of mutations, a proline-rich domain 
which provides flexibility, a stretch of highly conserved amino acid repeats and a 
hydrophobic C-terminal domain (Yother et al. 1992). PspA is an antigen with anti- 
complementary properties, is highly polar and electrostatically charged and its role is to 
stabilise the capsular negative charge and prevent complement binding (Jedrzejas 2001). 
Briles et al. demonstrated that PspA' mutants fix more complement than the wild type
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(Briles et al. 2000a). Protective monoclonal antibodies bind the N-terminus suggesting 
that this part is surface exposed. Although PspA is not required for transformation its 
absence affects transformation rates in vitro.
1.2.3.1.C Pneumococcal surface protein C -  PspC
Originally called CbpA choline binding protein, this protein was the first pneumococcal 
adhesin to be described. It is a surface protein that is essential for virulence. It is 
composed of 663 amino acids, has a molecular mass of 75kDa and has two distinct 
domains. The C terminal domain shares >95% homology with PspA and the N terminal 
domain shares an a-helical coiled coil structure with PspA, although their amino acid 
sequence is different. PspC has a proline rich region, characteristic o f choline binding 
proteins. PspC is thought to play a role in adhesion to human cells, it is up-regulated in 
transparent phenotypes and is essential during colonisation. It is essential for crossing 
the blood-brain barrier (Ring, Weiser, & Tuomanen 1998).
1.2.3.1.d Autolysins -  LytA, LytB and LytC
Autolysins are a family o f enzymes that degrade different bonds in peptidoglycan and 
eventually cause lysis of the cell (Lopez et al. 2000). Autolysins are cell wall associated 
and are able to recognise the choline in teichoic acid to which they bind via the choline 
binding domain, which functions independently from the catalytic domain (Sanchez- 
Puelles et al. 1990). It is thought that these proteins have evolved from the fusion of 
two independent functional domains, one containing the functional active site, and the 
other the choline binding domain (Garcia, Garcia, Garcia, Arraras, Sanchez-Puelles, & 
Lopez 1988).
1.2.3.1.e LytA
N-acetyl muramic acid-L-alanine amidase is the major pneumococcal autolysin enzyme 
responsible for splitting the bond between N-acetyl muramic acid and alanine in the 
muropeptide portion of the cell wall and is stimulated during the stationary phase or by 
deoxycholic acid or penicillin and is heavily dependent on choline residues in cell wall 
teichoic acid (Balachandran et al. 2001;Mosser & Tomasz 1970). Autolysis is required 
for the insertion of newly synthesised P1-4 N-acetyl glucosaminyl-N-acetyl muramyl 
peptide fragments into the cell wall during growth, although, peptidoglycan may also 
require other specific enzymes e.g. muramidase for linking new peptides into a growing 
mucopeptide polymer (Jedrzejas 2001). LytA’ mutants are unable to undergo daughter
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cell separation and form chains. Following the action of autolysis cell wall components 
are released which are highly toxic to the cell (Tuomanen 1999). It was previously 
thought that autolysin was required for the release of pneumolysin, but recently it was 
shown that this is not the case, that LytA' mutants are able to release pneumolysin 
(Balachandran, Hollingshead, Paton, & Briles 2001).
The secondary structure of LytA contains 19% a-helix, 47% p-sheet, 23% turns and 
11% irregular structures. Autolysin forms an ellipsoid tail-to-tail dimer with the N- 
terminal catalytic domain exposed at each end. This tertiary conformation results from 
interaction o f the choline binding C-terminal domains, which are 6 amino acids in 
length and capable o f binding to the choline phosphate residues of teichoic acid 
(Usobiaga et al. 1996). The shape of the molecule facilitates diffusion through the cell 
wall to the surface and the positioning of the catalytic domains are optimal for 
degrading peptidoglycan (Markiewicz & Tomasz 1990;Usobiaga, Medrano, Gasset, 
Garcia, Saiz, Rivas, Laynez, & Menendez 1996).
Autolysin induced pathogenicity is two-fold. Cell wall turnover, induced by autolysin, 
releases cell wall products which are highly inflammatory and contribute to shock. In 
addition, intracellular protein toxins, such as pneumolysin, are released. Reduced 
virulence has been reported from strains transformed with inactivated lytA (Berry et al. 
1989).
1.2.3.1.f LytB and LytC
Two other cell wall hydrolases have recently been described, LytB and LytC and have 
complicated the understanding of the role of the hydrolases (Lopez, Gonzalez, Garcia, 
Garcia, & Garcia 2000). The putative LytB protein is a 76 kDa composed o f 658 amino 
acids. It displays a different modular organisation from the other choline binding 
proteins in that the order of the active portion of the protein and the choline binding 
domains are reversed. LytB is thought to be required for daughter cell separation as 
deficient mutants form long chains (Garcia et al. 1999). The proposed LytC is a 
58.7kDa protein o f 501 amino acids and is a lysozyme (which cleaves the link between 
N-acetyl glucosamine and N-acetyl muramic acid) (Lopez, Gonzalez, Garcia, Garcia, & 
Garcia 2000).
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1.2.3.2 Intracellular or exported proteins
1.2.3.2.a Pneumolysin - Ply
Pneumolysin is a thiol-activated, pore forming cytolytic toxin that will lyse most 
eukaryotic cells under anaerobic conditions. It is produced by virulent strains and plays 
an important pathogenic role in otitis media, pneumonia and meningitis (Balachandran, 
Hollingshead, Paton, & Briles 2001;Canvin et al. 1995;Tuomanen & Masure 1997). 
Pneumolysin binds to host membranes via the cholesterol receptor and is thought to 
oligomerise to form trans-membrane channels that lead to lysis of host cells. It is 
important in toxicity to respiratory endothelium and epithelium which normally serve as 
a mechanical lung-capillary barrier, thus facilitating pneumococcal invasion and 
dissemination (Rubins et al. 1992;Rubins & Janoff 1998). Antibodies to pneumolysin 
rise in humans with pneumococcal infections and pneumolysin-deficient mutants are 
less virulent; hence pneumolysin is a virulence factor which is produced while the 
bacteria is growing in the host (Balachandran, Hollingshead, Paton, & Briles 2001). 
Pneumolysin is inhibited by cholesterol in vitro. Low concentrations of pneumolysin 
inhibit the respiratory burst, beating of cilia, chemotaxis and antimicrobial activity by 
polymorphonuclear leukocytes and macrophages, allowing further proliferation inside 
the host. Pneumolysin is a potent interleukin-6 agonist inducing production of 
interleukin-6, tumor necrosis factor-a and cyclo-oxygenase-2 inflammatory responses 
(Braun et al. 1999). Higher concentrations cause activation of the classical complement 
pathway and thus depletion of serum opsonic activity (Rubins et al. 1996). It is thought 
that complement activation takes place because domain 4 o f pneumolysin shares 
structural similarity between aggregated IgG negating the need for a specific antibody 
(Paton, Rowan-Kelly, & Ferrante).
1.2.3.2.b Neuraminidase
Neuraminidase is a glycosidase located at the cell surface and is released into the extra­
cellular environment (Camara et al. 1994). It causes injury to the host by cleaving 
terminal sialic acid residues from glycoproteins, glycolipids and oligosaccharides on the 
cell surfaces and in body fluids (Paton, Berry, & Lock 2000). A high concentration of 
free N-acetyl-neuraminic acid in the CSF of patients with meningitis correlates with 
coma and adverse prognosis. Its role in virulence is not fully understood (Schneider et 
al. 1999).
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1.2.3.2.C Hyaluronate lyase
Hyaluronate lyase is a surface protein which may be essential for full virulence, and acts 
to break down the extra-cellular matrix and connective tissues, playing a role in wound 
infections, pneumonia, bacteraemia and meningitis (Jedrzejas 2001;Paton, Berry, & 
Lock 2000). Hyaluronate lyase cleaves 1, 4 glycosidic linkages between N-acetyl-p-D- 
glucosamine and D-glucuronic acid in hyaluronan and catalyses the release of 
unsaturated polysaccharides. Hyaluronan is an important component o f the extra­
cellular matrix of vertebrates and is composed of D-glucuronic acid (l-p-3) N-acetyl-D- 
glucosamine (l-P-4). The enzyme has a sorting sequence, to direct its external 
positioning, at the C-terminus and a tail o f positively charged residues for attachment to 
the cell wall (Fischetti, Pancholi, & Schneewind 1990).
1.3 Interaction of S. pneumoniae with the host
1.3.1 Carriage
S. pneumoniae is a nasopharyngeal commensal organism and is carried by a significant 
portion o f a healthy population, especially by young children since the immune system 
is less well developed below two years, see section 1.3.4.e. (Kanungo et al. 
2000;Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, Makela, Broome, 
Facklam, Tiesjema, & . 1983;Sa-Leao et al. 2000;Tuomanen & Masure 1997). Carriage 
can last for between several weeks to more than a year and is important in the 
development of disease and the spread of infection because it provides a reservoir of the 
organism. Mulitple or co-colonisation, carriage by more than one serotype at the same 
time, was reported in 29.5% of children in Papua New Giunea (Gratten et al. 1989). 
Although carriage usually precedes infection, disease will usually result from a newly 
acquired strain. The central role of carriage in disease is shown in figure 1.8. All 
serotypes are capable of carriage, but only a sub-set of serotypes go on to cause disease 
(Kristinsson K 1999;Sa-Leao, Tomasz, Sanches, Brito-Avo, Vilhelmsson, Kristinsson, 
& de Lencastre 2000). In adults carriage is highest among prison inmates, in barracks 
and open dormitories, where there is close contact between individuals. In children 
carriage is highest among those attending day care centres, again because of close 
contact (Dagan et al. 2001;Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 
1999;Robinson, Edwards, Waites, Briles, Crain, & Hollingshead 2001). It is thought 
that the likelihood of transmission of S. pneumoniae between carriers is directly 
proportional to frequency and intimacy of their contact (Riley & Douglas 1981).
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Figure 1.8: Central role of carriage in passage of pneumococcal disease, reproduced 
from (Briles et al. 2000b).
1.3.1.a Adherence to human cells
Pneumococci bind avidly to epithelial cells of the upper and lower respiratory tract via a 
lectin1 with an electron dense haze filling a fine fibrillar mesh in the space between 
membranes. The site o f attachment is broad and strong enough for the pneumococci to 
“tent” or draw the host cell around itself at the site of interaction (Tuomanen & Masure 
2000). Pneumococcal adherence to human cells is achieved by presentation o f surface 
proteins that bind to a wide range of eukaryotic carbohydrates expressed on the cell 
surface. Carriage does not appear to trigger an overt inflammatory response, yet it leads 
to serotype specific immunity based on the structure of the capsular polysaccharide 
(Tuomanen & Masure 2000). The exact mechanism of binding in vivo is not fully 
understood.
1 Non-enzymic protein that binds to a specific polysaccharide
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1.3.1.b Carriage versus invasive strains
Little work has been published comparing the genetic relatedness of carriage and 
invasive isolates (Robinson, Edwards, Waites, Briles, Crain, & Hollingshead 2001). 
However, two studies both concluded that invasive isolates had a wide genetic diversity 
and were genetically related to carriage isolates, but that most carriage isolates were not 
found to be invasive (Robinson, Edwards, Waites, Briles, Crain, & Hollingshead 
2001;Takala et al. 1996). Robinson et al found that serogroup 19 isolates were carried 
more frequently than others, and that serotypes 14 and 23 tended to be more invasive. 
These findings may not represent relationships between S. pneumoniae carriage and 
invasive isolates on a global scale (Robinson, Edwards, Waites, Briles, Crain, & 
Hollingshead 2001).
1.3.1.C Duration of carriage
The duration o f carriage differs between studies. Hendley et al. in 1975 reported that 
carriage lasted on average two weeks, whereas Gray, Converse and Dillon found that it 
lasted between 1 and 17 months (Gray, Converse, III, & Dillon, Jr. 1980;Hendley et al. 
1975). The duration of carriage decreases with increasing age, that it is more common 
for serotypes 6, 19 and 23 and that immunity also plays a role (Gray, Converse, III, & 
Dillon, Jr. 1980;Scott, Hall, Dagan, Dixon, Eykyn, Fenoll, Hortal, Jette, Jorgensen, 
Lamothe, Latorre, Macfarlane, Shlaes, Smart, & Taunay 1996).
1.3.1.d Interaction with other throat commensals
An important aspect of S. pneumoniae carriage is that residence in the throat, in close 
proximity to other throat commensals such as S. oralis and S. mutans, allows genetic 
exchange between these organisms such as serotype switching, see section 1.2.2.7 and 
acquisition of antibiotic resistant genes or gene fragments, see section 1.5.
There is negative correlation between S. pneumoniae and Haemophilus influenzae 
carriage in the nasopharynx. S. pneumoniae was found to produce hydrogen peroxide at 
concentrations that are bactericidal to H  influenzae. The expression of the gene 
responsible for controlling production of H2O2 in S. pneumoniae, SpxB, is highest in 
conditions of high oxygen and increased carbon dioxide, corresponding to conditions at 
the mucosal epithelia (Pericone et al. 2000).
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1.3.2 Invasion by S. pneumoniae
The second step of interaction with the host is progression to colonisation o f areas other 
than the natural habitat of the nasopharynx, e.g. the bronchial epithelium. This is 
achieved via host cell surface exposed carbohydrates on resting epithelial cells, see table
1.1. This progression is restricted to around 20-30 serotypes. Those most commonly 
isolated from patients with invasive in Europe, North America and South Africa are 
those in the 23-valent polysaccharide vaccine see section.2.6.2.b
Table 1.1: Summary of host cell surface exposed carbohydrates to which pneumococci 
bind and establish colonisation (Andersson et al. 1983;Barthelson et al. 1998;Cundell et 
al. 1995a;Cundell & Tuomanen 1994).
Host Cell Carbohydrate Receptor
Buccal epithelium GlcNAc(pl-3) Gal
Bronchial and conjuctival epithelium NANA Gal (pi-4) GlcNAc
Alveolar epithelium and vascular endothelium GalNAc (p i-4) Gal
Alveolar epithelium and vascular endothelium GalNAc (P1-3) Gal
Activated alveolar epithelium and vascular GlcNAc
endothelium
1.3.2.a Regulation of adherence and invasion - Intra strain phase variation
S. pneumoniae is a population of mixed phenotypes differing in amount o f CPS, 
teichoic acid and choline binding proteins (Weiser & Kapoor 1999). Weiser et al. 
demonstrated that pneumococci are able to undergo bi-directional intra strain phase 
variation between opaque and transparent forms by varying the amount o f capsule 
expressed (Weiser, Markiewicz, Tuomanen, & Wani 1996) at a rate o f 10'3 -  10'6 per 
generation (Kim & Weiser 1998). The ability to regulate levels o f expression o f CPS 
is very important for the survival of pneumococci in their different host environments 
and is implicated as a factor in the pathogenesis of disease (Weiser et al. 1996). 
Adhesins can be up-regulated to enhance colonisation and the amount o f capsule can be 
up-regulated to hide proteins during invasion, properties of transparent and opaque 
variants are summarised in table 1.2.
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Table 1.2: Properties of opaque and transparent forms (Kim & Weiser 1998;Nesin, 
Ramirez, & Tomasz 1998;Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, 
Makela, Broome, Facklam, Tiesjema, & . 1983;Rosenow et al. 1997).
Transparent Opaque
2.1 -  3.8 fold more immunodetectable 1.2 -  5.6 fold greater amounts o f
teichoic acid and less capsular capsule polysaccharide and less
polysaccharide teichoic acid
Greater expression of surface choline- Reduced expression o f choline binding
binding proteins proteins
Less virulent More virulent
There is a marked intra strain difference in colony opacity that can be seen on 
transparent surfaces i.e. agar without blood (and it may be this feature that explains why 
phase variation has only recently been described since blood is commonly used for 
culture) and many strains can be separated into nearly uniform populations for 
comparison (Weiser 1998). Transparent variants were shown to have a greater ability to 
colonise in the infant rat model using nasopharyngeal washes following challenge with 
uniform populations of transparent and opaque colonies from cultures o f different 
serotypes. Transparent organisms were able to establish dense and stable colonisation of 
the nasopharynx, whereas the opaque variants were deficient in colonising ability. 
Colonisation was established after seven days following challenge with cultures o f the 
opaque variants and it was assumed that colonisation took place after the opaque variant 
had been cleared and the few transparent variants in the population had been selected 
for by the natural environment (Weiser 1994). The following year a model using type II 
lung endothelial cells in culture confirmed this (Cundell, Gerard, Gerard, Idanpaan- 
Heikkila, & Tuomanen 1995a).
Transparent pneumococci are responsible for adhering to human cells during 
colonisation (Weiser, Markiewicz, Tuomanen, & Wani 1996). Pneumococci bind to the 
receptor for platelet activating factor (PAF) and to the asialo-GMl glycolipid receptor 
on human epithelial cells. Choline binding proteins (e.g. CbpA) are also required for 
adherence during colonisation and are present at higher levels in transparent or 
colonising cells. The distribution of proteins anchored to the choline moiety on teichoic
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acid is altered in the transparent phenotype (Weiser, Markiewicz, Tuomanen, & Wani 
1996).
Adherence to human cells is a complex mechanism involving the regulation and 
interaction of many proteins and enzymes as well as transformation between opaque and 
transparent forms. Although opaque and transparent cells bind to human resting 
epithelia and endothelial cells to a similar degree, enhanced adherence to cytokine 
activated cells via up-regulated receptors such as PAF is limited to transparent variants 
(Cundell et al. 1995b). The shift to transparent variants is controlled by a quorum 
sensing mechanism (bacterial monitoring of outside environment) regulated by peptide 
permeases. Pneumococcal peptide permeases are essential for capture and transport of 
small peptides and or amino acids into the cell. Mutants deficient in two permeases, 
PlpA and AmiA show differences in cell density regulated phase transformation and 
changes in adherence. Loss of PlpA leads to phase transformation at low cell densities 
and elimination o f binding to GalNac (p i-3). Loss of AmiA leads to phase 
transformation at high cell densities and loss of binding to GalNac (p i-4).
1.3.2.b Transition from binding to invasion
Cellular invasion is rare and requires a molecular mechanism for transition to a state of 
invasion from colonisation. Colonising strains may sometimes invade the mucosal 
surfaces via invaginations of the cell surface membrane and become internalised in a 
receptor mediated fashion (Saeland, Vidarsson, & Jonsdottir 2000). Colonisation of 
cells o f a usually sterile site stimulates activation of the cells by thrombin or cytokine. 
This is thought to promote inflammation of host cells and the unmasking of additional 
receptors e.g. platelet activating factor (PAF). Receptors such as PAF are up regulated 
following viral infection, when hosts are thought to have increased susceptibility to 
pneumococcal infection. PAF is a G-protein coupled receptor but pneumococcal 
binding does not stimulate a G-protein mediated signal transduction or interfere with 
PAF signalling. PAF is also a powerful lipid chemokine and induces endothelial 
permeability and leukocyte extravasion, facilitating rapid internalisation o f the 
pneumococci into a vacuole, a step that only opaque cells may follow (Geng et al. 
1991;Tuomanen & Masure 2000). This is an important step in advancing disease, 
mediated by the host’s inflammatory response and by key pneumococcal virulence 
determinants determining why only certain, more virulent strains, are able to negotiate 
this route.
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The vacuole then transverses the host cell’s cytoplasm and extrudes at the farthest side 
accessing endothelial cells via the same mechanism. Pneumococci have been shown, by 
histological examination, to accumulate in epithelial and endothelial cells (Tuomanen & 
Masure 2000). Pneumococci, having established themselves with human cells, can 
multiply causing damage to the host cells mediated by specialised proteins such as 
pneumolysin, facilitating further migration and overt disease. If pneumococci are not 
eliminated by the host immune system or antibiotic therapy, they continue to multiply 
and damage and can induce a state of shock, eventually killing the host.
Following invasion the host responds by eliciting a complex array of immune responses, 
discussed briefly below. Mechanisms of pathogenicity are specific to individual disease 
and are further discussed in section 1.3.5.
1.3.4 H ost resp on se to p n eu m ococcal infection
The pneumococcus is adapted to interact with a variety of human cells and induce 
inflammatory responses. These mediated responses combine to produce characteristic 
symptoms of pneumococcal disease including changes in blood flow, fluid balance in 
the tissues and induction of leukocytes, which are summarised in figure 1.9.
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Figure 1.9: Summary of immune and inflammatory responses following pneumococcal 
infection (Khoosheh.G & Tuomanen 2000).
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Much of our understanding of human response to pneumococcal infection comes from 
studying individuals lacking a feature o f the immune system or from studies on mice. 
The pneumococcus is an extra-cellular pathogen and applies particular stress to the 
body’s capacity to remove bacteria by phagocytosis. Each component o f the phagocytic 
system; phagocyte, antibody and complement, must function at its best to fully protect 
the host (Johnston, Jr. 1981).
1.3.4.a Integrity of the respiratory epithelium
The integrity of the respiratory epithelium is important in protecting against 
pneumococcal disease. The role of viral induced histological damage to respiratory 
epithelia resulting in increased susceptibility to infection was first described in the 
1940s and confirmed in 1986 by Plotkowski et al who described bacterial attachment to 
basal epithelial cells following influenza viral infection (Plotkowski et al. 1986).
1.3.4.b Local defence responses
The first line o f defence against pneumococcal infection is the mucosal covering o f the 
epithelial cells lining the upper respiratory tract. The sticky mucus acts as a mechanical 
barrier by trapping the bacteria and is then carried back to the throat, by ciliary action, 
and swallowed. Mucus contains IgA which facilitates antigen to phagocyte interaction 
and blocks adhesin facilitated bacterial binding to epithelial cells. Oropharyngeal 
microflora protect against pathogenic bacteria by competing for cell surface binding 
proteins.
After infection has been established the humoral and cellular arms of the immune 
system act together to defend the host. The main mechanism of protection is 
opsonophagocytosis, which is antibody and complement dependent, requiring intact 
classical and alternate complement pathways.
1.3.4.C Cellular defence responses
Phagocytic cells include neutrophils and macrophages. Macrophages are amoeboid 
phagocytic leucocytes, originating from bone marrow, with cell surface receptors for Fc 
portions o f IgG, IgE and complement. However, they are unable to efficiently 
phagocytose encapsulated pneumococci. Once infection is established 
polymorphonuclear leukocytes (including neutrophils) are stimulated by the bacterial 
cell wall and C-polysaccharide interaction with the alternative complement pathway,
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which generates the necessary chemotactic factors (Vial, Toews, & Pierce 1984). 
Neutrophils are chemotactic cells involved in the early stages o f inflammation. They 
contain bactericidal enzymes including lysozyme. Neutrophils engulf opsonised 
pneumococci via membrane invaginations during the respiratory burst, within seconds 
of stimulation. The spleen is important in the early stages o f infection, before 
antibodies are produced, because it provides a highly phagocytic mass for poorly 
opsonised bacteria (Cohn & Schiffman 1988).
1.3.4.d Antibody mediated protection
Immuno-competent individuals will mediate an antibody response to the following 
pneumococcal structures: capsular polysaccharide, cell wall polysaccharide (mainly 
phosphorylcholine residues), pneumolysin and other proteins including PspA.
1.3.4.e Polysaccharide antibodies -  Thymus independent antigens
Antibodies to capsular polysaccharide are predominantly IgG2 and have the greatest 
protective power and result in rapid clearance mainly by the liver and to a lesser degree 
by the spleen, which has an additional role of enhancing the serotype specific 
production o f antibodies (Cohn & Schiffman 1988). It is because o f this strong serotype 
specific response that such a strong emphasis was placed on polysaccharide vaccines, 
until they were found to be ineffective in young children, see section 1.6. They are T 
cell independent (produced from direct B cell : antigen interaction) (Lee 1987). Infants 
have a decreased expression of complement receptor 2 on their B cells, which are thus 
too immature to respond to polysaccharide, hence children under two years are 
particularly prone to pneumococcal carriage and infection (Griffioen et al. 1991). Infant 
responses to purified polysaccharide are predominantly IgM and are weak. Children 
and adults differ in their response to capsular polysaccharide, for example, serogroup 6 
isolates are poor immunogens in children and thus carriage is persistent and frequent 
invasive episodes are seen, however, serotype 6 is strongly immunogenic in adults and 
invasive disease is rare (Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, 
Makela, Broome, Facklam, Tiesjema, & . 1983).
1.3.4.f Phosphoryl choline mediated antibodies
Detectible levels of IgM against phosphorylcholine are seen in infants under one year 
after pneumococcal infection. Antibodies to phosphorylcholine decrease after 5 0 - 6 0
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years of age (AlonsoDeVelasco, Verheul, Verhoef, & Snippe 1995), which is a 
contributing factor to the increase in incidence of pneumococcal disease after this age.
1.3.4.g Anti-protein antibodies
Pneumococcal proteins are considered T dependent antigens as they require the co­
ordination of B and T lymphocytes to mount an immune response. This has been 
shown by the lack of anti-protein antibody formation in nude mice. T cell dependent 
responses can be elicited in infants, who mount a normal antibody response to 
pneumococcal proteins, similar to that in adults (AlonsoDeVelasco, Verheul, Verhoef, 
& Snippe 1995). Primary antibody response to proteins normally comprises o f IgM and 
IgG.
1.3.5 Diseases caused by S. pneumoniae
Severe pneumococcal infections result from a complex interplay between the 
pathogenic effects exerted by the organism and from the host immune response to a 
variety of pneumococcal components.
1.3.5.a Otitis media
Otitis media is an infection of the middle ear that is thought to be a result o f the spread 
of infection up the eustachian (auditory) tube which vents the middle ear to the 
nasopharynx. However, some organisms present in cultures taken from the middle ear 
are not present in those taken from the throat and ‘vice versa’, suggesting either an 
alternative route of infection, or newly acquired strains in the throat since migration of 
the infecting strain along the eustachian tube (Klein 1981). This infection is more 
common in young children as the eustachian tube is more widely open at this age. 
Symptoms o f otitis media include earache, fever and deafness and the eardrum shows 
dilated vessels with bulging of the drum at later stages. Fluid often persists in the drum 
for weeks or months and contributes to deafness. Bacterial acute otitis media (AOM) is 
predominantly pneumococcal and causes an estimated 7 million cases annually in the 
US (Pichichero et al. 2000) and is a significant burden to the NHS in the UK (McNulty, 
Smith, & Graham 2001). Delayed or failed treatment may result in prolonged deafness, 
with chronic discharge through a perforated eardrum, and can be a particular problem in 
poor communities where educational and social disadvantages may follow (Leach et al. 
1994).
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Pneumococci can progress along the Eustachian tube by binding to sialic acid residues, 
which are cleaved by neuraminidase to unmask cell surface receptors (Tuomanen & 
Masure 1997).
1.3.5.b Pneumonia
Pneumonia is an infection of the lungs and is the most severe and life threatening o f the 
respiratory tract infections with 20 million cases annually worldwide (Klein DL 2000). 
Infection begins with the inhalation of pneumococcal-containing respiratory secretions 
that should normally be cleared rapidly by coughing, the micro-ciliary blanket and 
alveolar macrophages. These secretions could be aerosolised from another person or 
aspirated from the normal flora of the upper respiratory tract. Less frequently the lungs 
may become seeded with organisms spread via the blood from other infected areas. 
Healthy individuals are susceptible to organisms with adhesins, like S. pneumoniae, 
which allow the organism to adhere specifically to lung epithelia and failure o f local 
defence responses in non-immune individuals is followed by a rapid proliferation in the 
alveoli. The definition of the role of the pneumococcus in pneumonia was first 
described by Gram in 1884 (Gram C 1884). S. pneumoniae accounts for 10 to 25% of 
all pneumonias (Lee, Banks, & Li 1991) and usually requires the hospitalisation of 
infants and children, being a significant cause of death in developing countries 
(Drummond et al. 2000). However, data are scarce as children are unable to produce 
sputum and lung aspirates are rarely used since they are considered too invasive for 
routine use (Klein 1981).
The molecular mechanism for the transition from a state of pneumococcal binding to 
cellular translocation and invasion is thought to involve pro-inflammatory activation of 
the target cell. Inflammation is thought to increase the type and number o f receptors 
available on the cell and pneumococci take advantage of this (Tuomanen, 1999). PAF 
can be up regulated by TNFa, thrombin or interleukinl (IL-1). This takes place in the 
first four hours o f infection. Once pneumococci have gained access to the alveoli they 
multiply rapidly, this is followed by an influx of cytokines, TNF, IL-1 and IL-6 and 
serum IL also rises. Neutrophil chemotaxis is mediated by the cytokines TNFa, IL-1 
and IL-6 and complement activating properties of teichoic acid and pneumolysin. Lung 
damage results from the actions of pneumolysin causing alveolar injury and interstitial 
oedema. Type I and II pneumocytes are regenerated, which allows progression of 
pneumococci from the lung into the bloodstream, and the TNF and IL-1 levels in the
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lung are reduced. Bloodstream invasion, for which opaque variants are best suited, is 
facilitated by pneumolysin and CbpA. After 48 -  72 hours the final stage of infection is 
characterised by a sharp increase in alveolar monocyte and lymphocyte activity 
accompanied by nitric oxide release in the lung and the alveolar space {Bergeron, 1998 
538 /id}. The effects of bacteraemia are leucopenia (reduction in white blood cells), 
thrombocytopenia (reduction in the number of platelets) and an increase in cytokines. 
This results in massive tissue damage, further proliferation o f pneumococci and high 
mortality. The pathogenesis o f pneumococcal pneumonia is reviewed by Gillespie in 
(Gillespie & Balakrishnan 2000).
1.3.5.C Bacteraemia
Bacteraemia (infection of the blood stream), or transient bacteraemia, which is 
asymptomatic or accompanied by a brief episode of fever, is well documented in young 
children (Tuomanen & Masure 2000). In general bacteraemia often goes undiagnosed, 
especially in moderate cases not requiring hospitalisation (Klein 1981). Cases of 
bacteraemia that require hospitalisation carry a mortality rate o f about 20%, 50% of 
which are usually within 48 hours of admission (Balakrishnan et al. 2000). About 10% 
of bacteraemias reported in England and Wales are pneumococcal (Laurichesse et al.
1998). The increase in use o f blood culture techniques had led to more frequent 
diagnosis o f systemic pneumococcal infections (Klein 1981). Less than 1% of 
pneumococcal pneumonias result in bacteraemia (Tuomanen & Masure 2000), yet in 
adults 60-87% of pneumococcal bacteraemias are associated with pneumonia (Kuikka et 
al. 1992;Thore et al. 1985).
1.3.5.d Meningitis
Meningitis is an inflammation of the meninges due to infection. Symptoms include 
intense headache, fever, loss of appetite, intolerance to light and sound, and rigidity of 
muscles, especially in the neck. Severe cases include convulsions, vomiting and 
delirium leading to death. Pneumococcal meningitis has become the most common 
bacterial infection of the central nervous system (CNS) in the United States following 
the success of the meningococcal vaccine and world-wide is responsible for 75 000 / 
100 -  500 000 deaths annually (Greenwood 1999;Klein DL 2000). With early and 
effective treatment, antibiotics that achieve a bactericidal concentration at the site of 
infection (subarachnoid space filled with CSF), patients may survive. However, the 
case fatality rate is around 30% which is higher than for other causes and 30 -  50% of
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survivors are left with neurological sequelae; even with treatment, bacterial meningitis 
can frequently be fatal (Klein 1981) hence, it is the most serious infection o f early 
childhood (Ring, Weiser, & Tuomanen 1998).
A rabbit meningitis model was first described by Dacey and Sande in 1974, in which 
the rabbit was injected with bacteria and the CSF constantly sampled (Dacey & Sande 
1974). Pneumococcal meningitis develops during high-grade bacteraemia (or after 
cranial trauma) in relatively few individuals and each bacterial strain has its own unique 
infectious dose (Tuomanen & Masure 2000). Prior to invasion pneumococci must 
adhere to the surface of the blood brain barrier, a step requiring the adhesin CbpA. PAF 
receptor plays a role in trafficking across the blood brain barrier and once activated 
supports greater transmigration. After a lag phase around 10% of pneumococci are 
internalised and pneumococcal invasion of the cerebral epithelia is around 1 0  times 
more efficient than of the peripheral endothelial cells. This is dependent on the amount 
of capsular polysaccharide, not serotype, so that transparent pneumococci have a three 
to five fold selective advantage over opaque variants for blood brain barrier 
transmigration (Tuomanen & Masure 2000). Once inside the blood brain barrier cells, 
pneumococci will either be killed, recycled to the surface, or will progress to and exit at 
the basolateral surface. The latter route can only be travelled by transparent bacteria, 
and opaque cells are killed intracellularly. Within eight to ten hours there is a rapid 
influx o f white blood cells, particularly polymorphonuclear leukocytes (PMNL) into the 
CSF, but the CSF is low in opsonins (antibodies and complement) so the rate of 
bacterial proliferation goes relatively unchecked (Tuomanen & Masure 2000). In 
response to the inflammatory reaction mediated by TNF-a and IL-1, physiological 
changes in the cranial space occur. Cerebral oedema, leads to increased intra-cranial 
pressure and causes a reduction in cerebral blood flow and increased resistance to CSF 
resorption. Neuronal damage from nitric oxide increases the neuronal damage and 
sequelae in survivors. In vitro studies have suggested that components o f the 
pneumococcal cell wall, LTA and TA, might be responsible for brain tissue damage 
during the course o f the disease (Kim, Kennedy, & Tauber 1995). A high concentration 
of LTA and TA has been inversely correlated with clinical outcome (Schneider, Michel, 
Zysk, Dubuis, & Nau 1999). Bacteriolytic antibiotics, such as the P-lactams, increase 
the release o f LTA and TA while antibiotics that do not affect cell wall synthesis reduce 
the release of LTA and TA and hence reduce sequelae (Stuertz et al. 1998).
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1.3.5.e Treatment of pneumococcal infections
When patients present with a pneumococcal illness such as pneumonia, the etiological 
agent will not be known until the results of laboratory cultures are complete, and 
empiric treatment regimes frequently will have begun based on the patients’ symptoms. 
Once laboratory data indicates a pneumococcal infection, in particular if  a drug resistant 
strain is isolated, the regimen may be changed. Penicillin resistant pneumococci are 
often co-resistant to other drugs, see section 1.5, therefore, it is important to establish 
antibiotic sensitivity pattern. The following drugs are highly active against penicillin 
resistant isolates: clindamycin, fluoroquinilones and vancomycin.
1.3.5.f Pneumonia
British Thoracic society recommendation for the treatment o f pneumonia (British 
Thoracic Society 2001) are outlined below:-
Outpatient cases of community acquired pneumonia:
1. Amoxicillin
2. Erythromycin or clarithromycin
Inpatients with non-severe community acquired pneumonia:
1. Combination of oral amoxicillin and a macrolide (erythromycin or 
clarithromycin)
2. Combination of intravenous ampicillin or benzyl penicillin with erythromycin or 
clarithromycin
3. Levofloxacin in patients intolerant to penicillin 
Inpatients with severe community acquired pneumonia:
1. Second generation cephalosporin, such as cefturoxime, plus optional erythromycin 
or clarithromycin
2. Third generation cephalosporins, such as cefotaxime or ceftriaxone, plus optional 
erythromycin or clarithromycin
3. Levofloxacin in patients intolerant to penicillin
1.3.5.g Meningitis
Meningitis treatment is complicated because the tight junctions o f the blood brain 
barrier, restricting drug access, make it harder to achieve bactericidal concentrations in 
the meninges. Penicillin is no longer used to treat pneumococcal meningitis because of
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reports of treatment failure with non-susceptible organisms. Vancomycin in 
combination with third generation cephalosporins such as cefotaxime and ceftriaxone 
are recommended (Tunkel & Scheld 2002). With either of these drugs used alone, there 
have been reports of clinical failures.
1.4 General epidemiology
1.4.1 Populations most affected by pneumococcal disease
Pneumococcal disease is of some considerable consequence in all societies globally 
(Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 1999), and because of the ability of the 
pneumococcus to infect the very young and the very old, it has one of the largest public 
health and economic impacts of any infectious disease (Klein DL & Eskola J 1990). 
Predominant serotypes vary with age, time and geographic location (Klein 1981).
1.4.1.a The elderly
Pneumococcal infections are the largest cause of death resulting from infectious disease 
in the elderly (Klein DL & Eskola J 1990). Convincing evidence for age being a 
significant contributor to this comes from a study on early predictors o f mortality in 
pneumococcal bacteraemia. The study included 107 patients with a mean age of 56 
(range 6  weeks to 98 years) with 56% of patients older than 50 years. They found that 
21/22 deaths were in the >50 years age group (p=0.00003) (Balakrishnan, Crook, 
Morris, & Gillespie 2000). Another study found that the main risk factor in this age 
group is co-morbidity thus infections acquired in nursing homes differ in aetiology and 
clinical manifestations (Lieberman & Lieberman 2000).
1.4.1.b Children
S. pneumoniae is currently the major invasive pathogen of children and accounts for 9% 
of all child deaths (Klein DL 2000;Tuomanen & Masure 1997), mainly due to the 
inability o f the immature immune system to elicit a response to polysaccharide antigens 
below two years of age (Lee, Banks, & Li 1991). In industrialised countries e.g. 
Sweden and the USA, about 50% of children will be colonised at least once in their first 
year (Syrjanen et al. 2001). In high risk populations, such as Aboriginal infants in 
Australia, otitis media develops, in most individuals, before the age of three months and 
early colonisation is attributed to overcrowding, poor hygiene and high rates o f carriage 
(Leach 1999).
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The incidence o f pneumococcal disease in children is enhanced when large numbers of 
children come into close contact, see section 1.4.3. Children with predisposing factors 
are at greater risk of succumbing to pneumococcal disease, see section 1.4. I.e.
1.4.1.C Patients with predisposing factors
Immuno-compromised individuals e.g. those with HIV are at an increased risk (see 
table 1.3 for summary of predisposing factors), particularly o f acquiring systemic 
pneumococcal infections. Children especially are vulnerable, among whom attack rates 
of around 10% per annum have been described (King, Jr. et al. 2000). However, a study 
in the UK showed that patients with predisposing factors did not have a significantly 
higher mortality rate from bacteraemia than those without (Balakrishnan, Crook, 
Morris, & Gillespie 2000).
Table 1.3: Factors predisposing individuals to pneumococcal infection (Balakrishnan, 
Crook, Morris, & Gillespie 2000;King, Jr., Borkowsky, Mahidhara, Madore, Shapiro, 
Rutstein, Tan, Farley, Dankner, Nachman, Simoes, Flynn, Clemens, & Hamilton 
2000;Klein 1981;Ortqvist, Sterner, & Nilsson 1985).
Predisposing Factors for infection with S. pneumoniae
Immunosuppression HIV, chemotherapy
Anatomical defects Hyposplenia or removal of spleen
Inherited disease Sickle cell disease
Hypogamma globulinaemia
Diabetes mellitus
Disease / co-morbidity Chronic lung disease
Previous viral lung infection
Malignancy e.g. Hodgkin’s disease
Other Alcoholism
Smoking
1.4.l.d  Developing countries
Pneumonia is a major cause of death in developing countries (Obaro 2000b), and the 
increasing incidence of HIV and antibiotic resistance are important contributing factors 
(Musher, Breiman, & Tomasz A 2002). Around three million children die each year 
from pneumonia, nearly all o f which are in developing countries, with S. pneumoniae
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being the most important infectious agent (Leowski 1986). The incidence is several 
times higher than in industrialised countries (Greenwood 1999). Indigenous 
populations such as Alaskan natives (Davidson et al. 1993), Australian Aboriginals 
(Gratten et al. 1994;Leach, Boswell, Asche, Nienhuys, & Mathews 1994) and North 
American Indians (Cortese et al. 1992) suffer a higher incidence o f pneumococcal 
disease. The reason why these people are at such high risk is not fully understood. 
Socio-economic factors are likely to be important, especially if  people are suffering 
poor nutrition and overcrowded living conditions, but underlying medical or genetic 
factors are influential such as alcoholism and sickle cell disease. Alcoholism is often 
found to be a problem among indigenous populations living in urban areas o f developed 
countries and is frequently associated with disease (Greenwood 1999;Leach 1999). So 
far other genetic links have not been identified (Greenwood 1999).
1.4.2 The distribution of serotypes
1.4.2.1 Geographical distribution
Scot et al undertook a study involving 7,010 invasive pneumococcal isolates from 
around the world which was done by combining existing datasets (Scott, Hall, Dagan, 
Dixon, Eykyn, Fenoll, Hortal, Jette, Jorgensen, Lamothe, Latorre, Macfarlane, Shlaes, 
Smart, & Taunay 1996). The age, sex and geographical data were compared. Common 
paediatric serotypes were consistent in the study groups, but there were regional 
differences with the less common serotypes. Overall the most commonly isolated 
serotypes were 14, 6 , 19, 3, 23, 1, 9, 4, 8 , 18, 7, 5, 12, 15 and 11 over all age groups. 
The widest variation in isolation rates between countries was seen for serotypes 1 and 5, 
which was associated with increased risk in South America, but were rarely seen in 
North America and Canada. Spain also showed an increased risk from serotype 5 and 
Britain from serotype 1. Britain also had an increased risk associated with serotype 14. 
Serotype 3 and 8  were less common in North America and Canada than elsewhere, 
serotype 4 was more common in North America than South America and Europe.
1.4.2.2 Paediatric and adult Serotypes
Serotypes isolated from children are frequently distinct from those isolated from adults. 
A landmark study by Gray, Converse and Dillon described the major paediatric 
serotypes as being 19, 6 , 23, 14, 3, 18, 4, 9, 7 and 1 with some differences seen between 
otitis media versus pneumonia and meningitis (Gray, Converse, III, & Dillon, Jr. 1979). 
Although their work was done 23 years ago the importance of these serotypes has not
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changed dramatically in the years since, and more recent studies report the same 
serotypes (Syrjanen, Kilpi, Kaijalainen, Herva, & Takala 2001). Serotypes 6 A and B, 
19A and F, 23F and 14 are among the commonest serotypes o f children followed by 1, 
4, 11 and 18. Serotype 3 is most frequently isolated in adults (Tomasz A 2000).
1.4.3 Factors facilitating spread of pneumococcal infection
1.4.3.1 Micro-environments: Day care centres
Since carriage rate is usually maximal in the 2 - 3 years age group, it is not surprising 
that many reported outbreaks of antibiotic resistant pneumococcal disease have involved 
child day care centres and close contact among children is thought to be a contributing 
factor (Barnes et al. 1995;Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 1999;King, 
Jr., Borkowsky, Mahidhara, Madore, Shapiro, Rutstein, Tan, Farley, Dankner, 
Nachman, Simoes, Flynn, Clemens, & Hamilton 2000). In addition to high rates of  
carriage, the high treatment rates using antibiotics among young children means that 
day care centres are frequently responsible for the spread o f antibiotic resistant 
organisms and frequently include representatives of internationally spread clones. 
Studies which isolated pneumococci from children attending a day care centres describe 
high carriage rates, especially of antibiotic resistant strains and those that have been 
frequently reported world wide (Dagan, Sikuler-Cohen, Zamir, Janco, Givon-Lavi, & 
Fraser 2001;Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 1999;Sa-Leao, Tomasz, 
Sanches, Brito-Avo, Vilhelmsson, Kristinsson, & de Lencastre 2000). A study in 
southern Israel conducted in one day care centre (Yagupsky et al. 1998) showed 
extensive person to person spread of S. pneumoniae, including resistant strains, 
illustrating how such environments are important factors in augmenting the spread of 
disease and resistance. A larger and more recent study in the US which included eight 
day care centres in which 772 cultures were obtained from 264 children, further 
highlighted the role of micro-environments as a reservoir for S. pneumoniae, especially 
resistant strains (Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 1999). 77% of cultures 
were found to be positive and the carriage rate in each centre ranged from 64 - 82% and 
there was no significant difference in carriage among children <2 and >2 years. 43% of 
isolates were found to be non-sensitive to penicillin, though only 1 % were fully 
resistant. Multi drug resistance (resistance to more than three drugs) was found in 11% 
of isolates and as many as 56% were resistant to at least one antibiotic. Carriage of 
resistance was 1.72 times greater in children less than 2 years. Serotypes 6 A, 6 B, 14, 
15, 19F and 23F constituted 6 6 % of all isolates. 23F was the most common strain and
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was resistant to penicillin and trimethoprim-sulphamethoxazole while 19F which was 
susceptible to all antibiotics tested. Each day care centre had a unique pattern of 
pneumococcal clones, by ribotyping and susceptibility patterns and hence was a micro­
environment with unique serotype resistance patterns and genotypic patterns.
1.4.3.2 Hospitals
A recent report from a study of private paediatric wards in Johannesburg described high 
carriage rates (40%) that were significantly associated with prior hospital admission and 
day care attendance. They found 69% of isolates had antibiotic resistance and 37% had 
resistance to multiple antibiotics and 38% had erythromycin resistance. Prior antibiotic 
use was significantly associated with resistance (Huebner, Wasas, & Klugman 2000). 
Outbreaks of antibiotic resistant pneumococci sometimes occur in hospitals because 
there is a population of people in close proximity often with underlying respiratory or 
immunosuppressive disease, all o f which pre-dispose to pneumococcal infection. Due 
to the high consumption of antibiotics in hospitals there is also high selection pressure 
for resistant isolates (Weiss et al.).
1.4.3.3 The influence of climate and weather on carriage and disease
There have long been associations made between climate and disease which, despite the 
buffering effect o f clothing and housing still has a profound effect on human disease. It 
is commonly acknowledged that the more northerly and southerly parts o f the 
hemispheres experience increased upper respiratory tract infections (URTIs) such as the 
common cold and influenza during winter months. Lower respiratory tract infections 
show a similar trend, with a peak of illness in winter. For example, every year in the 
UK for each degree Celsius decrease in average temperature there is an increase in 
deaths by around 8,000 (Alderson M 2003). Over the years, many theories have been 
posed to explain such a trend. Lower respiratory tract infection (LRTI) bacterial disease 
agents, such as S. pneumoniae, are generally thought to be influenced by two 
compounding factors; low temperature and preceding viral disease.
1.4.3.3.a Historical perspective
In the nineteenth century it was commonly believed that exposure to cold weather 
conditions was sufficient to cause the symptoms described as catarrh, which today 
would be described as URTI. It was also believed that coryza, or a runny nose, could 
occur epidemically and that dwellers in the same house or even whole armies could
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succumb together (Eccles 2002;Mackenzie 1884). At the beginning o f the twentieth 
century this theory was changed and it was believed that crowding in stuffy rooms was 
the method by which infections were spread. This crowding was in response to cold 
weather, and the cold itself was thought to have nothing to do with disease. This was 
widely accepted as there was no other competing theory (Eccles 2002).
1.4.3.3.b Temperate versus tropical climates
In tropical climates, although temperature fluctuations may be less pronounced, a 
similar trend of increased URTIs in the colder months has been observed. In 1925 
Rogers observed correlations between low humidity and low temperature with an 
increased fatality rate in Indian prisons, recognising the role of the pneumococcus as a 
disease causative (Rodgers 1925). Cold conditions were described to be a contributing 
factor for pneumococcal disease in the 1930s in Nairobi, Kenya, reviewed by Paul in 
(Paul 1997). This trend, seen in tropical climates has been used to dispel theories that 
temperature is responsible for seasonal fluctuations. However, a convincing study 
conducted in the Virgin Islands in 1931 by Milam et al found evidence that seasonal 
temperature differences were sufficient to explain a cold weather association with 
increased URTIs (Milam & Smillie 1931).
1.4.3.3.C Recent theories explaining the influence of cold weather
More recently, Eccles put forward a plausible argument, backed with scientific 
evidence, reverting back to the old theory of cold air being the main influencing factor 
for acute upper respiratory tract viral infections (Eccles 2002). He postulates that 
lowering temperatures in the winter cool the airway respiratory epithelia, which in turn 
leads to a reduction in local immune respiratory defences such as mucociliary clearance 
and leukocyte phagocytosis. For his evidence, he cites three studies that demonstrate 
that animal and human ciliary clearance is reduced by low temperatures and furthermore 
that in rats the number of macrophages capable of phagocytosis is reduced at low 
temperatures (Baetjer 1967;Diesel, Lebel, & Tucker 1991;McFadden, Jr. et al. 
1985;Salman et al.). Although Eccles cites these data as evidence for an increased risk 
o f acquiring viral URTI, it is likely that the same factors influence bacterial infection in 
the same way, especially in pneumococcal infections since macrophages are at the 
front-line if  the primary immune response.
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1.4.3.3.d Viral infection predisposing to bacterial infection
Viral infection, following the winter trend and influenced by temperature, compounds 
the effect o f bacterial pathogens by damaging lung epithelia, and facilitating the 
progression of bacterial disease. The influence of viral disease and temperature are not 
immediate, and the delay in onset of bacterial infections after the start winter is often 
described as the lag effect (Dowell et al. 2003;Tong et al. 2001).
1.5 Antibiotic resistance
Preliminary observations in the Huruma area suggested that the major drugs being 
prescribed were penicillins and the major drug that was accessible for self directed 
medication was co-trimoxazole due to its low cost, see the introduction to chapter eight. 
For this reason onliy penicillin, co-trimoxazole and macrolides (which are relevant to 
chapter seven) are dliscussed here.
1.5.1 Introduction of specific anti-bacterial chemotherapy and the role of the 
pneumococcus in tihe development of antibiotics
Early attempts at chemotherapy were frequently unsuccessful as the drugs were as likely 
to be toxic to the host as to kill the parasites infecting them. Quinine, which had been 
successfully used to treat malaria, was tried for treatment o f pneumococcal disease 
without success, but a quinine derivative optochin was known to inhibit pneumococci in 
vitro and it was shown to be active in treating mice (Morganroth & Kaufmann 1912). 
However, resistance was discovered to optochin in laboratory animals as early as 1912, 
after which it was found to exhibit high optic toxicity in humans and quickly withdrawn 
from use (Moore & Chesney 1917), reviewed by Hackenbeck in (Hakenbeck et al. 
1999).
Modem chemotherapy owes much to the pioneering work of Erhlich who established a 
number of principles which are fundamental to modem chemotherapeutic practice. He 
first devised the therapeutic index, which is ratio of the dose tolerated by the host to the 
dose that cures the infection. In 1929 Fleming discovered the bactericidal effect of 
penicillin-producing mould which was contaminating bacterial cultures (Fleming 
1929;Perez-Trallero et al. 2001). Penicillin was not used in treatment until Chain and 
Florey were able to produce penicillin on a large scale, reviewed in (Hakenbeck, Grebe, 
Zahner, & Stock 1999;Hakenbeck & Coyette 1998). Widespread use o f penicillin,
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following World War II, reduced the fatality rate from pneumococcal pneumonia from 
30% to 5% (Harwell & Brown 2000).
Although the application o f anti-bacterial chemotherapy is generally considered a 
success, it had a very negative effect on vaccine development, which lost prominence 
dramatically after the introduction of sulphonamides in the 1930s. Although 
pneumococcal mortality overall was dramatically reduced, for some groups it remained 
high: older patients with bacteraemia showed no improvement in prognosis with or 
without therapy (Austrian & Gold 1964). Clinically important antibiotic resistant 
isolates were discovered in the 1960s followed by a surge in interest in vaccines.
1.5.2 Emergence of antibiotic resistance
Resistance to penicillin was first demonstrated in vitro in 1945 by sub-culturing S. 
pneumoniae on media containing increasing concentrations of penicillin (Eriksen 1945). 
The first in vivo non-susceptible organism was isolated in Boston in 1965, but the 
clinical significance was not realised (Kislak et al. 1965). The first report of a clinical 
infection from penicillin non-susceptible S. pneumoniae (PNSSP) came from Australia 
and was reported by The Lancet in 1967 and soon after in Papua New Guinea (Hansman 
1972;Hansman & Bullen 1967). It became commonplace in South Africa in the late 
1970s and the first clinical case of infection with multi-drug resistant pneumococci was 
reported in 1977 (Appelbaum et al. 1977), in Europe in the 1980s and in America in 
1990s (Tomasz A 2000). The increasing use of antibiotics is thought to be the driving 
force for the spread of antibiotic resistance in the community (Guillemot et al. 
1998;Neu 1992).
1.5.3 The spread of drug resistant pneumococci
Clonal isolates of S. pneumoniae that are reported from countries around the world are 
now recognised to carry multi-drug resistance genes and pose a greater threat each year. 
Two determinants for spread within a community are selective pressure and inter­
individual transmission (Soares et al. 1993). Low dose and long duration o f treatment 
are associated with increased risk of resistance carriage for both aminopenicillin and 
cephalosporins (Guillemot, Carbon, Balkau, Geslin, Lecoeur, Vauzelle-Kervroedan, 
Bouvenot, & Eschwege 1998) and horizontal gene transfer from other nasopharyngeal 
isolates e.g. Streptococcus oralis increases the number of resistance genes available to 
S. pneumoniae (Coffey etal. 1991).
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1.5.4 Penicillin
1.5.4.a Mode of action of penicillin
Tipper and Strominger proposed the first theory to explain killing by penicillin in 1965. 
They proposed that penicillin bound to PBPs inhibiting peptidoglycan synthesis and that 
the cells were lysed by osmotic pressure on mechanically weakened walls (Tipper & 
Strominger 1965). However, it is now understood that PBPs interact with penicillins 
enzymatically (Grebe & Hakenbeck 1996). The exact mechanism is still not understood 
but is thought to involve two separate events (Bayles 2000). The interaction at the 
serine active site is via a covalent bond, and the affinity for the beta-lactam is dependent 
on the PBP(Grebe & Hakenbeck 1996). Culture viability is lost shortly after exposure 
to penicillin but lysis occurs only after a distinct lag phase and is thought to be a 
secondary and distinct event, hence why in the absence of murein hydrolases (on which 
lysis is dependent) penicillin is still lethal (Bayles 2000).
1.5.4.b Structure and function of penicillin binding proteins
Penicillin binding proteins are minor membrane components functioning as catalysts in 
the late steps o f murein biosynthesis (Hakenbeck & Coyette 1998). In S. pneumoniae 
there are five high molecular weight PBPs, four of which contribute to resistance. The 
structure of PBP2x has been determined by x-ray crystallography. It consists o f 3 
domains, an N-terminal domain (sugar tongue), a central penicillin binding domain and 
a C-terminal domain which is connected via a 28 residue flexible loop. The penicillin 
binding domain is the active site and is homologous to other PBPs and beta-lactamase 
enzymes, it has three conserved amino acid motifs in a close spatial relationship; 
S337TMK serine active site (found in all PBPs), S394SN (triad) and K547SG (box) 
(Pares et al. 1996). The active site catalyses the transpeptidation o f two muropeptides 
and cross-links them. Beta-lactams bind covalently to the active site serine nucleophile, 
this complex is eventually de-acylated and the p-lactam is de-activated.
1.5.4.C Penicillin resistance
S. pneumoniae has acquired a complex mechanism of resistance to penicillins by 
altering the structure of the penicillin binding proteins (PBPs) so that PBPs from 
resistant isolates have reduced affinity for the drug (Sibold et al. 1994). PBPs are the 
products of mosaic genes; genes that have been remodelled by the transfer sequences 
from related species facilitated by short homologous sequences (Smith et al. 1993a). 
Complex mosaic structures have evolved so that PBP la, 2b and 2x contain regions
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from the corresponding genes o f other related streptococcal species (Dowson, Coffey, & 
Spratt 1994) and can vary by more than 20% between resistant and sensitive strains 
(Sibold, Henrichsen, Konig, Martin, Chalkley, & Hakenbeck 1994). Sibold et al 
showed that genetic exchange was possible between S. pneumoniae, S. oralis and S. 
mitis, all o f which are genetically closely related and are nasopharyngeal carriage 
organisms (Sibold, Henrichsen, Konig, Martin, Chalkley, & Hakenbeck 1994). It is 
thought that these recombination events occur at low frequency (Coffey et al. 
1993;Dowson, Coffey, & Spratt 1994). Mosaic genes in different geographic regions 
have different genetic backgrounds and, because of the exchange o f sequences back and 
forth among naturally transformable streptococcal species, it can be difficult to decipher 
the geographical origins of individual sequences (Dowson, Coffey, & Spratt 
1994;Sibold, Henrichsen, Konig, Martin, Chalkley, & Hakenbeck 1994). Since 
streptococci are naturally sensitive to penicillin, it was not clear where the resistant 
variants originally came from (Sibold, Henrichsen, Konig, Martin, Chalkley, & 
Hakenbeck 1994). Studies on S. pneumoniae have developed our understanding of 
penicillin binding protein mediated resistance (Hakenbeck 1995).
1.5.4.d Mutation of the active site leads to resistance
Mosaic genes encode PBPs with altered active sites that have reduced binding affinity 
to beta-lactams, such that binding can only take place at higher antibiotic 
concentrations. The importance o f certain sites has been demonstrated by PCR studies. 
Nine successive rounds of transformation with PCR induced point mutations, showing 
that several mutations may be required for a substantial decrease in binding affinity and 
that mutation o f sites thr446 in PBP2b and thr550 in PBP2x are especially important as 
they are involved in drug interaction (Grebe & Hakenbeck 1996). PBP2b and PBP2x 
confer primary resistance with PBPla and PBP2a being responsible for higher level 
resistance (Laible et al. 1992).
Rapid emergence of high-level resistance to p-lactam antibiotics has resulted in a need 
for alternative strategies (Farrell et al. 2001).
1.5.4.e Penicillin binding protein 2b
Restriction fragment length polymorphism (RFLP) analysis o f PBP2b transpeptidase 
encoding regions has shown more extensive remodelling o f mosaic genes among 
resistant strains compared to sensitive ones (Smith & Klugman 1995). Sequence
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alterations are seen in isolates with minimum inhibitory concentrations (MICs) greater 
than 0.06|ig/mL but not below. Smith and Klugman described 58 penicillin resistant 
isolates from South Africa with a wide range of MICs (<0.015 to 8 pg/mL), among 
which there were 18 resistant profiles by RFLP analysis, suggesting that PBP2b mosaic 
rearrangements are associated with clinically relevant penicillin resistance (Smith & 
Klugman 1995). They went on to show that changes in the DNA sequence were 
observed in all resistant strains but that changes in the amino acid sequences were only 
seen in isolates with a MIC greater that 0.06pg/mL. An isolate representing one o f each 
o f the 18 different patterns was chosen for nucleotide sequencing and was compared to 
that o f a R6  sensitive strain. An isolate with a MIC of 0.06pg/mL had seven nucleotide 
differences, but these did not translate to changes in the amino acid sequence. The 
remaining 17 strains had a multiplicity of nucleotide difference, translating to up to 38 
amino acid alterations, >50% of the nucleotide substitutions did not alter the amino acid 
sequence (Smith & Klugman 1995).
Smith and Klugman showed that all o f the resistant isolates showed the same diversity 
in the region ±300 bp close to the centre of the transpeptidase encoding region. This 
area is within the locality of two of the three conserved amino acid motifs which are 
common to all penicillin serine transferases (Ghuysen 1991), namely the Ser-X-X-Lys 
tetrad which houses the serine active site and the Ser-X-Asn triad. This area is likely to 
form the penicillin binding site that interacts with the R1 side chain of the penicillin 
(Dowson, Hutchison, & Spratt 1989). It is likely that changes in this area are a strong 
influence on penicillin resistance, at least to an intermediate level, with MICs up to 
0.25pg/mL (Smith & Klugman 1995). Mutations in this area were arranged into five 
profiles, on the basis o f sequence, suggesting that five mosaic recombination pathways 
exist for PBP2b to remodel itself.
1.5.4.f Penicillin binding protein 2x
PBP2x appears to be multi-functional, and the crystal structure shows three domains, 
one o f which corresponds to the transpeptidase domain and the other two are unknown 
(Ghuysen 1994). PBP2x does not have a transglycosylase domain, but it is essential for 
growth (Ghuysen 1991). PBP2x is a primary target for penicillin and is essential for 
high-level penicillin resistance (Hakenbeck, Grebe, Zahner, & Stock 1999;Hakenbeck 
& Coyette 1998;Smith, Klugman, Coffey, & Spratt 1993a). The biochemical properties 
of PBP2x were examined by Zhao et al (Zhao et al.). They created four expression
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constructs to produce soluble forms of PBP2x, both resistant and sensitive, and purified 
them so the molecular mass agreed with the predicted mass from the amino acid 
sequence. Both proteins bound I-labeled penicillin V but did not hydrolyse the 
antibiotic. They went on to show that R(resistant)-PBP2x had a ten fold lower affinity 
for S2d (an analogue of stem peptides used in colorimetric assays as a substrate for 
PBPs) and approximately 30 fold lower activity than S(sensitive)-PBP2x and 
hypothesised that branched peptidoglycan intermediates are the preferred substrate for 
R-PBP2x for cell wall synthesis, but the latter can only be tested if  the branched cell 
peptides are available. The abnormal peptidoglycan structure is thought to be a separate 
phenomenon from resistance, because the same altered (more highly branched) 
peptidoglycan structure is not seen in laboratory-generated mutants, which are slower 
growers and have a lower level of resistance than their natural counterparts. They 
showed that the level of expression of R-PBP2x was not altered from S-PBP2x and that 
resistance does not arise from the overproduction of resistant enzymes, rather than the 
alteration of the structure o f the enzymes. It is also likely that the altered structure of 
peptidoglycan arises from the fact that resistant mutants are able to use the branched 
substrates in the presence of penicillin and that the susceptible enzymes are completely 
inactivated by the drug. These results suggest that if  a drug could be produced with the 
features o f the branched stem peptides as well as penicillin, then the molecule would 
have activity against penicillin sensitive and resistant organisms (Zhao et al. 1997).
1.5.4.g Penicillin bindind protein la
PBPla has been shown to be essential for high-level resistance in S. pneumoniae by 
Smith and Klugman. They transformed susceptible strains with resistant PBP2b and 
PBP2x resulting in transformants with MICs around 0.25pg/mL. When these were 
further transformed with PBPla, they reached MICs of 1.5pg/mL (Smith & Klugman
1998). The penicillin binding domain contains three important conserved sequences: 
STMK3 7 3 , SRN4 3 0  and KTG5 59  and is thought to start ±60 amino acid residues before 
the serine active site and end ±60 residues after the conserved Lys-Thr-Gly motif 
(Smith & Klugman 1998). The penicillin binding domain was sequenced for sensitive 
and resistant strains. Up to seven amino acid alterations were observed in isolates with 
MICs up to 0.25pg/mL but widespread alterations were seen only in isolates for which 
the MICs were >0.25pg/mL, suggesting that 0.25 to 0.5pg/mL represents a breakpoint 
at which mosaic remodelling in PBP 1A begin to play a role in resistance to penicillin 
(Smith & Klugman 1998). In addition they found that as the MIC increased, so did the
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number o f amino acid differences so that for isolates with MICs of 2|ag/mL, the 
sequence divergence from the sensitive R6  strains was 21% resulting in 43 amino acid 
substitutions covering the whole penicillin binding domain (Smith & Klugman 1998). 
Only isolates with high level of resistance had alterations in the region of STMK373 and 
SRN430, and a particularly important substitution was Thr37i to serine or alanine which 
was only seen in isolates with a MIC >2pg/mL. PCR based site directed mutagenesis 
experiments were performed and showed that the mutations at residues 574 to 577 are 
important and were found in all resistant isolates; if the alterations were reversed the 
MIC was significantly lowered. In the presence of these four alterations, mutation of 
Thr371 allowed development of full resistance (Smith & Klugman 1998).
1.5.4.h Collective action of multiple altered PBPs
The final resistance pattern of a clinical isolates is likely to depend on more than one 
PBP being remodelled (Smith, Klugman, Coffey, & Spratt 1993a). A multi-step 
process for resistance emergence was first described by Zighelboim and Tomasz in 
which resistance starts with PBP2x, then 2b and then la. This was confirmed by Smith 
and Klugman when they showed that transformation of R6  strains with PBP2b and 
PBPla and subsequent growth on plates containing 0.03pg/mL penicillin generated low 
level mutants with unaltered penicillin binding proteins PBP2b and PBPla. However, if  
transformation was performed with resistant PBP2x then 2b genes, followed by 
selection on 0.03pg/ml plates, intermediate resistant isolates with altered PBP2b and 
PBP2x were generated with MICs of 0.06pg/mL. High level resistance was only 
achieved by a further transformation experiment with PBPla. Therefore altered PBP2x 
is essential for the transformation of PBP2b, and both of these are required for further 
transformation with 1A (Smith, Klugman, Coffey, & Spratt 1993a).
1.5.4.i Penicillin resistance in the UK
Until recently the UK was considered to have low levels of resistance to penicillin, and 
even in 1990 a study involving 7255 pneumococcal strains reported no penicillin 
resistant pneumococci (Spencer et al. 1990). Since then levels have risen and there have 
been a few hospital outbreaks (Goldsmith, Moore, & Murphy 1997). A study in 
Northern Ireland involving 3171 isolates collected between 1988 and 1995 showed an 
increase o f 0.8% to 10.6%. A study involving 778 isolates collected from public health 
laboratories in the south and west o f England and from Primary Care Centres in the
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north of England between 1996 and 1998 found only 2.2% to be resistant, however, the 
study group was small (Priest et al. 2001).
1.5.5 Co-trimoxazole
1.5.5.a Co-trimoxazole resistance
Soon after the trimethoprim-sulphamethoxazole combination (co-trimoxazole) was 
introduced in the late 1960s resistant organisms were isolated (Howe & Wilson 1972). 
In recent years high levels o f co-trimoxazole resistance have been recorded, especially 
in South Africa, Spain, Hungary and Portugal (Padayachee & Klugman 1999). 
However, the WHO has recommended co-trimoxazole for the treatment o f respiratory 
infections in developing countries due to its low cost (Straus et al. 1998).
In Spain, USA and South Africa, co-trimoxazole resistance varies between 15 and 80% 
and is frequently observed in isolates also resistant to penicillin and with multi-drug 
resistance (Padayachee & Klugman 1999).
1.5.5.b Mode of action of trimethoprim
Trimethoprim selectively inhibits dihydrofolate reductase DHFR, preventing the 
reduction of dihydrofolate to tetrahydrofolate. Trimethoprim can be used to treat 
urinary tract infections, but the synergy from combination with sulphamethoxazole is 
required for pneumococcal infections (Adrian & Klugman 1997).
1.5.5.C Trimethoprim Resistance Mechanism
Until 1997 there had been no published reports on the mechanisms of trimethoprim 
resistance. A study by Adrian and Klugman showed that a single amino acid change 
lie ioo to Leu, in the putative trimethoprim binding site of the DHFR gene is enough to 
transform to a resistant phenotype (Adrian & Klugman 1997). DHFR genes from 11 
clinical strains were amplified by PCR and sequenced. The sequences were dominated 
by two groups, both o f which had six amino acid substitutions in common, and each 
group having other substitutions in addition. Transformation experiments were 
performed with whole DNA, and a successful resistant transformant was produced from 
a truncated DHFR gene. Key mutation points in the gene were narrowed down to one, 
the Ileioo. This mutation being the only one present in all resistant mutants. The Ileioo 
is homologous to Ile94 in E. Coli DHFR which forms Van der Waals forces with the 
pyrimidine ring of trimethoprim (Matthews DA 1985). Cloned PCR products
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containing only the IleiooLeu mutation were introduced into ATCC strain 49619 and a 
MIC 50 fold greater was observed, suggesting that this single mutation is enough to lose 
affinity for trimethoprim but not dihydrofolate in S. pneumoniae. The single mutation 
may explain the rapid emergence of resistance to this drug. Lack of DHFR sequence 
data means it is not known whether other closely related streptococcal species provided 
the gene pool from which interspecies recombination may have taken place (Adrian & 
Klugman 1997).
1.5.5.d Mode of action of sulphamethoxazole
Sulphamethoxazole is a structural analogue for para-amino benzoic acid and binds 
competitively with di-hydropteroate synthase (DHPS). The role of DHPS is to catalyse 
the condensation of para-amino benzoic acid with 7,8 dihydro- 6  hydroxymethyl-7, 8 - 
dihydropterin pyrophosphate to form 7, 8 -dihydropterate, which in turn goes on to form 
tetrahydrofolate. Tetrahydrofolate is an essential metabolite for purines, pyrimidines 
and amino acids which most bacteria synthesise themselves, and interruption o f this 
pathway has been an important target for drug development (Lopez & Lacks 1993).
The pathway for folate synthesis was elucidated by transformation experiments where a 
1 0  kb fragment containing a marker for sulphonamide resistance was expressed on a 
plasmid using S. pneumoniae as a host species. Portions were then expressed in E. coli 
and the function determined (Lopez et al. 1987;Lopez, Greenberg, & Lacks 1990).
DHPS is encoded by the sulA gene, shown to have considerable sequence diversity, and 
produces a 34kDa protein called sulA. SulA is arranged together with sulB, sulC  and 
sulD on a lOkbp chromosomal fragment, and is transcribed as a polycistronic unit 
(Lacks, Greenberg, & Lopez 1995). SulA is called folP  in other species and Haasum 
and co-workers proposed that sulA be changed to folP  for comparison with other species 
(Haasum et al. 2001).
1.5.5.e Sulphamethoxazole Resistance Mechanism
A mutation, sul-d, was identified on the folP  gene as a 6  base pair repeat, o f an adjacent 
segment, resulting in a duplication of two amino acids 966 and 670 and is thought to lie 
in an alpha-helical region (Lopez, Espinosa, Greenberg, & Lacks 1987). Other 
mutations responsible for sulphonamide resistance were found close to, but distinct 
from, sul-d on sulA and were demonstrated to be three or six base pair duplications
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which resulted in the repetition of one or two amino acids between Arg5g and Tyr63 in a 
region of extended or coil formation, in clinical isolates o f serotype 9V (Maskell, 
Sefton, & Hall 1997). These mutations expand the sulphonamide binding site on DHPS 
resulting in a conformational change and loss of affinity for the drug (Padayachee & 
Klugman 1999). The duplications are thought to have limited effect on the kinetics of 
the enzyme and therefore on the fitness of the organism (Haasum, Strom, Wehelie, 
Lima, Roberts, Maskell, Hall, & Swedberg 2001).
However, sulphonamide resistance may be more complicated than this, also involving 
sulB, sulC and sulD. Isolates have been found without folP  mutants but with co- 
trimoxazole resistance. It may be possible that a permeability change is in effect or that 
a thymine auxotrophy conveys resistance (Padayachee & Klugman 1999).
1.5.5.f WHO/UNAIDS initiative to use co-trimoxazole as prophylaxis in HIV/AIDS 
patients
The WHO and UN AIDS has proposed the use of low dose co-trimoxazole for 
prophylaxis against Pneumocystis carnii infections in HIV infected patients in Africa. 
The proposal is to use 480 mg per day or 960 mg three times a week in adults with 
HIV/AIDS WHO clinical stages 2 -  4 or CD4 count <500x 106 /I or an equivalent total 
lymphocyte count and has been shown to be effective. However, concern has been 
raised that this will increase resistance in major pathogens in Africa, where co- 
trimoxazole is still widely used to treat respiratory pathogens due to its low cost (Badri 
etal. 2001).
1.5.6 Macrolides
1.5.6.a Macrolide resistance in S. pneumoniae
Macrolides are useful for treating patients who are allergic to one o f the p-lactams or 
where the infectious agent is known to be resistant to p-lactams due to their efficacy and 
safety (Farrell, Morrissey, Bakker, & Felmingham 2001;Lagrou et al. 2000a). Hence, 
macrolides are now commonly used to treat respiratory infections and are often used as 
first line treatment for adults and increasingly children in North America and Canada 
(Farrell, Morrissey, Bakker, & Felmingham 2001;Hyde et al. 2001) and in children in 
Japan (Farrell, Morrissey, Bakker, & Felmingham 2001;Nishijima et al. 1999).
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Erythromycin was introduced into clinical practice in 1952 (Farrell, Morrissey, Bakker, 
& Felmingham 2001;McGuire et al. 1952). An early report o f Streptococcus 
pneumoniae with increasing erythromycin resistance was reported in 1952 (Farrell, 
Morrissey, Bakker, & Felmingham 2001;Haight & Finland 1952;Perez-Trallero, 
Fernandez-Mazarrasa, Garcia-Rey, Bouza, Aguilar, Garcia-de-Lomas, & Baquero 
2001). Since then macrolide resistance has increased reaching high levels in Spain 
(35%) (Perez-Trallero, Femandez-Mazarrasa, Garcia-Rey, Bouza, Aguilar, Garcia-de- 
Lomas, & Baquero 2001), France (29%) (Geslin et al. 1992), Belgium (31%) (Lagrou et 
al. 2000b), Italy (31%) (Marchese et al. 1999;Oster et al. 1999), and Japan (30%) 
(Nishijima, Saito, Aoki, Toriya, Toyonaga, & Fujii 1999). Among the highest levels of 
macrolide resistance in the world are those in Taiwan where an incidence o f 82% to 
erythromycin was recorded (Hsueh et al. 1999).
1.5.6.b Mechanisms of macrolide resistance
Two macrolide resistant phenotypes have been described. The M phenotype which is 
characterised by resistance to 14 and 15 membered macrolides including erythromycin, 
clarithromycin and azithromycin and the MLSb phenotype which exhibits resistance to 
macrolides, lincosamides and streptogramin group B (Latini et al. 1999). Both 
phenotypes are often associated with resistance to penicillin and other agents and are 
mainly dominated by serotypes 6 A, 6 B, 14, 19F and 23 F (Hyde, Gay, Stephens, Vugia, 
Pass, Johnson, Barrett, Schaffner, Cieslak, Maupin, Zell, Jorgensen, Facklam, & 
Whitney 2001).
1.5.6.C The MLSb phenotype
This confers resistance to the three antibiotics, is common to streptococci and 
enterococci and is determined by the target modification of the 23 s ribosome (Robinson, 
Edwards, Waites, Briles, Crain, & Hollingshead 2001). In S. pneumoniae a ribosomal 
methylase, encoded by the ermB gene, methylates adenine residues on 23 s rRNA’s 
peptidyl transferase centre, domain 5, and causes a conformational change that reduces 
drug binding affinity (Hyde, Gay, Stephens, Vugia, Pass, Johnson, Barrett, Schaffner, 
Cieslak, Maupin, Zell, Jorgensen, Facklam, & Whitney 2001). The MLSb phenotype is 
more common in Europe than the M phenotype. A study in Italy involving 161 
erythromycin resistant strains showed, using pulsed field gel electrophoresis, there to be 
substantial heterogeneity among erythromycin resistant isolates, and hence, are not the 
spread of one or only a few clones (Marchese, Tonoli, Debbia, & Schito 1999). This
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target modification can be expressed in a constitutive or inducible manner 
(Descheemaeker et al. 2000). The ribosome is the binding site common to macrolides, 
lincosamides and streptogramins, thereby conferring cross resistance (Farrell, 
Morrissey, Bakker, & Felmingham 2001;Sutcliffe et al. 1996). The MLSb phenotype is 
associated with high resistance and MICs are typically >64pg/mL (Hyde, Gay, 
Stephens, Vugia, Pass, Johnson, Barrett, Schaffner, Cieslak, Maupin, Zell, Jorgensen, 
Facklam, & Whitney 2001). The ermB gene is carried on transposon Tnl545 along 
with TetM (conferring tetracycline resistance) hence macrolide and tetracycline 
resistance are frequently associated (Marchese, Tonoli, Debbia, & Schito 1999), see 
section 1.5.6.f.
1.5.6.d The M phenotype
The M phenotype confers only macrolide resistance and is determined by an efflux 
pump. The membrane associated pump is a 405 amino acid hydrophobic protein with 
12 trans-membrane spanning regions and no recognisable signal sequence. It is 
encoded by mefE in S. pneumoniae which is 90% homologous to the mefA gene o f S. 
pyogenes (Clancy et al. 1996;Descheemaeker, Chapelle, Lammens, Hauchecome, 
Wijdooghe, Vandamme, Ieven, & Goossens 2000;Sutcliffe, Grebe, Tait-Kamradt, & 
Wondrack 1996;Tait-Kamradt et al. 1997). Tait-Kamradt probed whole S. pneumoniae 
DNA from erythromycin and azithromycin resistant strains susceptible to clindamycin 
and streptogramin Bs with a mefA sequence. The identified fragment was cloned and 
expressed in E. coli, conferring erythromycin resistance. The same genomic DNA was 
then used to transform fully susceptible pneumococcal R6  laboratory strain, which 
became erythromycin resistant. In addition R6  was also transformed with mefE 
disrupted DNA resulting in susceptible transformants, proving that mefE is capable of 
conferring erythromycin resistance (Tait-Kamradt, Clancy, Cronan, Dib-Hajj, 
Wondrack, Yuan, & Sutcliffe 1997). The mefE pump is effective for 14- and 15- 
membered macrolide rings, but not the 16-membered macrolides (Shortridge et al.
1999). Resistance is usually moderate with MICs between 1 and 32pg/mL (Hyde, Gay, 
Stephens, Vugia, Pass, Johnson, Barrett, Schaffner, Cieslak, Maupin, Zell, Jorgensen, 
Facklam, & Whitney 2001). The M phenotype dominates in North America and recent 
studies have found the M phenotype to be increasing and that the MICs of M phenotype 
strains are increasing. Hyde et a l examined 15481 isolates, between 1995 and 1999, 
collected across 8  states of North America which showed an increase in macrolide 
resistance from 10.6% to 20.4%, with a proportional increase in the M phenotype from
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7.4% to 16.5% and that this increase was mainly associated with children younger than 
5 years (Hyde, Gay, Stephens, Vugia, Pass, Johnson, Barrett, Schaffner, Cieslak, 
Maupin, Zell, Jorgensen, Facklam, & Whitney 2001).
1.5.6.e Other reported mechanisms
Other reported mechanisms of resistance are rare; MLSb phenotypes in the absence of 
m ef or erm genes were reported in a study involving 5029 isolates collected between 
1993 and 1996 across all 10 provinces in Canada in which 147 (2.9%) were 
erythromycin resistant (Johnston et al. 1998).
1.5.6.f Macrolide resistance is frequently associated with resistance to other 
antimicrobial agents
Many studies have shown that macrolide resistance is frequently associated with 
resistance to other antibiotics in particular penicillin, trimethoprim / sulphamethoxazole 
and tetracycline (Latini, Ronchetti, Merolla, Merolla, Guglielmi, Bajaksouzian, Villa, 
Jacobs, & Ronchetti 1999) also reviewed in (Garau 2001a). A study in 1997 found 
erythromycin resistance in 3% of penicillin susceptible strains, 16% intermediate 
resistant strains and 57% of resistant strains, among respiratory tract isolates collected 
from 12 out-patent clinics across continental USA (Barry, Fuchs, & Brown 1997). In 
Taiwan erythromycin resistance was found to be heavily associated with penicillin 
resistance; 96.7% of PNSSP isolates were found to have erythromycin resistance 
(Hsueh, Teng, Lee, Yang, Ho, & Luh 1999). These data suggest that the use o f either 
drug will select for resistant isolates, which may be multi-drug resistant.
1.5.6.g The spread of macrolide resistance and the role of multi-drug resistant 
clones
The spread of drug resistant clones is well documented and is a known facilitator for the 
dissemination of resistance from an area of high antibiotic consumption to other 
countries (Ip et al. 1999;Sa-Leao, Tomasz, Sanches, Brito-Avo, Vilhelmsson, 
Kristinsson, & de Lencastre 2000), see section 1.5.10 for a summary o f internationally 
recognised resistant clones. An example of transmission of an erythromycin resistant 
strain from Spain (where macrolides are frequently used) to South Africa (where 
macrolides were not frequently used) was reported by Klugman et al. A variant o f the 
23F Spanish multi-drug resistant clone was isolated from a child in South Africa and 
was shown to be resistant to erythromycin. Questioning o f family members found that
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one family member had travelled to Spain, suggesting that person was a possible route 
for transmission (Klugman et al. 1994).
1.5.6.h The clinical impact of macrolide resistance
It is well known that PNSSP infections (excluding meningitis) can successfully be 
treated with higher doses of penicillin, however, there are reports o f clinical failure with 
macrolides in patients with community acquired pneumonia (Garau 2001b). A study of 
patients with bacteraemic pneumococcal infection was conducted in the USA to assess 
the clinical relevance of macrolide resistance. They found 5/21 (24%) o f patients with 
low level macrolide resistance (M phenotype) were taking macrolides, compared with 
none out of 40 controls (P=0.00157). They also showed that a breakthrough 
bacteraemia during macrolide therapy is more likely to occur among patients infected 
with an erythromycin resistant pneumococcus (Lonks et al. 2002).
1.5.6.i Controlling macrolide use
High resistance levels to macrolides were observed in Finland in the early 1990s. 
Recommendations were issued which called for the reduction o f the use o f macrolides 
in out patients for respiratory and skin infections. There was a significant decline in use 
from 2.4 defined daily doses per 1000 inhabitants in 1991 to 1.38 in 1992, resulting in a 
decline in macrolide resistance in group A streptococci (Seppala et al. 1997).
1.5.6.j Overcoming macrolide resistance: The ketolides
Ketolides are a semi-synthetic derivative of erythromycin and overcome macrolide 
resistant mechanisms in S. pneumoniae, and additionally have improved potency and 
longer post-antibiotic effects while maintaining the broad spectrum of the macrolides 
class. The new ketolides cethromycin and telithromycin are undergoing clinical trials 
and antibacterial properties suggest they will be useful new antibiotics (Nilius & Ma 
2002).
1.5.7 The epidemiology and monitoring of antibiotic resistance
It is now understood that the levels of antibiotic resistance in hospitals has reached very 
high levels in some areas (Gould et al. 2000). Large scale programs are now in place, or 
currently being put into place, to monitor and hopefully control antibiotic resistance, 
such as the Alexander Project in the USA and the European Strategy for Controlling
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Antibiotic Resistance (Gould, MacKenzie, Struelens, & van der Meer 2000). Antibiotic 
resistance is still rising except in a few countries, see section 1.5.7.3.
1.5.7.1 The Alexander Project
The Alexander Project was established in 1992 to monitor the susceptibility of the 
major community acquired lower respiratory tract pathogens to a range o f antibacterial 
drugs. It has revealed increasing resistance in S. pneumoniae isolates, particularly to 
penicillin and macrolide therapy (Adam 2002).
1.5.7.2 European strategy for controlling antibiotic resistance
In 1999 a group of experts met in Nijmegen, Holland, to discuss the formulation o f a 
European strategy for controlling antibiotic resistance. The conclusions were that more 
data needs to be generated before guidelines can be issued and a definitive control 
program begun. However, antibiotic consumption should be reduced without 
compromising patient care, a cost effective surveillance system should be established 
and hygiene should be improved in hospitals. Recently the medical profession has been 
criticised for spending too much time studying antibiotic resistance but not doing 
enough about it and it is thought that about 50% of prescriptions made in the EU are 
inappropriate (Gould, MacKenzie, Struelens, & van der Meer 2000).
1.5.7.3 Successful control strategies
1.5.7.3.a Iceland
In Iceland a reduction of antibiotic consumption has lead to a decrease in the rates of 
penicillin resistant pneumococci (PRP). A reduction of 35% in the use of antibiotics for 
children was seen between 1992 and 1997 and a 5% drop in the incidence of PNSSP 
was seen in two years (Kristinsson K 1999;Kristinsson 1997). This was achieved not by 
an intervention project organised by an official body, but by key opinion leaders using 
the media and medical journals to encourage GPs and parents in the prudent use of 
antibiotics. Antibiotics used for treating viral infections and parents demanding 
antibiotics for the treatment o f upper respiratory tract infections was reduced.
1.5.7.3.b Sweden -The South Swedish Pneumococcal Intervention Program
The most comprehensive strategy worldwide to reduce the spread o f drug resistant 
pneumococci was the “South Swedish Pneumococcal Intervention Program” where a 
state-wide intervention program was established in the state o f Malmohus, South
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Sweden, in 1995, to halt the further spread of PRP. Whenever individuals with a 
clinical infection due to PRP were identified (“index cases”), nasopharyngeal cultures 
were obtained from family members and close contacts to identify asymptomatic 
carriers (“contact cases”). All carriers were followed until two culture-negative 
samples were obtained, however, they were not treated. School children and adults 
carrying PRP were advised to stay at home. Children attending day care centres were 
denied attendance whilst carrying PRP and other children and staff members were also 
screened. The proportion of contact cases decreased from 81% in the first six months o f 
the project to 52% in the last six months, showing an overall decline in carriage and 
disease associated with PRP (Ekdahl et al. 1997;Ekdahl et al. 1998).
1.5.8 Geographic variation in antibiotic susceptibilities
Pneumococcal antibiotic susceptibilities vary greatly between countries. Spain has a 
high consumption of antibiotics and elevated levels of resistance have evoked concern 
(Baquero 1996). Norway has a low consumption with a strong bias towards penicillin, 
and has low levels o f resistance (Lindbaek et al. 1999). In developing countries 
antibiotics are available “over-the-counter” for self-directed medication and much 
resistance is seen in the community rather than in hospitals (Magee JT 20010). Within 
the African continent, antibiotic sensitivity patterns vary between countries, which 
probably reflects a variation in availability of antibiotics. For example in Morocco S. 
pneumoniae are 90.8% sensitive to penicillin and 14.8% resistant to co-trimoxazole 
while on the Ivory coast 77.5% are sensitive to penicillin and 60.5% are resistant to co- 
trimoxazole (Obaro 2000b).
1.5.9 Multiple drug resistance
The clinical importance (treatment failures) of resistance to multiple drugs including 
penicillin was first noted in South Africa in the mid to late 1970s (Jacobs et al. 1978). 
Multiple drug resistance in pneumococci is defined as resistance to three or more 
classes o f antibiotics (Givon-Lavi, Dagan, Fraser, Yagupsky, & Porat 1999).
1.5.10 The association between serotype and antibiotic resistance and the 
importance of clonal spread
Recent papers on serotypes o f pneumococci frequently focus on the spread o f clones, 
often carrying drug or multi-drug resistance. There are 16 important well recognised 
clones, which are being recorded and monitored worldwide, summarised in table 1.4
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(McGee et al. 2001). One important clone is the 23F multi-drug resistant clone that has 
been prevalent in Spain since 1984 (Munoz et al. 1991). It was first isolated in Utah, 
USA in 1985 and is now prevalent in America where the strain was recovered from 
14/72 children carrying pneumococci in a day care centre in North Carolina (Barnes, 
Whittier, Gilligan, Soares, Tomasz, & Henderson 1995). Most resistant strains belong 
to a limited number of, mainly paediatric, serotypes (Givon-Lavi, Dagan, Fraser, 
Yagupsky, & Porat 1999).
Table 1.4: Properties of 16 pneumococcal clones (McGee, McDougal, Zhou, Spratt, 
Tenover, George, Hakenbeck, Hryniewicz, Lefevre, Tomasz, & Klugman 2001). PEN, 
penicillin; CTX, cefotaxime; ERY, erythromycin; CLI, clindamycin; CHL, 
chloramphenicol; TET, tetracycline; SXT, trimethoprim-sulphamethoxazole; CSR, 
Czech Republic.
Clone MIC (pg/ml) of:
PEN CTX ERY CLI CHL TET SXT
Spain23h-1 2 0.5 0.06 0.06 16 32 4/76
Spain513-2 2 1 0 . 1 2 0 . 1 2 16 32 4/76
Spain yv-3 2 1 0 . 1 2 0 . 1 2 2 <0.5 8/152
Tennesse23h-4 0 . 1 2 32 32 0 . 1 2 2 <0.5 4/76
Spainl4-5 2 1 0.06 0 . 1 2 16 32 2/38
Hungary19 A- 6 2 0.5 >32 >32 16 16 2/38
South Africa1 yA-7 0.5 0.5 0.25 0.25 2 <0.5 4/152
South Africa5U- 8 0.5 0.25 0 . 1 2 0 . 1 2 2 <0.5 1/19
Englandl4-9 0.03 0.03 32 0 . 1 2 2 <0.5 0.12/4.2
CSR14-10 8 1 >32 >32 16 32 0.25/4.8
c s r 19A- h 4 1 >32 >32 32 32 4/76
Finland513-12 1 >32 >32 4 32 8/152
South AfficaiyA-13 8 2 > 8 > 8 32 8 8/152
Taiwaniyh-14 2 1 4 0 . 1 2 2 16 4/76
Taiwan231^  15 1 - 2 1 >32 >32 2 16 0.5/9.5
Poland23h-16 8 8 > 8 0.25 16 16 4/76
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1.5.11 Antibiotic resistance in Africa
Antibiotic sensitivity testing in Africa is limited and is frequently done by research 
projects rather then routine surveillance. Studies performed frequently report high 
levels of resistance, especially to older antibiotics which are cheap such as penicillin 
and co-trimoxazole: in Kenya a study found 56.7% of pneumococcal strains from adults 
were non-susceptable to penicillin (Kariuki, Muyodi & Mirza 2003), in Malawi a study 
found 46% of pneumococci were non-susceptable to co-trimoxazole and 21% to 
penicillin (Feikin, Davis & Nwanyanwu 2003), in Uganda a study found 83.5% of 
isolates were non-susceptible to pencillin and 83% to co-trimoxazole (Joloba, 
Bajaksouzian and Palvecino 2001).
1.6 Vaccines past and present
1.6.1 History of pneumococcal vaccines
The initial impetus for developing a pneumococcal vaccine was driven by the high 
morbidity and mortality due to pneumococcal infections among workers o f the gold and 
diamond mining industry in South Africa in the early 1900s. Among immigrant mine 
workers 8 / 1 0 0 0 /month were ill with respiratory disease resulting in 2 / 1 0 0 0  deaths per 
month. S. pneumoniae was isolated in workers who had died (Brodie, Rogers, & 
Hamilton 1899), and pneumococcal disease was thought to be so common as to pose a 
threat to the mining industry, reviewed by Austrian (Austrian 1977). In response, in 
1911 Wright, inventor of the typhoid vaccine, was invited to South Africa to tackle the 
problem and he established trials of the first pneumococcal vaccine. He made a crude 
vaccine from heat-killed pneumococci, without consideration o f either serotype or 
dosage, despite a publication describing different pneumococcal types one year 
previously (Neufeld & Handel 1910). He established six mass inoculation experiments 
involving over 50 000 people and although the vaccine was pronounced a success, there 
was no supporting evidence. Lister, Wright’s protege, was enlisted by Wright to 
continue the work and established, independently of investigations in the USA and 
elsewhere, that immune response was serotype specific and that pneumonia was caused 
by a multiplicity of serotypes. He demonstrated type specific immunity in mice and that 
one billion heat-killed pneumococci were necessary to achieve an immune response in 
man (Lister 1916). Lister developed an early vaccine which was never put into general 
use, reviewed by Austrian (Austrian 1977). In 1930 Tillet and Francis found that 
purified polysaccharide induced specific antibodies in humans. Felton showed type 
specific disease protection for purified type 1 and 2  polysaccharide and clinical trials
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went underway. The required dosages for polysaccharide vaccines were worked out by 
Macleod, Hodges and Heidelberger (Macleod, Hodges, & Heidelberger 1943). In 1946 
a hexa-valent vaccine was produced but widely available antibiotics lead to decreased 
interest in vaccines. In 1964 Austrian and Gold demonstrated that even in patients 
treated with antibiotics mortality remained high, which rekindled interest in developing 
pneumococcal vaccines. In 1977 the 14-valent polysaccharide vaccine was licensed and 
then the 23-valent vaccine was licensed in 1983 (Robbins, Austrian, Lee, Rastogi, 
Schiffman, Henrichsen, Makela, Broome, Facklam, Tiesjema, & . 1983). Recently 
other strategies have been investigated including protein -  polysaccharide and protein 
only vaccines.
1.6.2 Polysaccharide vaccines
1.6.2.a 14-valent vaccine
A 14-valent vaccine containing 50pg/ml of each purified capsular polysaccharide was 
developed and licensed for use in the United States in 1977. The types included were 
responsible for around 70 -  80% of episodes of bacteraemia or meningitis in the US, 
parts o f Europe and South Africa. Limited immunochemical information available at 
the time was also considered (Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, 
Makela, Broome, Facklam, Tiesjema, & . 1983). Following the license of the vaccine, a 
pneumococcal surveillance system was established in the US by the Centre for Disease 
Control, Atlanta, Georgia, to monitor the effect of the vaccine. At a similar time the 
World Health Organisation (WHO) organised laboratories on a global basis to collect 
and identify pneumococci from blood and CSF and other internal body fluids.
1.6.2.b. Consideration for a second-generation vaccine: 23-valent
Results from the WHO directed surveys and additional studies, which included data 
from Argentina, Brazil, Canada, Columbia, Israel, Japan, Senegal, Papua New Guinea, 
Peru and Uruguay, were considered along with data from the UK, USA and South 
Africa, for the second-generation polysaccharide vaccine. No data from African 
countries, where the burden of disease is very high, was considered. Priority was given 
to some paediatric serotypes, although it was still not known that polysaccharides 
produced limited immunity in children (Robinson, Edwards, Waites, Briles, Crain, & 
Hollingshead 2001).
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It was not known at the time whether purified capsular polysaccharide would cross react 
with antibodies, i.e. if  6 A polysaccharide stimulated antibodies would react with 6 B and 
vice versa, in the same way that closely related whole isolates do with rabbit sera. 
Finland and Ruegsegger observed a greater cross-reaction for convalescent phase sera 
from patients, than in volunteers vaccinated with purified polysaccharide (Finland & 
Ruegsegger 1935;Ruegsegger & Finland 1935). Many studies were conducted to 
measure the generation of antibodies following injection of polysaccharide in different 
combinations e.g. Robbins et al (Robbins et al. 1979). In the late 1970s factor sera was 
new and available to relatively few European countries and the US, consequently 
epidemiological data concerning sub-types was limited. After the release of the 
vaccine, factor sera (sera specific for a sub-type such as 6 A) became more widely used 
and epidemiological data was more detailed in relation to sub-types. More information 
was becoming available regarding the stability of purified polysaccharide e.g. 6 A being 
more stable than 6 B. A new vaccine formula was devised taking the above criteria and 
epidemiological data into account.
Table 1.5: Serotypes included in the 14- and 23-valent polysaccharide vaccines (Butler, 
Shapiro, & Carlone 1999;Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, 
Makela, Broome, Facklam, Tiesjema, & . 1983).
14-valent vaccine 1, 2, 3 ,4 , 5, 6 A, 7F, 8 , 9N, 12F, 14, 19F, 23F and 25F
23-valent vaccine 1, 2, 3, 4, 5, 6 B, 7F, 8 , 9N, 9V, 10A, 11 A, 12F,14, 15B, 
17F,18C, 19A, 19F, 20, 22F, 23F and 33F
1.6.2.C Clinical efficacy
The effectiveness of other bacterial polysaccharide vaccines had been directly related to 
formation o f serum bactericidal antibodies. The “protective” level o f antibodies to 
pneumococcal polysaccharides, correlating to opsonisation in vitro, has been shown to 
be 100-300ng of antibody N to capsular polysaccharide per mL depending on the 
polysaccharide type (Gardner et al. 1982;Simberkoff et al. 1980). This response is age 
related, and under two years, children respond poorly to types 6 A, 14, 19F and 23F 
(Austrian 1981b;Makela et al. 1980) yet type 3 induces a good response in around 80% 
of infants and children. Detection of antibody levels in adult vaccinates, who develop 
bacteraemia, show that 100 -  300 N/mL (depending on the individual) will be 
protective (Robbins, Austrian, Lee, Rastogi, Schiffman, Henrichsen, Makela, Broome, 
Facklam, Tiesjema, & . 1983).
85
Introduction
1.6.2.d Problems of dosage
When considering dosage for the 14- and 23-valent vaccine, the amount of 
polysaccharide required for the stimulation of a protective level o f antibodies must be 
weighed up against discomfort and / or pain and swelling at the site o f injection. The 
14- and 23-valent vaccine dosages were based on dose data at the time. 50pg of each 
polysaccharide was used in the 14-valent vaccine, which was reduced to 25pg for the 
23-valent vaccine because data suggested that there was only slight difference in post 
immunisation levels of antibodies in volunteers who received 25pg rather than 50pg, 
and this had little or no impact on the efficacy of the vaccine (Robbins, Austrian, Lee, 
Rastogi, Schiffman, Henrichsen, Makela, Broome, Facklam, Tiesjema, & . 1983).
1.6.3 Protein only vaccine
The impetus for developing a protein vaccine is derived from known and potential 
limitations o f polysaccharide and conjugate vaccines, see section 1.6.4. A protein 
vaccine would protect against all serotypes since the targeted protein would be present 
in all serotypes, whereas the polysaccharide and conjugate vaccine only protect against 
vaccine serotypes. Protein and conjugated vaccines are known to offer some protection 
against carriage as well as invasive disease. Protection against carriage leads to a 
phenomenon called herd immunity. Herd immunity is the protection o f non-vaccinated 
individuals by removing exposure through vaccination of other individuals. Since new 
strains are generally acquired from carriers rather than those with invasive disease, 
immunising against carriage protects vaccinees and non-vaccinees. Protein and 
conjugate vaccines are both immunogenic in children (Briles et al. 2000a). In addition 
the conjugate vaccine is likely to be too expensive for widespread use in developing 
countries, and a protein vaccine may offer a cheaper alternative (Briles et a l 2000b).
Three proteins have been investigated for their potential use as vaccine candidates, 
pneumolysin, PsaA and PspA, however, only PspA has undergone phase I/II clinical 
trials (Klein DL 2000).
1.6.3.a Protection against carriage
One study details the experimental vaccination of mice with three purified proteins, 
PsaA, PspA and PdB (truncated pneumolysin) followed by challenge with strains 
known to colonise but not cause invasive disease in mice. Mice were immunised with 
0.5pg PsaA, 0.5pg PspA or lOpg PdB. After challenge nasal washes were enumerated
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by plating and culture and antibody levels determined using immunoglobulin serum. 
All three immunogens elicited antibodies in serum and saliva with PsaA giving the 
highest titre and PspA the second highest. Immunisation with PspA reduced carriage 
after challenge with only one out of two strains, but PsaA protected against challenge 
with both strains with a 1 0  and 1 0 0  fold decrease in carriage compared with controls. 
Combination of PsaA and PspA offered the greatest protection, but combination with 
PdB did not increase protection from PsaA or PspA alone. The fact that PdB did not 
protect against carriage when it is known to protect against invasive disease is thought 
to be due to the different environment of the nose compared with the lung, which is 
consistent with pneumolysin knock strains being able to colonise mice as effectively as 
wild type strains. If PsaA and PspA were added to a vaccine they might improve the 
vaccines’ ability to confer herd immunity (Briles et a l 2000b).
1.6.4 Polysaccharide -  protein conjugate vaccines
The most current approach to vaccination against an encapsulated bacterium is to 
present the carbohydrate molecule as a protein-polysaccharide conjugate, which makes 
the polysaccharide more immunogenic; the antigen acquires the immunogenic nature of 
its carrier and becomes T cell dependent. A seven-valent pneumococcal conjugate 
vaccine has been licensed in the United States for use among children under nine years 
(Prevnar; Wyeth Lederle Vaccines), see table 1.6, and is recommended for routine use 
in children under two years (O'Brien et al. 2000). The effect of this, and other conjugate 
pneumococcal vaccines on carriage and disease of pneumococci is under intense 
investigation (Klein DL 2000). Table 1.6 summarises pneumococcal conjugate 
vaccines.
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Table 1.6: Current protein-conjugate vaccines under development and in use. Wyeth 
Lederle vaccines currently being used in the United States are highlighted (Klein DL 
2000).
Manufacturer Protein Carrier Vaccine serotypes
Pasteur/ Merieux/ 
Connaught
Tetanus and 
diphtheria toxoid
1, 3, 4, 5, 6 B, 7F, 9V, 14, 18C, 19F and 23F
Wyeth/ Lederle CRM 197 7-valent: 4 ,6B, 9V, 1 4 ,18C, 19F and 23F 
9-valent: 1 ,4 ,5 , 6B, 9V, 14 ,18C, 19F, 23F
11-valent: 1, 3, 4, 5, 6 B, 7F, 9V, 14, 18C, 
19F and 23F
Merk Research 
Laboratories
OMP- 
meningococcus B
4, 6 B, 14, 19F, 23F
SmithKlein Non-typeable H. 4-valent: 6 B, 14, 19F and 23F
Beecham influenzae OMP 11-valent: 1, 3, 4, 5, 6 B, 7F, 9V, 12, 18C, 
19F and 23F
1.6.4.a Effect of pneumococcal conjugate vaccine
Several studies, using different vaccines, have demonstrated that conjugate vaccines 
reduced the rate of nasopharyngeal carriage of vaccine serotypes in Israel, The Gambia, 
South Africa, Iceland and the USA (Dagan et al. 2002;Mbelle et al. 1999;Obaro et al. 
1996). The following study performed in Israel included 262 healthy children attending 
a day care centre and was large enough to demonstrate type specific protection (Dagan, 
Givon-Lavi, Zamir, Sikuler-Cohen, Guy, Janco, Yagupsky, & Fraser 2002). 132
children received the pneumococcal conjugate vaccine and 130 received the control. 
The 9-conjugate vaccine contained 2|ng of serotypes 1, 4, 5, 9V, 14, 18C, 19F and 23F 
and 4jag of serotype 6 B coupled to diphtheria toxin CRM197 and presented as a 
lyophilised preparation provided by Wyeth Lederle Vaccines. The control vaccine 
included lOpg meningococcal group C carbohydrate coupled to diphtheria toxin 
CRM197 (WLV). Children aged 12-17 months at the time of enrolment received two 
doses, 2 - 3  months apart and those aged 1 8 - 3 5  months received a single dose 
(intramuscular). Follow ups took place over two years. The first nasopharyngeal swab 
was taken > 1  month after complete immunisation and every month for one year, and 
then every 2 months for a further year. Significant protection was seen for serotypes 
6 B, 9V, 14 and 23F, but not 19F (which is the poorest immunogen in the group). Cross 
protection was seen for 6 A in particular among subjects less than 36 months, but not for
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19A. The carriage rate of non-vaccine serotypes was higher among those who received 
the vaccine than control subjects, in addition, in the vaccine group there was an increase 
in the carriage of related types to the vaccine types e.g. group 18 that were not type 18C. 
Significantly fewer children from the vaccine group acquired new vaccine-type strains 
and significantly more acquired non-vaccine type strains (excluding 6 A). The mean 
duration o f carriage did not differ. This is the first study to be large enough to 
demonstrate individual protection against four serotypes and there was no evidence that 
the vaccine failed to protect against vaccine serotypes, although protection against 19F 
was weak. There is not enough data in the literature to suggest whether cross protection 
in other serogroups should be expected (Dagan, Givon-Lavi, Zamir, Sikuler-Cohen, 
Guy, Janco, Yagupsky, & Fraser 2002).
1.6.4.b Serotype replacement
Conjugate vaccines protect against carriage and invasive disease (polysaccharide 
vaccines do not protect against carriage) (Douglas et al. 1986). Protection against 
carriage leads to a phenomenon called herd immunity where non-vaccinated individuals 
are protected by vaccinated contacts being free of carriage isolates. However, there is 
much concern that population wide reduction in carriage of S. pneumoniae will open up 
an ecological niche for other serotypes and a temporary reduction in carriage will be 
replaced by new serotypes and no long-term reduction. Several studies have shown 
antagonism between different species of streptococci colonising the nasopharynx and it 
is thought that competition between bacteria plays a role in the regulation of 
nasopharyngeal colonisation (Lipsitch 1997;Lipsitch et al. 2000). Studies in Papua New 
Guinea showed that colonisation with multiple serotypes is less frequent in areas where 
there are fewer serotypes in circulation (Gratten et al. 1989;Smith et al. 1993b) and 
competition experiments in mice have suggested that there is a biological mechanism to 
explain serotype replacement (Lipsitch, Dykes, Johnson, Ades, King, Briles, & Carlone 
2000). Mathematical models have been proposed to predict the effect o f serotype 
specific vaccines and suggest that such vaccines will increase the prevalence of 
serotypes excluded from the vaccine that compete with vaccine serotypes and may 
include novel serotypes which were previously unable to compete (Lipsitch 1997).
Preliminary studies offer conflicting evidence for serotype replacement, with clear 
evidence from the Gambia of serotype replacement (Obaro, Adegbola, Banya, & 
Greenwood 1996) but no evidence in Israel (Dagan et al. 1996). Clearly more research
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is needed and the use of conjugate vaccines must be monitored. Even though 
significant serotype replacement may be seen, it is likely that replacement will be with 
less common types and therefore those that do not usually harbour drug resistance. This 
alone will have a positive impact on the mortality attributable to the organism, be it only 
temporarily. There is little evidence of serotype replacement following the Hib vaccine, 
but the virulent strain of Haemophilus influenzae is less frequently carried, especially in 
developed countries and optimism from this may not be warranted when considering 
other bacterial species (Lipsitch 1997).
1.7 The work in this Thesis
A community wide distribution of azithromycin for the treatment of trachoma (a 
blinding infectious eye disease) was established by collaboration between Pfizer Inc. 
and the London School of Hygiene and Tropical Medicine. The work in this thesis 
originated and was funded by an extension of collaboration to include a monitoring of 
the affect o f the treatment with azithromycin on induction or selection of macrolide 
resistant in S. pneumoniae. This was conducted by the Department o f Medical 
Microbiology o f The Royal Free and University College medical School, University 
College London which is detailed in chapter seven. For a description o f the trachoma 
control program see section 7.1.11.
1.7.1 Chapter Three
A quantitative evaluation of two transport and storage media for use in field studies of 
carriage o f S. pneumoniae was performed. Two media are discussed, STGG (containing 
skimmed milk, tryptone soya broth, glucose and glycerol) which has been published and 
used in field studies, but has not been quantitatively evaluated, and SGG which is a 
modification of STGG. Different serotypes were analysed to confirm that there is no 
bias entering studies as a result of the transport and storage medium. Both media were 
found to be suitable for transport and long-term storage. SGG media was used to 
collect samples for chapter seven.
1.7.2 Chapter Four
Chapter four evaluates and modifies for use on clinical specimens a technique for 
predicting serotype using PCR and RFLP that was described by Lawrence et al 2000 
(Lawrence et al. 2000).
90
Introduction
1.7.3 Chapter Five
Chapter five describes the design of a long-range PCR method to amplify the 
capsulation locus and an RFLP digestion, which is capable o f distinguishing serotypes 
(including sub-types), and is the first reported molecular technique capable o f  
discrimination to serotype specific level.
1.7.4 Chapter Six
Evaluation o f the PCR based method described in chapter five shows the method to be 
capable of serotyping pneumococci. Amplimers were produced from strains not 
contained in the 23-valent vaccine and isolates was serotyped which had produced an 
equivocal result using typing sera.
1.7.5 Chapter Seven
A cross-sectional and longitudinal field study in Northern Tanzania was performed to 
investigate the effect of community wide distribution of azithromycin, to treat trachoma, 
on macrolide resistance in S. pneumoniae. A previous study (Leach et al. 1997) 
describes an increase in macrolide resistance following a community wide distribution 
o f azithromycin among an Aboriginal community in the Northern Territory of Australia. 
It was important to test the conclusion of this study in a different population, and on a 
larger scale. The study in Australia sampled 80 children initially, 46 o f which were 
repeatedly sampled, whereas the study presented in this thesis involved the collection 
and processing of -3700 nasopharyngeal swabs collected over three sampling periods. 
The study in Australia also found background resistance, whereas our study did not. 
The outcome o f this study differed from the previous findings in that no significant 
increase in macrolide resistance was observed.
1.7.6 Chapter Eight
Chapter eight examines the nasopharyngeal carriage isolates. Antibiotic sensitivity 
testing was performed for all isolates with penicillin and co-trimoxazole. The 
community under investigation is rural and is served by only one hospital, so many 
people will not visit primary health care providers if  they can buy antibiotics over-the- 
counter. Since co-trimoxazole is the cheapest o f the over-the-counter drugs, it is likely 
to be the most frequently used (Stronge 2002). Only penicillin and co-trimoxazole were 
investigated (in addition to erythromycin in chapter seven), on the basis that other 
available drugs e.g. tetracycline would not frequently be used in the community, see
91
Introduction
section 8.1.1 for drugs locally available. The relationship between drug resistance and 
serotype was examined. Penicillin and co-trimoxazole were found to be significantly 
associated and co-trimoxazole resistance was much more common, reflecting 
availability to the drug.
1.7.7 Chapter Nine
An evaluation o f PBP2b and PBP2x genes, using a simplified PCR and RFLP 
technique, was performed on the penicillin non-susceptible isolates from Tanzania. A 
polymictic population was revealed and patterns were not found to be strongly 
associated with either MIC or serotype. Sensitive patterns revealed by Gillespie et al. 
were found in intermediately resistant strains, demonstrating that there are not just a few 
patterns representing eiither sensitive or resistant strains (Gillespie et al. 1997).
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Chapter Two
General Materials and Methods
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2.1 Tanzania
2.1.1 Ethical Approval
Approval for this study was obtained from the Ethics committee o f the Kilimanjaro 
Christian Medical College, Moshi, and the Tanzanian National Institute o f Medical 
Research. In addition consultation was undertaken with Balozi (village) leaders from 
the study villages prior to the study. The Balozi leaders were in agreement with all 
protocols and with their blessing village people were very co-operative. Informed 
consent was obtained from parents or carers before samples were taken, in the form of 
signatures or fingerprints on a consent form printed in English and Kiswahili.
2.1.2 Throat Swabs from Tanzania
Throat swabs were taken from children under 7 years in the Huruma community before 
azithromycin distribution and these will be referred to as baseline samples. Throat 
swabs were again taken at two months and six months afterwards. Samples were taken 
from random houses within the villages and every child in the household present that 
day was sampled. All children had received a single dose of oral azithromycin. 
Children older than 7 years were occasionally sampled, as were some adults, if  it 
facilitated the swabbing o f younger children.
The sampling was performed by three teams who took between 300 and 400 swabs per 
day over five days. The name and date of birth was recorded for each child on the 
consent form. Frequently the exact date of birth was not known, so it was recorded as 
January 1st o f the appropriate year. For some children no date o f birth was recorded.
2.1.3 Sample Numbering
Each child was given a demographic number, the first two digits represents the Balozi, 
the second two digits the house number, and the decimal place representing the child 
beginning with the eldest. Hence 8802.2 represents balozi 8 8 , house number 02 and the 
second eldest child.
2.1.4 Collection and Handling of Specimens
Throat swabs were touched onto the back of the oropharynx and then immediately 
dipped into 5mL SGG media in bijoux bottles. SGG media was used instead of the 
charcoal transport media supplied with the throat swab, because it obviates the need for 
culture before freezing, see chapter three. Two lmL aliquots for each specimen were
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archived at -70°C in the laboratory at KCMC in 1.8mL cryo tubes (Nunc, supplied by 
Fisher Scientific, Leicestershire, UK). One aliquot for transportation back to the UK 
and one as a back up (remaining in Tanzania). Samples were transported back to the 
UK, frozen on dry ice as hand luggage, about six months later.
2.2 Preparation of culture / transport media, UK
Unless stated otherwise all reagents used were purchased from Sigma (Poole, UK), all 
media, including ready prepared media, from Oxoid (Hampshire, UK), blood from E&O 
Laboratories (Paisley, UK) and ethanol (absolute alcohol) from the Royal Free Hospital 
pharmacy.
2.2.1 Brain Heart Infusion -  BHI
37g BHI was dissolved in 1 litre of distilled water and autoclaved at 121°C, 15psi for 15 
minutes (BMM Western). The media was stored at room temperature.
2.2.2 Blood Agar -  BA
Ready prepared blood agar plates were used.
2.2.3 Gentamicin Blood Agar -  GBA
37g Columbia agar was dissolved in 1L distilled water and autoclaved. The media was 
equilibrated to 50°C in a water bath. 50mL defibrinated sheep blood (E&O 
Laboratories, Stirlingshire, UK) was added. 5pg gentamicin sulphate was dissolved in 
lmL sterile distilled water and added to the media. 20mL liquid media was then poured 
into sterile disposable Petri dishes (Sterilin, supplied by Western Laboratory Services, 
Hampshire, UK). Plates were cooled and stored at 4°C. Plates were dried at 37°C for 
30 minutes, or until no condensation was seen, before use.
2.2.4 Meuller Hinton -  MH
38g o f Meuller Hinton was dissolved in 1L distilled water and autoclaved. The media 
was equilibrated to 50°C in a water bath and 50mL defibrinated sheep blood (E&O 
Laboratories, Stirlingshire, UK) was added. 20mL liquid media was then poured into 
sterile disposable petri dishes (Sterilin, supplied by Western Laboratory Services). 
Plates were cooled and stored at 4°C. Plates were dried at 37°C for 30 minutes, or until 
no condensation was seen, before use. Plates were prepared in accordance with NCCLS 
specifications (1997).
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2.2.5 Skimmed milk glucose glycerol broth media -  SGG (Tanzania)
2g skimmed milk, 0.5g glucose and lOmL glycerol were mixed together with 90mL 
distilled water and dispensed into lmL aliquots in cryo tubes with internal threads 
(Nunc, supplied by Fisher Scientific, Leicestershire, UK) and autoclaved for 10 minutes 
at 121°C using a bench top autoclave (Tanzania). In the UK SGG was sterilised by 
Tindalization, see section 3.2.2. Prepared media was stored at 4°C.
2.3 Preparation of Buffers and solutions
2.3.1 EDTA (0.5M)
18.6g EDTA disodium salt was dissolved in 80mL distilled water and adjusted to pH 
8.0 (with NaOH) and then the volume adjusted to lOOmL.
2.3.2 Tris-Borate EDTA buffer (TBE)
5 X TBE solution contained 0.446M Tris base (Promega, Hampshire, UK), 0.28M boric 
acid (BDH, Leicestershire, UK), 0.01M EDTA (pH 8.0) and the volume adjusted to 1L 
with sterile distilled water. A magnetic stirrer and flea was used until the buffer 
appeared clear, the pH was not adjusted.
2.3.3 Tris EDTA Sucrose buffer (TES)
TES solution contained 1M Tris base (Promega, Hampshire, UK), 1.09M EDTA, 35% 
sucrose, adjusted to pH8.0 (with NaOH) and made up to 1L with sterile distilled water.
2.2.4 RNAse
lOpg/mL stock solution was prepared by dissolving 100pg RNAse in lOmL sterile 
distilled water. lmL aliquots were stored at -20°C.
2.25 Proteinase K
20pg/mL stock solution was prepared by dissolving 200pg proteinase K in lOmLs 
sterile distilled water. 1ml aliquots were stored at -20°C.
2.2.6 Lysozyme
lOpg/mL lysozyme solution was prepared by dissolving 200pg lysozyme in 20mL 
sterile distilled water. lmL aliquots were stored at -20°C.
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2.2.7 Bile
10% bile was prepared by dissolving lg  deoxycholic acid in lOmL sterile distilled 
water. Solution was stored at room temperature.
2.3 Isolation of Streptococcus pneumoniae
SGG media, containing throat swab inoculations, was streaked onto Columbia agar 
plates containing gentamicin (5mg/L). Sub-culturing of the specimen was performed 
without defrosting. The tubes of SGG were kept on ice and frozen SGG was scraped 
from the top of the sample using a blue plastic 10pL loop, (Nunc, supplied by Fisher 
Scientific, Leicestershire, UK) and spread over half of the plate. Plates were incubated 
in 5% CO2 incubator, over night at 37°C. Colonies with alpha-haemolysis and typical 
morphology were sub-cultured onto blood agar plates with optochin discs (Oxoid, 
Hampshire, UK) and incubated. Optochin sensitive isolates were sub-cultured to obtain 
pure growth, harvested and frozen in duplicate in STGG at -70°C. Suspected optochin 
resistant pneumococcal blood agar cultures were spotted with 1 0 % bile and incubated 
for 10 minutes at 37°C. No optochin resistant strains were found.
2.4 Antibiotic Sensitivity Testing
Minimum Inhibitory Concentrations (MIC) tests were performed using E-test strips 
(supplied by Cambridge Diagnostics, Cambridge, UK) following the manufacturers 
guidelines, in accordance with NCCLS specifications. 1 MacFarland standard S. 
pneumoniae suspensions 0.9% saline (Oxoid Hampshire, UK) water were prepared. 
Immediately a sterile cotton wool bud was dipped into the suspension and excess fluid 
removed. This was then used to spread S. pneumoniae in three directions onto a 
Mueller-Hinton agar plate with 5% defibrinated sheep blood (E&O Laboratories, 
Stirlingshire, UK). The E-test strip was added, holding the strip end only with a gloved 
hand, and ensuring no air bubbles remained under the strip. The plates were incubated 
at 37°C in 5% CO2 overnight to obtain confluent growth. The MIC reading was taken 
using a magnification glass (hand held) and recorded as the doubling dilution value 
against or just above the point at which growth was inhibited. A positive control was 
included for each antibiotic for every experiment performed using S. pneumoniae 
ATCC strain 49619. All of the MIC and serotype data was entered into an EXCEL 
(Microsoft, California, USA) spread sheet with a column for each dataset and a separate 
sheet for each collection period. Data was entered into this spreadsheet each day as the 
work was completed.
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2.5 Serotyping Using Anti-sera -  Slide Agglutination
The “pneumo-test” kit (Statens Serum Institut, Copenhagen, Denmark) was used for 
serotyping. The kit only includes the serogroups or serotypes contained in the 23-valent 
polyvalent polysaccharide vaccine.
Isolates were grown overnight at 37°C in lOmL BHI broth in conical based test tubes 
(Western Laboratory Services, Hampshire, UK). The cultures were spun at 2,000 rpm 
for 1 0  minutes and the supernatant was removed leaving only a few drops, into which, 
the cells were then re-suspended using a disposable Pasteur-pipette (Western Laboratory 
Services, Hampshire, UK). 5pL of the culture was spotted four times onto a plain glass 
slide. lpL of the anti-sera was added to each spot and mixed using the Gilson tip end. 
The slide was held up to an electric angle poise lamp and a positive reaction was 
observed when agglutination could be seen. Sometimes it was necessary to add a 
second lpL of the serum to see a clear reaction, an eye-glass was also used when 
reactions were not very strong. The order in which the pooled antisera was applied is as 
follows: the most common pools are applied first, these being A, B, D and H; if  no 
agglutination is seen the process is repeated with pooled sera C, E, F, G. When a 
reaction was recorded the process was repeated with the cross-reacting sera, P, Q, R, S 
and T. For example, if  B reacted then P, Q, R and S were tested. With two positive 
reactions the serogroup could be recorded. Table 2.1 shows the “chess board” 
combination of reactions (Sorensen 1993).
Table 2.1: “Chess board” representing cross reaction of pooled pneumococcal antisera.
A B C D E F G H
p 1 19 7 14
Q 18 6 23
R 4 3 9 1 2
S 5 8 1 0 17 15
T 2 2 0 1 1 33 2 2
If no reaction was seen with any sera, the organism could either be a serotype not 
included in the 23-polyvalent vaccine or non-typeable. Some isolates react with all 
pooled sera and are classed non-typeable. All isolates that could not be typed were 
recorded as not-typed, as they were not necessarily non-tyeable.
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2.6 Techniques for molecular biology
2.6.1 DNA Extraction -  Crude
Cells were harvested from an overnight blood agar culture using a sterile loop and 
transferred into lOOpL sterile distilled water. Tubes were heated to 95°C for five 
minutes and then centrifuged at 13000 rpm for five minutes. A Vio dilution was made 
in sterile distilled waster. Extracts were stored for no longer than 48 hours at 4°C.
2.6.2 DNA Extraction -  Phenol chloroform / chloroform
20mL BHI was inoculated with S. pneumoniae from an overnight blood agar culture. 
BHI was incubated overnight at 37°C. Cultures were centrifuged at 4000g for five 
minutes and cells transferred to 1.5mL microfuge (Eppendorf, spplied by Western 
Laboratory Services, Hampshire, UK) tubes. Cells were washed in 0.5mL TES and 
resuspended in 0.5mls TES with 1% deoxycholic acid. Tubes were incubated at 37°C 
until lysis occurred, this was detected when the suspension turned gelatinous. The 
suspension was incubated with lOpg Rnase for 10 minutes at 37°C and then with 20pg 
proteinase K for a further 10 minutes. An equal volume of phenol chloroform (BDH, 
Poole, UK) was added and mixed by shaking, tubes were centrifuged at 13000g for five 
minutes and the supernatant (containing DNA) was transferred to a fresh tube. An 
equal volume of chloroform (BDH, Poole, UK) was added and centrifuged as before. 
The supernatant was transferred to a fresh tube and equal volume of 100% ethanol 
added with 3mM final concentration ammonium sulphate. Tubes were placed at -20°C 
for 20 minutes and then spun for 20 minutes at 4°C at 13000g. The pellet was washed 
twice in 70% ethanol and dried at room temperature for 15 -  20 minutes. The pellet 
was re-suspended in lOOpL sterile distilled water overnight at 4°C. DNA was stored at 
4°C for one week or at -20°C for longer periods. N.B. All handling o f chloroform 
reagents was undertaken in a fume cupboard. Method obtained from a personal 
communication (Gail Whiting).
2.6.3 DNA Extraction -  Promega Kit
DNA was extracted following the manufacturers’ guidelines. Reagents supplied were 
cell lysis solution, nuclei lysis solution, RNAse solution, protein precipitation solution 
and DNA rehydration solution.
Cells were harvested from a fresh overnight culture on blood agar using a sterile loop 
and suspended in 0.48mL 0.05M EDTA. 120pL lytic enzyme and 60pL lysozyme
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(10p,g/pL) were added and mixed by gentle inversion and incubated at 37°C for 30-60 
minutes. The tubes were centrifuged at 13000g for 2 minutes and the supernatant 
discarded. The cells were re-suspended in 600pL nuclei lysis solution and mixed by 
gentle pipetting. The tubes were incubated at 80°C for 5 minutes and cooled to room 
temperature. 3jnL RNAse solution was added and the tubes incubated at 37°C for 15-30 
minutes and cooled to room temperature. 200pL protein precipitation solution was 
added and the tubes vortexed for 20 seconds and then incubated on ice for 5 minutes. 
Cell debris was precipitated by centrifuging at 13000g for 3 minutes and the supernatant 
transferred to a fresh tube containing 0.6mL room temperature isopropanol (BDH, 
Poole, UK). The suspension was mixed by gentle inversion until DNA could be seen. 
Tubes were then centrifuged for 10 minutes and the pellet washed in 70% ethanol and 
dried for 15 minutes at room temperature. The pellet was then re-dissolved in lOOpL 
DNA rehydration solution and incubated at 65°C in a water bath for 60 minutes, mixing 
by inversion every 20 minutes. The DNA was used the same day and then stored at -  
20°C.
2.6.4 Agarose Gels
Long range PCR products (chapter five) were electrophoresed through 0.7% lOOmL 
agarose gels, CpsAB PCR (chapter four) products through 2% 30ml gels and PBP 
(chapter nine) PCR products through 1% 30mL gels. Agarose powder (Bioline, 
London, UK) was weighed and melted into 0.5 X TBE buffer by heating until boiling in 
a microwave oven. Agarose was allowed to cool before ethidium bromide was added to 
a final concentration of 0.05pg/mL. 5pL of Hyperladder I (Bioline, London, UK), 
Hyperladder II (Bioline, London UK) or lOObp ladder (Invitrogen, Stirlingshire, UK) 
was added to each gel to size PCR amplimer bands.
2.6.5 Gel Photography
Gels were photographed with a digital camera on a UV transilluminator (UVP Inc., 
California, USA) using and digital camera DC 120 Kodak Digital Science software 2.0 
(Kodak, California, USA). Images were stored as JPEG files. RFLP images were 
stored as TIFF files.
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2.6.6 Restriction Fragment Length Polymorphism
The following reagents were mixed in 0.5pl tubes: 20pL PCR product, 0.5pL enzyme, 
4pL of buffer (specific for each enyme) and 0.2pL bovine serum albumin (BSA). The 
tubes were pulsed in a microfuge and incubated at 37°C for four hours or overnight on a 
heating block, and then stored at 4°C. RFLP digests were electrophoresed through 
agarose gels, 4% lOOmL for CpsAB PCR (chapter four), 3% 30mL for long range PCR 
(chapter five) and 2% lOOmL for PBP (chapter nine).
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Chapter Three
Quantitative Evaluation of STGG and SGG 
Media for Transport and Long-Term Storage of 
Streptococcus pneumoniae
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3.1 Introduction
3.1.1 Transport media and field studies : STGG
Any field study requires protocols for the transport of samples and specimens between 
the field and laboratory, and if necessary between the country from which the samples 
are being taken to the country where the laboratory work is taking place. Numerous 
programs have been hampered by loss or variation of stock cultures due to improper 
preservation (Ghema R.L. 1981). In addition the cost o f equipment and high 
temperatures in tropical climates introduces complications that would otherwise not be 
encountered in developed and temperate countries.
The work detailed in chapters seven and eight involved the collection samples in a rural 
village in Tanzania, transporting them to a -70°C freezer at the end of each day and 
storing them for the duration of the study. The samples were then brought back to the 
UK for bacterial isolation. Pure isolates were then archived for further work e.g. 
sensitivity testing and serotyping, and a strain collection generated for long-term 
studies.
The media that was chosen for use was a modification of STGG (skimmed milk, 
tryptone soya broth, glucose and glycerol) media, which has been used in several field 
studies (Gratten et al. 1989;Leach et al. 1997). Until now, there has been no fully 
quantitative investigation o f STGG media. This chapter details the first such study and 
investigates the suitability and reliability of STGG and SGG (modified STGG; skimmed 
milk, glucose and glycerol) for field studies, especially those in developing countries.
3.1.2 Transport media used in UK hospitals
Transport media typically used in the UK are Stuart and Amies, and are supplied with 
commercial throat swabs. Stuart media contains sodium glyerophosphate lOg/L, 
sodium thioglycollate 0.5g/L, cysteine hydrochloride 0.5g/L, calcium chloride 0.1 g/L, 
methylene blue 0.001 g/L agar 5g/L and is pH 7.4. Amies is contains charcoal 
pharmaceutical lOg/L, sodium chloride 3g/L, sodium hydrogen phosphate 0.2g/L, 
potassium dihydrogen phosphate 0.2g/L, potassium chloride 0.2g/L, sodium 
thioglycollate lg/L, calcium chloride 0.1 g/L, magnesium chloride 0.1 g/L, agar 4g/L and 
is pH 7.2 (www.Oxoid.com). No quantitative evaluation of either o f these media could 
be found in the literature for S. pneumoniae or streptococcal species. For this the 
following key words were used to search PubMed databases: Amies, Stuarts, transport
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media, S. pneumoniae, streptococcal species and streptococci.
3.1.3 The evolution of STGG media
The use of skimmed milk, glucose and glycerol for cryo-preservation was published in a 
laboratory manual (Ghema R.L. 1981). From this Gibson et al derived and qualitatively 
evaluated STGG for the preservation of many species o f bacteria in 1986 (Gibson & 
Khoury 1986). The medium comprised 30g of Tryptone soya broth, 20g skimmed milk 
powder, 5.0g glucose, 40mLs glycerol and lOOOmL double glass-distilled water. The 
group transferred organisms, grown as a lawn culture at 37°C overnight, into three tubes 
containing lmL aliquots. The tubes were inoculated on ice and then transferred to a -  
70°C to -80°C freezer fitted with an alarm to warn against excess warming. Viability 
checks were done at fortnightly or monthly intervals by partially defrosting one of the 
ampoules and sub-culturing onto agar. The same ampoule was used each time. S. 
pneumoniae was kept viable for 40 months.
3.1.4 How does STGG work?
Each o f the ingredients contribute to the preservation of pneumococci. Skimmed milk 
replaces the need for glass beads which have been traditionally to agglutinate bacterial 
cells during freezing. Skimmed milk agglutinates cells and can be used on its own for 
freezing (Ghema R.L. 1981;Siberry et al. 2001). Tryptone soya broth provides the 
nutrients required for survival in temperatures at which the bacteria will be 
metabolically active. Glycerol passes readily through the cell membrane and provides 
intra- and extra-cellular protection against freezing. Glucose exerts a protective effect 
against freezing outside the cell membrane (Ghema R.L. 1981).
3.1.5 Qualitative and semi-quantitive evaluation of STGG media for use in 
nasopharyngeal carriage studies
A qualitative and semi-quantitative evaluation was performed on STGG media by 
O’Brien et al in which direct plating was compared to transfer of the fresh 
nasopharygeal swab into STGG before processing (O'Brien et al. 2001). The semi- 
quantitative evaluation was done by innoculating the swab onto one quarter plate and 
then streaking across the remaining quadrants or transferring lOOpl STGG and 
spreading across the plate. After overnight incubation the growth was scored as 
follows: <25 colonies in quadrant 1, >25 colonies in quadrant 1 and <25 in quadrant 2, 
>25 colonies in quadrant 2 and <25 colonies in quadrant 3, >25 colonies in quadrant 3
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and <25 colonies in quadrant 4 and >25 colonies in quadrant 4. They prepared the 
STGG media according to Gibson and Khoury (Gibson & Khoury 1986). They 
collected two naso-pharyngeal swabs from each child included in the study. One of 
each of the two samples was plated directly (DP sample) and then the swab was placed 
in STGG, the tip cut and left immersed in the STGG and vortexed (DP-residual 
sample). The second swab was transferred directly to the STGG medium (STGG-fresh 
sample). The recovery from DP-residual swab was concordant with the DP sample and 
produced growth equal or greater than the DP sample. Fresh STGG samples agreed 
closely with the DP samples, there were six discordant samples; four grew only from 
the DP specimens and two only from the STGG fresh specimens. Some STGG fresh 
samples were stored before being processed, at either -70°C, -20°C or 4°C, there was 
95% concordance between the stored and fresh samples. The semi-quantitive recovery 
was at least as good from the frozen samples as the fresh, but there was some reduction 
of pneumococcal growth in the samples stored at 4°C for 5 days. They concluded that 
STGG performed well compared to direct plating, which is the standard technique for 
naso-pharyngeal studies. In addition STGG enhanced the recovery o f pneumococci 
compared to direct plating for samples with low colony counts.
3.1.6 Comparison of different storage media for long-term preservation of S. 
pneumoniae in the tropics
The following media were compared for the long-term preservation of S. pneumoniae in 
the tropics: glycerol-chocolate broth, skimmed milk, rabbit blood, sheep blood, 
lyophilization and sand desiccation (Siberry, Brahmadathan, Pandian, Lalitha,
O
Steinhoff, & John 2001). They stored cultures with colony counts in excess o f 10 
CFU/mL in skimmed milk and glycerol-chocolate broth at 4°C. They found that the 
CFU count dropped several thousand-fold after one week for the glycerol-chocolate 
broth and after four weeks for the skimmed milk. Strains stored at -70°C were all still 
viable after 16 months but the decline in colony counts varied. Sand desiccated and 
lyophilised cultures were non-viable after four weeks and four months respectively, but 
remained viable at 4°C for five years 8  months and 16 months respectively. All strains 
stored frozen were viable after 64 weeks in sheep blood, rabbit blood, glycerol- 
chocolate broth and skimmed milk. Colony counts remained above 106 for glycerol- 
chocolate broth and above 1 0 8 for rabbit blood, sheep blood and skimmed milk at -  
70°C. At -20°C all strains were non-viable after 16 weeks regardless of the media. It is 
clear that storage o f pneumococci long-term at -20°C is not suitable regardless o f the
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medium, but that storage at -70°C is a reliable for long term storage in a variety of 
media and that temperature is more of a critical factor than the medium for long term 
storage.
3.1.7 Advantages of STGG/SGG media
One of the advantages of STGG/SGG media is its versatility. The media is cheap, SGG 
very cheap, and easy to prepare and store, but above all it is useful because specimens 
can be transferred into the media for transport and storage. Swabs can be transferred to 
STGG media and transported at ambient temperature to the laboratory, either frozen 
before processing or processed straight away and the clinical samples can then be kept 
for re-examination at a later date, for example if  they were revisited because 
pneumococcal isolates were lost, to check the validity of the isolation protocols or to 
screen for another organism, e.g. H. influenzae.
3.1.8 The work in this chapter
Isolates o f four serotypes were incubated for 96 hours in STGG and SGG media in 
different temperature conditions. Viability counts were performed every 24 hours. 
Statistical analysis was performed to show firstly that there was no significance 
associated with serotype on the survival times in either of the media, and then the 
serotype data pooled to show no significant difference between the two media. Having 
completed the serotype data for chapter seven, the STGG experiment was repeated to 
include representative isolates o f the serotypes that were least commonly isolated, as 
well as different isolates of the original serotypes for validation. The isolates of the 
original serotypes showed the same pattern of decline as before and the comparison 
with less common serotypes did not change the overall result. Lastly, a serotype 14 
isolate was inoculated with a very low CFU/mL starting inoculum in STGG to see 
whether isolates could be grown in STGG. Although S. pneumoniae can be grown in 
tryptone soya broth, it was not known what affect glycerol and skimmed milk would 
have on the growth o f S. pneumoniae. The serotype 14 isolate grew at 30°C and 37°C 
meaning that colony picks, from a mixed culture on solid media, can be cultured in 
STGG before being directly frozen to obviate additional culture on solid media to obtain 
pure growth.
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3.1.9 Aim
To quantitatively evaluate SGG and STGG media for transport and storage o f S. 
pneumoniae, by measuring the survival of different serotypes at different temperatures, 
to ensure that no bias could enter field studies as a result of these transport media.
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3.2 Methods
3.2.1 STGG and SGG media were prepared as follows:
3g tryptone soya broth, 0.5g glucose, 2 .0 g skimmed milk powder were weighed and 
added to a 250mL Pyrex bottle (Duran, BDH, Leistershire, UK). For SGG media the 
tryptone soya broth is omitted. lOmLs glycerol and lOOmLs distilled water were added 
and mixed until all reagents had dissolved. lmL aliquots were dispensed into 1.8mL 
cryo-tubes (Nunc, supplied by Western Laboratory Services, Hampshire, UK) for cryo 
preservation and 4mls into 7mL glass bijoux for viability counts, ensuring that the 
mixture was mixed by swirling at regular intervals.
3.2.2 Tindalization
STGG and SGG media were sterilized by tindalization because the medium caramelises 
when autoclaved for more than 1 0  minutes, unless an autoclave is available which can 
run for only 10 minutes. The medium was steamed for 20-25 minutes and mixed 
thoroughly by vortexing to break up the sediment. The medium is then incubated 
overnight at 37°C, re-steamed and re-incubated overnight, and then steamed for a third 
time.
There is always a globular sediment which must be re-suspended, if the medium is 
steamed or autoclaved for too long the sediment will not break up.
3.2.3 STGG and SGG Storage
The medium is stored at 4°C and has a shelf life of several months. It can also be frozen 
for long-term storage.
3.2.4 Sub-Culturing and incubation of organisms
The strains were sub-cultured onto blood agar plates, from frozen STGG, and incubated 
at 37°C overnight in 5% CO2 . Five plates for each strain were prepared for each 
experiment. The cells were harvested from the plate using a sterile cotton wool bud, 
and suspended in the media, four or five plates were used for each 4mLs o f media 
depending on density of growth. The media was then vortexed and a Miles and Misra, 
see section 3.2.5, viability count was performed to establish cell count for 0 hours. The 
cell suspension was divided into lmL aliquots. One tube of each serotype was placed at 
4°C, 30°C, room temperature (RT, 23°C) and -70°C. Every 24 hours the viability 
counts were repeated to obtain a death curve.
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3.2.5 Viability counts -  Miles and Misra (Miles AA and Misra SS 1938)
The cell suspension in STGG or SGG was vortexed before dilution. lOOpl o f medium 
was transferred into 900pl sterile distilled water in an eppendorf tube (Eppendorf) and 
vortexed briefly. A Vio dilution series was prepared until a dilution of 1 x 106 was 
obtained. 20pi o f each dilution was then spotted onto a blood agar plate (Oxoid ready 
prepared media), in triplicate, and dried on a flat surface. The plates were incubated 
overnight and cells were counted the following day. Each experiment was performed in 
triplicate and on three separate occasions (nine times in total). The mean colony counts 
for each separate experiment was calculated. The colony forming units per mL values 
were then calculated using the following equation for each experiment and for each 
serotype:
Mean colony count x dilution x 50 = cfu/mL
3.2.6 Statistical Analysis
3.2.6.1 Calculation of i}li
The data was entered into GraphPad software version 3.00 for Windows (GraphPad 
Software, California, USA) and statistical analysis was performed. The mean and 
standard error values were calculated from the three experiments for each serotype. The 
t ! / 2  (time at which half of the cells will have died) was calculated using non-linear 
regression analysis with a mono-phasic exponential decay curve. Exponential decay 
curves were calculated for each serotype, and at each temperature (excluding -70°C) 
using the following equation:
V, =  V ,e -h
Vt is the t lA value at each temperature, VQ is viable count at time zero, e is the Napierian 
constant and k is the exponential decay constant.
From the tV2 and the standard error (SE) of k, the SE of tV2 was calculated using the 
following equation:
SE{k)xt\  = SEfr j )  
k
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The correlation coefficient (r2) was calculated as an estimate of goodness of fit using 
GraphPad Prism as follows:
r2 = (sum of squares of the distance from the best fit curve)
(sum of squares of distance from the mean Y value)
The half-life was calculated from the following equation:
tVi = ln(0.5) 
k
To determine whether the viability o f isolates were significantly different from each 
other their f / 2  values were analysed by a one-way analysis of variance - ANOVA.
3.2.6.2 Paired T-test
A two-tailed paired t-test (confidence interval 95%) was used to compare the t l / 2  values 
of pooled serotypes at different temperatures of STGG versus SGG.
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3.3 Results
3.3.1 Comparison of STGG versus SGG
3.3.1.a Survival of four serotypes in STGG
Isolates of serotypes 19 (RFH 5), 23 (RFH 6 ), 18 (RFH 9) and 6  (RFH 23) were chosen 
for investigation because they are known to be common paediatric serotypes, and are 
the types most likely to be encountered in the sort o f study for which these media are 
being qualitatively investigated. When this experiment was begun, the serotyping of the 
carriage isolates collected in Tanzania for chapter seven had not been completed.
The mean and standard error of the mean viable counts from the three experiments 
performed for each serotype were calculated and shown as semi-log plots in figure 3.1. 
The graph o f freeze thaw cycles, figure 3.1(A) demonstrates clearly that repeat freeze 
thaw cycles do not reduce viability o f the culture after 4 cycles, irrespective of serotype. 
However, for the other temperatures 3.1 (B, C and D) it is not clear whether serotype 
has an effect on the death rate; it appears that serotype 6  (red) dies more rapidly than the 
other three at room temperature and 30°C but at 4°C there is little difference. The 
remaining serotypes show little difference at any temperature.
To test the hypothesis that serotype has a significant impact on survival statistical 
analysis was performed. The tV2 was calculated for each serotype at each temperature 
using non-linear regression analysis see table 3.1. Then a one-way analysis of variance 
(ANOVA) was performed for all four serotypes at each o f temperatures 4°C, RT and 
30°C. It showed that at for all three temperatures there was no significant difference; p- 
values are shown in table 3.2.
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Figure 3.1: Survival curves of isolates of serogroups 19, 23, ^ “ 18 and —  6  at
-70°C, 4°C, room temperature and 30°C. The values plotted are the mean with standard 
error bars from the three experiments.
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Table 3.1: tV2 values calculated using non-linear regression analysis for STGG medium
Temperature Serotype TV2 (hours) SEM tV2 N
4°C 19 9.426 9.4862 3
23 57.98 27.214 3
18 93.04 53.81 3
6 22.2 13.257 3
23°C 19 8.431 7.721 3
23 9.191 1.6113 3
18 15.70 3.144 3
6 6.114 7.295 3
30°C 19 6.46 8.465 3
23 3.760 8.9636 3
18 7.747 2.4011 3
6 2.419 35.0142 3
Table 3.2: P-values for one-way ANOVA showing that there is no significant
difference between serotypes in STGG medium; calculated from the mean and standard 
error of the three values for each serotype, test repeated for each temperature.
Temperature P value ?
4°C 0.2976 0.3531
RT 0.6689 0.1681
30°C 0.9967 0.06424
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3.3.l.b  Survival of four serotypes in SGG
Experiments for the four serotypes were repeated for SGG medium and the statistical 
analysis repeated. This showed that there is no difference between serotypes in SGG.
Table 3.3: tV2 values calculated using non-linear regression analysis for SGG medium.
Temperature Serotype TV2 (hours) SEM tV2 N
4°C 19 18.77 8.88 3
23 20.91 6.76 3
18 27.38 12.06 3
6 2.904 22.64 3
23°C 19 5.84 5.53 3
23 4.69 5.60 3
18 6.90 6.28 3
6 2.26 30.20 3
30°C 19 3.33 28.34 3
23 2.337 25.67 3
18 2.58 30.53 3
6 2.29 29.99 3
Table 3.4: P-values for one-way ANOVA showing that there is no significant
difference between serotypes in SGG medium; calculated from the mean and standard 
error o f the three values for each serotype, test repeated for each temperature.
Temperature P value r2
4°C 0.6610 0.1415
RT 0.9971 0.00589
30°C 1.0 0 . 0 0 0 0 1
3.3.1.C Values combined for all serotypes -  STGG versus SGG
The mean and standard error values were calculated by combining all four serotypes; to 
give values for STGG and SGG at each temperature. For graphical purposes the mean 
values were then transformed (Logio) and a linear regression analysis performed in 
order to gain a line of best fit. The transformed values were plotted with the linear 
regression line, figure 3.2. For a statistical analysis, to compare the rates, the mean
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values were used to calculate the tV2 using a non-linear regression analysis (as before). 
The SE of the tV2 was then calculated as before and a paired t-test performed to 
compare SGG with STGG.
Table 3.5: Paired t-test showing no significant difference between STGG and SGG for 
serotypes 19, 23, 18 and 6 . Mean of mean values were used in non-linear regression 
analysis (plateau constant = 0) using GraphPad.
STGG SGG Significant
Difference
Y/N
Temp t ‘/2
(hours)
SE tV2 n R2 t V2
(hours)
SE tV2 n R2
4°C 40.41 32.99 4 0.985 18.23 1.44 4 0.998 no
RT 9.50 0 . 1 2 4 1 . 0 0 5.143 0.15 4 1 . 0 0 no
30°C 4.83 0.03 4 1 . 0 0 2 . 2 0 1.3x10^ 4 1 . 0 0 no
t-test shows no significant difference 
p = 0.2598 (Cl = 95%)
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Figure 3.2: Mean viable counts at (A) 4°C, (B) RT and (C) 30°C temperatures,
comparing SGG with STGG. Data points were calculated using non-linear regression 
analysis and a line o f best fit was drawn using linear regression analysis (graphical 
purposes only).
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The tJ/2  values, compared in table 3.5, show clearly that there is a difference between 
STGG and SGG and that the tV2 is less in SGG, however, statistical analysis shows that 
this difference is not significant.
3.3.2 Survival of less frequently isolated serotypes
Having established using four serotypes, that there is no significant difference in the 
survival in STGG versus SGG for the four isolates tested, the whole experiment was 
repeated for STGG using different isolates of the same serotypes. Also included were 
isolates of the less frequently isolated serotypes from the chapter seven. At this point 
the serotyping for the strains from Tanzania had been completed. Serotypes 7 and 14 
had low prevalence among isolates collected in Tanzania and were included also to 
ensure that this was not due to bias introduced by the transportation medium. Serotype 
1 was included because through working with and frequently sub-culturing strains from 
-70°C it was noted that isolates o f serotype 1 often grew weakly from -70°C and 
typically had very small colonies, since serotype 1 was not a frequently isolated in 
chapter seven, it was included to ensure that this was not as a result o f the transportation 
of specimens. The results are shown in tables 3.6 and 3.7, no difference was found in 
survival rates for any of the serotypes.
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Table 3.6: 1}  12 values calculated using a non-linear regression analysis.
Temperature Serotype Tl/2 SEM tl/2 N
4°C 19 3.05 27.92 3
23 21.78 14.08 3
18 5.03 6.03 3
6 13.47 3.41 3
7 3.99 1.72 3
1 23.67 7.73 3
14 12.67 3.50 3
RT 19 2.90 33.10 3
23 17.44 12.99 3
18 3.76 8.04 3
6 6.15 2.98 3
7 6.82 8.91 3
1 5.36 0 . 1 2 3
14 8.46 2.64 3
30°C 19 2.19 93.34 3
23 5.71 11.98 3
18 5.474 4.99 3
6 2.96 13.106 3
7 7.49 9.50 3
1 3.21 6.99 3
14 6.34 3.05 3
Table 3.7: P-values for one-way ANOVA showing that there is no significant
difference between serotypes in STGG media when less frequently isolated serotypes 
are included.
Temperature P value r*
4°C 0.8311 0.1626
RT 0.9928 0.0473
30°C 1 . 0 0 0 0.0013
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3.3.3 Maximum storage times for STGG and SGG
Maximum storage times were calculated, for STGG and SGG, from the time taken for 
the viable count to decrease by one logio.
Table 3.8: Maximum storage times, in hours. Figures are based on the time taken to 
decrease the viable cell count by one log.
STGG SGG
4°C 194.5 77.7
21-23°C 31.1 18.5
30°C 16.0 7.6
3.3.4 Incubation of STGG medium with low starting inoculum
A colony pick, from a fresh overnight culture on blood agar, of a serotype 14 isolate 
was transferred to 3mL of STGG. lmL aliquots were then incubated in STGG at 30°C 
and 37°C. Viable counts were measured at 0, 6  and 24 hours, see table 3.9, and show an 
increase in viable counts in 24 hours.
Table 3.9: Comparison of 30°C and 37°C with low initial inoculum. Three lmi aliquots 
were incubated, and viability counts performed after 6  and 24 hours.
Serotype 14 at 30°C Serotype 14 at 37°C
Time (hours) CFU/mL SEM n CFU/mL SEM n
0 716.7 0 3 83 0 3
6 1.47xl04 2862.824 3 3.27x10s 8.63 xlO4 3
24 5.0xl08 - 3 9.27x107 l.OSxlO7 3
1 1 9
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3.4 Discussion
These results show that there is no significant difference in survival rates o f different 
serotypes in the transport media tested; meaning that there will be no bias introduced 
into a study as a result o f either of these media. Looking at the semi-log plots for 
STGG, figure 3.1, serotype 6  appeared to die more rapidly. This may be true, but it is 
not statistically significant and therefore, the reduced survival rate is acceptable.
Following completion o f the work for chapter seven, the serotype prevalence showed a 
surprisingly low isolation rate for serotype 14, which is the most common serotype 
worldwide (Scott et al. 1996). Even though a different serotype profile was expected to 
that commonly found in developed countries, it was surprising to have only isolated 
2/382 serotype 14 isolates. This cast doubt over the conclusion that there was no 
difference in survival rates between different serotypes; and that only serotypes that 
survived well had been tested in this chapter. The experiment was repeated to include 
three more serotypes with lower prevalence. An additional rationale for including 
serotype 1 was the observation that serotype 1 isolates, sub-cultured from frozen 
samples, frequently grew very weakly and often had to be sub-cultured before DNA 
extractions. Different isolates o f the same four serotypes were included to ensure that 
the results were genuine, and not just a feature of the four particular strains. However, 
the conclusion remained unchanged, thus proving that the serotype profile from 
Tanzania was not altered by sub-optimal recovery of certain serotypes as a result o f the 
transportation media used, and that the low prevalence o f serotype 14 is a reliable 
observation
The storage temperature appears to be a critical factor for the survival of S. pneumoniae 
in STGG or SGG; in general the lower the temperature the longer the organism 
survived. The literature describes -70°C as being the optimal temperature for long-term 
storage, and that different media may be used, however, the effect of freeze thaw cycles 
has not been previously examined. For all serotypes tested all serotypes withstood four 
successive freeze thaw cycles without a reduction in the viable count. Storage at -20°C 
was not investigated in this chapter since Siberry et al. clearly stated that freezing at - 
20°C was not an acceptable method o f storing pneumococci (Siberry, Brahmadathan, 
Pandian, Lalitha, Steinhoff, & John 2001). If a field study does not have access to a - 
70°C freezer then the samples should be transported to where there is access to one as 
soon as is feasible. It was surprising that strains in STGG at 30°C did not show a rise in
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CFU/mL before a decline, as it was expected that at such a temperature the organisms 
would grow a little before dying since it was in tryptone soya broth, which is frequently 
used for culturing pneumococci. The STGG inocula were very high and pneumococci 
only grow to a maximum density before they begin to autolyse, so a STGG culture with 
a very low count was incubated at 37°C and 30°C to see whether there would be any 
growth from a lower starting inoculum or whether there were inhibiting factors in the 
other ingredients. It is very useful to know that pneumococci can be grown in STGG 
because colony picks could be transferred to the media, incubated for 6 - 8  hours or 
overnight and then frozen as a dense suspension, see table 3.9. This may save time 
during investigations or field studies. At room temperature there is a logio fall in 24 
hours followed by a steeper fall with all strains dying within 96 hours. This shows that 
specimens should not be kept at ambient temperatures, especially in hot climates as the 
fall at 30°C is even greater, but should be refrigerated or frozen as soon as possible. 
Temperatures above 30°C were not evaluated because this temperature is not regularly 
exceeded in northern Tanzania, which enjoys fairly constant temperatures all year 
round, 22°C -  38°C, Kilimanjaro region, (Stronge 2002). However, if  a study was being 
performed in a location with a hotter climate, a brief evaluation should be included 
before-hand.
There is no significant difference between SGG and STGG so omitting tryptone soya 
broth to cut cost or if it is not easy to obtain is acceptable and will not lead to loss of 
strains. This had been indicated by preliminary, not quantitative, experiments in 
Tanzania. SGG was used in the field work in Tanzania, and this chapter confirms the 
accuracy o f the data obtained. It was observed that omitting TSB resulted in less 
caramalisation of the media. This is preferable as it is easier to pipette and since the 
milk replaces glass beads, non-caramalised media gives a more even suspension which 
is important when scraping ice from frozen samples that the pneumococci are not all at 
the bottom of the tube.
The standard error is large for some experiments, especially for the freeze thaw 
experiments. This is due to the nature of the methods; counting cells at high dilution 
factors exacerbates a small error i.e. one extra colony counted at a dilution of 1 x 1 0 6 
will add 1 x 106 cfu/ml to the final number. However, this error is unavoidable and in 
order to reduce bias each viable count were performed in triplicate and each experiment 
in triplicate also.
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For transportation overseas the data in this chapter would suggest that pure cultures i.e. 
with an inoculum density similar to the starting CFU/ml counts as these experiments, 
could be air-freighted at ambient temperature, particularly if sent as cargo (assuming 
that the cargo hold on an aeroplane gets very cold during the flight). However, 
following this assumption around 100 pure strains were air-freighted from Tanzania to 
London, a journey which should take no more than two days, this was done with 
duplicate strains as a quality control before specimens for the study detailed in chapter 
seven were transported. Unfortunately only around 10% of the samples survived the 
journey. There was an unforeseen delay in that the journey took an additional 24 hours, 
however, a survival rate o f greater than 10% would have been expected. There may be 
other factors at work, namely the pressure changes in cargo. From this point on all 
samples were transported frozen on dry ice with 100% survival. A liquid transportation 
media which would allow transportation at ambient temperature would be useful. Dry 
ice can be difficult to obtain in developing countries and slopes or plates of solid media 
take up much more room, slopes in 1 .8 ml tubes are a lot more tedious to prepare than 
STGG media, however, for the time being dry-ice will be used.
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Chapter Four
Evaluation of CpsAB PCR Method for Predicting 
Serotype for Streptococcus pneumoniae
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4.1 Introduction
Evaluation of CpsAB PCR for predicting serotype of Streptococcus pneumoniae
4.1.1 Serotyping
Serotyping methods are currently based around pneumococcal antiserum, produced 
exclusively by the Statens Serum Institut (Henrichsen 19790). The antibodies are 
polyclonal, raised in rabbits and specific for sub-types, and can be purchased as type, group 
or pooled sera. The group sera are a mixture of the type sera. The main two methods for 
serotyping are the Quellung reaction, which is the “Gold Standard” and is used at the 
Statens Serum Institut (the pneumococcal reference laboratory in Denmark) and the slide 
agglutination method, a slightly easier method published later as a modification to the 
Quellung reaction (Sorensen 1993). The Public Health laboratory in London, at Colindale, 
uses its own modification of the slide agglutination method (S Martin, personal 
communication), which has been used in this project. Both methods involve the strain 
being serotyped to be grown in broth so that cells are not clumped together. For the slide 
agglutination method a drop of the heavy cell suspension is then spotted onto a glass slide 
and the sera is added and mixed. Agglutination is seen between cross-reacting sera and 
cells. The “chess board” method using pooled sera was published in 1993, and was 
intended for typing or grouping 90-95% of pneumococcal strains most commonly isolated 
from blood or CSF. The pooled sera react with 11 single types, together covering the 23 
serotypes in the polysaccharide vaccine, and some additional cross-reacting types 
(Sorensen 1993). For the Quellung reaction cell suspensions are spotted onto a glass slide 
and dried. Anitsera and methyline blue are added and mixed. The slide is examined under 
a confocal1 microscope and a positive reaction is when the capsules swell and cells 
agglutinate together in clumps. The slide agglutination method is quicker, as the reactions 
are rapid and easy to see, and it does not involve the focusing of a microscope for each 
slide. Equivocal results, more than one reaction seen from a set of pooled sera, are often 
seen and have to be resolved using the Quellung reaction. The main problem with the 
existing methods is the high cost of the sera. Sera are sold only from the Statens Serum 
Institut and cost £60 per lmL bottle (http://www.serum.dk). A set of pooled sera contains 
13 bottles, and can only group serotypes in the 23-valent polysaccharide vaccine. If used to
1 A confocal microscope filters out any objects out of focus. Defocusing does not create blurring but cuts out 
parts of the object as they move out of the focal plane allowing three-dimensional images to be seen. The 
pneumococcal capsule can be seen through a con-focal microscope.
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type strains from developing countries this method results in a large number of non- 
typeables (refer to table 7.3). Each group or type specific serum must then be purchased if  
type specific data is required, for example for serogroup 19 there is one group specific 
serum and four type specific sera. A complete set of sera which (will subtype any type for 
which there is sera) will cost, at full price, around £ 1 0 ,0 0 0 .
4.1.2 Alternative methods for serotyping
Due to the clinical importance of S. pneumoniae and to overcome the high cost of antisera, 
a number of attempts have been made to harness the serological reaction and reduce the 
amount of sera required, some of which are described in sections 4.1.2 a-d.
4.1.2.a Fluorescence antibody
The fluorescence antibody technique has been compared to the Neufeld test or Quellung 
reaction, but fluorescence makes the reaction easier to read and is more reliable in 
identifying pneumococci especially in body fluids when the number of organisms may be 
low (Wicher et al. 1982).
4.1.2.b Latex agglutination
Latex beads are coated in the antisera which is then mixed with a cell suspension of the 
pneumococcal test strain in a microtitre plate. After incubation a positive reaction is 
detected by a swelling around the precipitate, seen as a hazy ring (Kaldor, Asznowicz, & 
Dwyer 1988). However, the technique requires optimising and antisera of known titre, 
which is more expensive than normal sera.
4.1.2.C Co-agglutination
This uses a staphylococcal protein from the Cowan strain. The proteins are agglutinated to 
different type sera by a series of incubations. The strain to be serotyped is then mixed with 
the prepared protein solutions in a micro-titre plate. A positive reaction is detected by a 
swelling around the precipitate (Smart 1986;Smart & Henrichsen 1986).
4.1.2.d Dot blot assay
A simple dot blot assay was developed at a reference laboratory in Spain, and is used 
routinely in their laboratory (Fenoll et al. 1997). The method involves dotting heavy cell
125
Evaluation ofCpsAB PCR for predicting serotype of Streptococcus pneumoniae
suspensions, in saline, onto nitrocellulose membranes which are then dried and blocked 
with milk and then incubated with pneumococcal antisera followed by goat anti rabbit dye 
labelled antibodies and then developed. The method is reported by the group to be quick, 
sensitive, specific, easy to perform and in-expensive compared to the Quelling reaction as it 
uses less sera. However, they also found equivocal results with some of the sera, and 
around 20% of strains had to be typed using the Quellung reaction.
4.1.3 CpsAB PCR
A novel approach was published in 2000 by Lawrence at al. using PCR which targets the 
first two genes of the capsulation locus CpsA and CpsB, followed by a restriction fragment 
length polymorphism RFLP digestion with either two or three enzymes (Lawrence et al. 
2000). The RFLP digests can only resolve serogroups not types, so the only advantage 
over using the “pneumo-test” kit is the reduction in cost. If the PCR could be adapted for 
use directly on un-cultured clinical specimens, it may be very useful for epidemiological 
studies and routine diagnostic use especially for culture negative samples, for example from 
patients taking antibiotics. Additionally, since identifying multiple colonisation relies upon 
two different serotypes displaying different morphologies it is likely that multiple 
colonisation is under reported. The PCR was tested for identifying mixed serotypes before 
being adapted for use directly on clinical samples.
4.1.4 The Capsulation Locus of S. pneumoniae
Capsulation locus genes are denoted by the letters cps or cap in the literature, cps is used in 
this document. The genes required for serotype specific capsular carbohydrates are 
arranged together, as an operon, at the capsulation locus, and all appear to be transcribed as 
a single unit (Ramirez & Tomasz 1998). This is with the exception of type 37 which is a 
binary encapsulated strain. The genes responsible for the synthesis o f type 37 are located 
outside the capsulation locus which itself, is almost identical to type 33F. For the rest of 
the serotypes, the locus contains most of the genes required for the synthesis, translocation 
and precursor linkage of the individual enzymes and transport proteins required, see 
illustration 4.1, although some non-type specific genes are located elsewhere. Hence, the 
size o f the capsulation locus varies among different serotypes from around 15kbp to 23kbp 
in serotypes 3 and 23, or 3 to 18 genes (Garcia et al. 2000). The locus is arranged as a 
cassette and is universally flanked at the 5’ and 3’ ends by dexB and aliA genes respectively
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that do not contribute to CPS synthesis. The locus contains various insertion sequences 
which are serotype specific and may also be found elsewhere in the genome, see illustration
5.1 (Jiang, Wang, & Reeves 2001;Morona, Morona, & Paton 1999b). A highly conserved 
promoter site is located immediately upstream of the first gene and the transcriptional start 
site has been determined by primer extension analysis of serotype 1 locus (Morona et al. 
1999). All genes are arranged within open reading frames and have the same 
transcriptional direction from dexB to aliA. The 5’ portion contains four conserved genes 
involved in the regulation of CPS synthesis. The central highly specific portion contains 
glycotransferases, a CPS polymerase and CPS repeat unit flipase. Nucleotide sugar 
biosynthesis genes (for CPS only, housekeeping sugar genes are located elsewhere) are 
generally located at the 3’ portion of the locus (Jiang, Wang, & Reeves 2001).
C p sl9F  CPS locus
dexB IS1202 cpsA B C D E F  G H I J K L M N  O aliA
I 3 kbp I
Illustration 4.1: Shows the genes of the capsulation locus from type 19F in purple. Gene:
dexB (5’) and aliA (3’) flank the locus. CpsA -  D are conserved regions common to all 
serotypes, except type 3, and E - O  are serotype specific. IS1202 is an insertion sequence 
found in serogroup 19 strains (Morona, Morona, & Paton 1999b).
4.1.4.1 Diverse nature of the capsulation locus
The capsulation locus is genetically diverse since only a few genes are conserved among 
different serotypes and even the conserved genes frequently have different arrangements 
within the locus. One of the conserved genes is cpsA, which is 90% identical in all of the 
gene clusters. There are at least two classes of cpsCDE genes reported (Morona, Miller, 
Coffey, Vindurampulle, Spratt, Morona, & Paton 1999). The gene cluster cpsLMNO are 
not present in all serotypes. They are highly conserved among some serotypes including 
serotype 1, but not serotype 8 where the gene products are not required for capsular 
polysaccharide synthesis (Garcia, Hull, Munoz, Mollerach, & Lopez 2000). This 
heterologous organisation of the locus is similar to that of several lactic acid bacteria such 
as lactococci and lactobaccili (de Vuyst & Degeest 1999).
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4.1.4.2 Characterisation of CPS genes
During the 1990s and beyond, extensive studies were conducted to investigate and 
characterize the genes responsible for the biosynthesis of the capsule (Arrecubieta, Lopez, 
& Garcia 1994;Ramirez & Tomasz 1998). The genetic basis has been determined for a 
number of serotypes using PCR and DNA sequencing. Protein functions have been 
assigned, mainly using sequence comparison with proteins of known functions and knock 
out mutants (Morona, Miller, Coffey, Vindurampulle, Spratt, Morona, & Paton 
1999;Morona, Morona, & Paton 1997a;Morona, Morona, & Paton 1997b;Morona, Morona, 
& Paton 1999a). Only a few proteins have been biochemically characterised (Garcia, Llull, 
Munoz, Mollerach, & Lopez 2000).
During capsule construction the component monosaccharides are first synthesised then 
activated to a nucleotide precursor, transferred in sequence to the repeating oligosaccharide 
for polymerisation, exported across the cell wall and attached to the cell surface (Morona, 
Morona, & Paton 1997a). Serotype 3 is an exception, it has a very simple chemical 
structure consisting of glucose and glucuronic acid, and is synthesised by a processive 
transferase (Arrecubieta, Lopez, & Garcia 1994).
4.1.4.3 Regulation of CPS Production by cpsA - cpsD
Functions of cpsA, B, C and D genes have been proposed (Morona et al. 2000). CpsA 
regulates capsule production but is not an absolute requirement, yet cpsB-D are 
constitutively required for complete encapsulation. A non-polar in frame deletion which 
removed >95% of cpsA-D was constructed by Morona et al.. CpsA' mutants have reduced 
capsule production and so cpsA is thought to regulate CPS production, however, the exact 
function o f cpsA is unknown (Morona, Paton, Miller, & Morona 2000). CpsB', cpsC  and 
cpsD' were all rough (unencapsulated) but CPS-related material was detected on the surface 
by immunogold electron microscopy and immuno-flouresce microscopy, suggesting that 
they were required for full encapsulation (Morona, Paton, Miller, & Morona 2000). CpsC 
and cpsD were predicted to be functional homologues of ExoP (involved in the synthesis of 
an exopolysaccharide) from Sino-rhizobium meliloti (soil bacterium) which has similarity 
to autophosphorylating tyrosine kinases in Acinetobacter johnsii and Eschericia coli 
(Guidolin et al. 1994;Morona, Paton, Miller, & Morona 2000). A tyrosine phosphorylated 
protein was probed for in wild type and cpsA-D knockouts and found in all but cpsC  and
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cpsD\  The phosphorylated protein was found to be cytoplasmic by cell fractionation, 
which is consistent with CpsD. CpsD is autophosphorylating, and is de-phosphorylated by 
cpsB, as proved by showing that if cpsD is in a form that cannot be phosphorylated, then 
cpsB is not required for capsule production. The de-phosphorylated form is able to bind to 
cpsC and then interact with ATP. CpsC undergoes a conformational change that allows 
capsule production to proceed and thus autophosphorylation of cpsD negatively regulates 
CPS production (Morona, Paton, Miller, & Morona 2000).
CpsA-D were alternatively called wzg, wzh, wzd and wza respectively by Jiang et al 
following a system applicable to classes of genes commonly found in many species (Jiang, 
Wang, & Reeves 2001).
4.1.4.4 Genetic determinants of serogroup 19 polysaccharide
Serogroup 19 was the first group for which all of the members were characterised and 
includes types F, A, B and C which are closely related. Type 19F is one of the commonest 
causes o f invasive disease in young children and is one of the poorest immunogens in the 
group; type 19B and C are rare causes of disease. Functions have been assigned with either 
gene complementation or sequence similarity to proteins of other known functions 
(Guidolin, Morona, Morona, Hansman, & Paton 1994;Morona, Morona, & Paton 
1997a;Morona, Morona, & Paton 1997b). The polysaccharide for the four types includes 
three sugars, glucose, rhamnose and manose in different repeating structures (Morona, 
Morona, & Paton 1997b), see illustration 4.2. The arrangement of the genes between the 
four types is highly conserved with genes 19A-H and K-O  being common to all four types, 
see illustration 4.3. These genes encode functions required for the synthesis o f the shared 
tri-saccharide component. Type B and C capsular polysaccharides contain an extra sugar, 
ribose, and both have side chains (Morona, Morona, & Paton 1997b).
Sequencing of the locus in serotypes 19F, A, B and C showed that sequences for 19A and F 
are very closely related; they have the same number of open reading frames in the same 
order with homologies ranging from 70.1% to 99.4% but there are differences in the length 
of the intergenic sequences. A distinct crossover point was found in 19M  where homology
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between 79/21k/ 1 and 19aM went from 80% to 98%. Comparison of sequences 79/7 and 19al 
show regions with a cluster of non-conservative amino acid substitutions which are 
predicted to account for the (a 1-3) bond in 19A and the (a 1-2) bond in 19F. The location 
of the extra gene predicted to be in 19C was investigated using long range PCR with a 
variety of primer pairs, and it was found to be between 19cK and 19cL. A partial putative 
biosynthetic pathway was proposed by (Morona, Morona, & Paton 1999b).
19F -2)-a-L-Rha-(l-P-4)-p-D-ManMAc-(l-4)-a-D-Glc-(l-
19A -3)-a-L-Rha-(l-P-4)-P-D-ManMAc-(l-4)-a-D-Glc-(l-
19B -4)-p-D-ManNAc-(l-4)-a-L-Rha-(l-P-4)-p-D-Glc-(l-
I
n-»3^
P-D-Rib-(l-4)-a-(j-Rha
B-D-Glc
I
a -» 6 i
19C -4) -P-D-ManNA*-(l-4)-a-L-Rha-(l-P-4)-p-D-ManNAc-(l-4)-p-D-Glc-(-l-
I
(1^3)
p-D-Rib-(l-4)-a-V<-Klia
Illustration 4.2. Chemical structures for the polysaccharide of serotypes 19F, 19A, 
19B and 19C. Structures for 19F and 19A were proposed by Lee and Fraser 
(Lee & Fraser 1980).
1 Where the serotype (subtype) and gene are described together, the type is in lower case and the gene upper 
case. This is standard in the literature.
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C p sl9 F
dex B  IS A B C D E F G H I J K L M N O  aliA
C p sl9 A
Y/X '/S
dex B  IS A B C D E F G H I J K L M N O  aliA
C p sl9B
dexB IS A B C D E F G H P I Q R  J K L M N  O aliA
C p sl9C
dex B  IS IS A B C D E F G H P I Q R  J K S L M N  O aliA
IS120
/S19C
>90% identity to cpsf
cpsl9b and cpsl9c 
specific
5kbp
70-90% identity to cpsl9f 
Cpsl9c specific
Illustration 4.3: Comparison of the cps loci for group 19. Reproduced from (Morona, 
Morona, & Paton 1999b).
4.1.4.5 Genetic determinants of serogroup 23
Serogroup 23 contains types 23F, 23A and 23B which are structurally quite distinct from 
other serotypes. Regions dexB to 23fB and 23fL to aliA are similar to the corresponding 
genes in 19F, but the internal portion is 4kb larger in 23F than 19F (Ramirez & Tomasz
1998).
4.1.4.6 Genetic determinants of serotype 3 polysaccharide
Type 3 is the only case where the CPS synthesis has been fully determined biochemically 
and genetically and it shows considerable differences to other serotypes (Munoz et al.
1999). Type 3 CPS is synthesised by a monomeric mechanism in which the two precursors 
UDP-glc (glucose) and UDP-glcA (glucuronic acid) are synthesised and then polymerised
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into the polysaccharide (Arrecubieta, Lopez, & Garcia 1994;Dillard, Vandersea, & Yother 
1995). A UDP glucose dehydrogenase is responsible for converting UDP-glc into UDP- 
glcA and is absolutely required, although knockout mutants will still produce CPS if the 
glucuronic acid moiety is provided as a nutrient (Dillard, Vandersea, & Yother 1995). 
Cps3A is the first gene to be transcribed as the downstream open reading frames and genes 
with homology to other sequences are not transcribed (Arrecubieta, Lopez, & Garcia 1994), 
see illustration 4.4. The first sequence downstream of dexB is over 90% homologous to 
cpsA of other serotypes, see fig 5.4 (Garcia, Llull, Munoz, Mollerach, & Lopez 2000). 
Open reading frames 1 and 2 share 93% sequence homology to cpsl9fC  and cpsl9fD. 
Dillard et al. reported the whole nucleotide sequence of the serotype 3 CPS from WU2 
(which is a derivative of a clinical strain) and described genes cps3D, cps3S and cps3U 
which showed 99%, 97.6% and 99.7% homology with cps3A, cps3B and cps3C as 
described by Arrecubieta et al. (Arrecubieta, Lopez, & Garcia 1994;Dillard, Vandersea, & 
Yother 1995). Sequence analysis suggested that cpsA-C are arranged as a single unit and 
transcribed as an operon (Dillard, Vandersea, & Yother 1995) and a promotor sequence 
was located upstream of the start codon of cpsA (Garcia, Garcia, & Lopez 1993). Many 
genes required for the CPS synthesis of other serotypes are not present in serotype 3 CPS 
locus e.g. 19fB (Arrecubieta, Lopez, & Garcia 1994). The biochemical pathway of serotype 
3 CPS synthesis is summarised in illustration 4.5.
dexB
Illustration 4.4: Genetic arrangement of serotype 3 capsulation locus. F  Shows
transcriptional start point. Genes with sequence homology to other capsulation locus 
genes but that are not transcribed in serotype 3, redrawn from (Munoz, Mollerach, Lopez, 
& Garcia 1999).
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GIc-6-P
I
Phosphoglucomutase
I
Glc-l-P
Glucose 1 P uridylyltranserase
I
UDP-Glc + Ppi
UDP glucose dehydrogenase
T
UDP-GlcA
Tvoe 3 polysaccharide svnthase
T
-(GlcA-Glc)-n
Illustration 4.5. Biochemical synthetic pathway for serotype 3 CPS, redrawn from (Dillard, 
Vandersea, & Yother 1995).
4.1.4.7 Genetic determinants of serotype 37 polysaccharide
The type 37 capsule is the simplest of all capsular polysaccharides, being composed of a 
homopolysaccharide of glucose in the form of polymerised glucose (|3-D-Glc-(1—»2)-(3-D- 
Glc) linked by p-1, 3 bonds. The biosynthesis of this capsule is driven by a single gene, tts, 
which is located outside of the capsulation locus. CPS 37 locus is found to be almost 
identical to cps33f sequences, although some of the genes have been inactivated by 
mutations. It is the first naturally stable binary strain and a novel strategy for capsule 
synthesis in S. pneumoniae (Llull et al. 1999;Llull, Lopez, & Garcia 2000).
4.1.4.8 Comparison of sequences between serotypes
The first few genes downstream of dexB and upstream of aliA are highly homologous 
among most serotypes. A comparison between 19F and 23F was made by Morona et al.
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1999. They found that genes dexB to cpsB (inclusive) and cpsL to aliA were completely 
conserved. CpsC to cpsE were less, but still significantly homologous and genes cps23fT, 
I, U, V, J, W, X, Y and Z showed little similarity to 19F. Serotype 3 is different in its gene 
arrangement containing untranscribed genes, see illustration 5.4 (Morona, Morona, & Paton 
1999b).
4.1.4.9 Insertion Sequences
IS1202, found in 19F, was the first insertion sequence to be described for S. pneumoniae. It 
has all o f the characteristics of a transposable element and is thought to have originated in 
S. pneumoniae as it is unrelated to previously characterised sequences from other 
organisms and its GC1 content (39.5%) is consistent with pneumococci. IS1202 is 
integrated downstream of dexB and is found in other locations in the 19F genome, copy 
number between one and five, but is rarely seen in other serotypes (Morona et al. 1994). 
Insertion sequences are frequently found in the capsulation loci and are serotype specific, 
although there is homology between some serotypes, e.g. 8  and 2  contain the same insertion 
sequence.
4.1.4.10 Recombination of capsular polysaccharide genes allow for capsular switching
Griffith was the first to recognise and study capsular transformation in vitro and in vivo to 
see to what extent it affected the outcome of infection (Griffith F 1928). Knowledge of the 
fact that transformation resulted in loss of the original type, with a few exceptions (see 
binary encapsulation, section 1 .2 .2 .6 ), suggested that the genes were transferred as a single 
unit or cassette, with the new genes replacing the old genes (Austrian et al. 1959).
The Spanish multiple resistant serotype 19A, 19F and 23F isolates and a Polish multiple 
resistant 19F strain are all clones of the same isolate having undergone natural 
transformation in vivo at the CPS locus on multiple occasions. The recombination gave rise 
to clones differing only by serotype, shown by repetitive element primer PCR (REP-PCR) 
and the sequencing of housekeeping genes. The crossover points were partially located and 
cpsM  and N  were implicated as well as locations upstream of dexB and downstream of aliA. 
The size of the fragments could not be determined as only the internal crossover points
'Guanine and cytosine, percentage differs between bacteria
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were located, but were thought to be in excess of 15kbp. Homologous crossover points 
were found in two strains suggesting that homologous recombination took place, rather 
than an illegitimate or a transposon mediated event, however, the possibility of transduction 
cannot be ruled out. Variants of 19F isolates were found suggesting that transformation 
took place on more than one occasion and that not all 19F strains are the result of the 
dissemination of a single clone (Coffey et al. 1998).
4.1.4.11 Common gene
Understanding the genetic and biochemical nature o f the mechanism of the synthetic 
pathway of the capsular polysaccharide could help in the design of a drug capable of 
blocking the expression of this important virulence factor (Ramirez & Tomasz 1998). Such 
a drug would need to target a protein that is common to all serotypes. So far, cpsA is the 
only gene common to all serotypes that can be found within the capsulation locus, however, 
this is not a suitable target since it is not an absolute requirement for capsule production.
4.1.4.12 The work in this chapter
The work in this chapter describes an evaluation of CpsAB PCR (Lawrence, Arias, Duke, 
Beste, Broughton, Efstratiou, George, & Hall 2000) and adaptation for use on clinical 
specimens.
4.1.4.13 Aim
To evaluate a previously published PCR/RFLP method for serotyping S. pneumoniae and to 
adapt the method for use directly on clinical specimens for field studies during this thesis.
135
Evaluation o f  CpsAB PCR for predicting serotype o f  Streptococcus pneumoniae
4.2 Materials and Methods
4.2.1 Polymerase chain reaction
The PCR was used as described previously (Lawrence, Arias, Duke, Beste, Broughton, 
Efstratiou, George, & Hall 2000). Primer sequences were as follows Cps A3 5’- 
ATCCTTGTCAGCTCTGTCTC-3 ’ and CpsB2 5 ’-TCACTTGCAACTACATGAAC-3 ’ 
(Amersham, Buckinghamshire, UK). The primers were re-hydrated and diluted to lOOmM 
stock solutions and frozen in lOOpL aliquots. Fresh aliquots were taken from the freezer 
and stored at 4°C. For each PCR reaction the master mix consisted of 5pL KC1 buffer 
(Bioline, London, UK), 2.5mM MgCk, 0.2mM of each dNTP (Promega, Southampton, 
UK), lOOng of each primer, 1.2 units Taq polymerase (Bioline, London, UK) and lpL 
template DNA (crude or genomic preparations) made up to a final reaction volume of 
lOOpL with PCR grade water. The cycling conditions were as follows: 95°C for 3 minutes 
followed by 30 cycles of 95°C for 1 minute, 50°C for 2 minutes and 72°C for 2 minutes 
followed by a final elongation at 72°C for 7 minutes. Amplimers were electrophoresed 
through 1% 30mL agarose gel according to materials and methods section 2.5.4 and 
visualised according to materials and methods section 2.5.5.
4.2.2 Restriction fragment length polymorphism
10 to 18pL of PCR amplimers were digested with 0.5pL Hinfi, Alul and Rsal (Promega, 
Southampton, UK) according to materials and methods section 2.6.6. Amplimers were 
separated through 4% agarose gels and visualised according to materials and methods 
sections 2.5.4 and 2.5.5.
4.2.3 Control DNA
Genomic DNA was prepared according to materials and methods section 2.5.2 from 
invasive pneumococcal isolate RFH 9 (serotype 18C), and used where appropriate.
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4.2.4 Thermocyclers
Two thermocyclers were used throughout this chapter. Originally an Omnigene (Hybaid, 
Middlesex, UK) in which 0.5mL tubes were used and the reaction mixture overlayed with 2 
drops of mineral oil. Then a Progene (Techne, Cambridge, UK) in which 0.2mL tubes 
were used and due to a heated lid mineral oil was not required. The Progene has a cooling 
block and the ramp rate (rate at which temperature change is achieved) is much faster.
137
Evaluation o f  CpsAB FCR for predicting serotype o f  Streptococcus pneumoniae
4.3 R esults
Section O ne: E stab lish in g  the PC R  and RFLP
4.3.1 The CpsAB PCR
The CpsAB PCR produced amplimers from cride (boil extracted) DNA from S. 
pneumoniae of different serogroups, figures 4.1 and L.2. 35 amplimers were obtained from 
41 isolates (85%).
H yperladder 1
Figure 4.1: CpsAB PCR using crude DNA extracted from blood culture S. pneumoniae 
isolates of different serotypes. Lane 1 contains Hypirladder I (Bioline). Lane 2 contains 
isolate number RFH 298 (14), lane 3 RFH 239 (unknown), lane 4 RFH 217 (unknown), 
lane 5 RFH 80 (11), lane 6 RFH 184 (unknown), hne 7 RFH 83 (5), lane 8 RFH 216 
(unknown), lane 9 RFH 210 (unknown), lane 10 RFH 186 (unknown), lanes 13 and 14 
blank and negative controls and lane 15 positive contnl RFH 9 (genomic DNA).
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H yperladder I
1.75 kbp
1.75 kbp
Figure 4.2: Lanes 1 and 19 contain Hyperladder I (Bioline), lane 2 contains isolate number 
RFH 366 (unknown), lane 3 RFH 262 (14), lane 4 RFH 300 (14), lane 5 RFH 270 
(unknown), lane 6 RFH 369 (unknown), lane 7 RFH 231 (9), lane 8 RFH 202 (23), lane 9 
RFH 232 (19), lane 10 RFH 54 (4), lane 11 RFH 292 (12), lane 12 positive control RFH 9 
(genomic DNA), lane 13 negative control, lane 14 RFH 265 (12), lane 15 RFH 302 (11), 
lane 16 RFH 61 (19), lane 17 RFH 51 (7), lane 18 RFH 194 (19), lane 20 RFH 56 (9), lane 
21 RFH 252 (8), lane 22 RFH 207 (1), lane 23 RFH 192 (1), lane 24 RFH 346 (unknown), 
lane 25 RFH 263 (17), lane 26 RFH 272 (16), lane 27 RFH 55 (14), lane 28 RFH 200 (6), 
lane 29 RFH 276 (unknown), lane 30 RFH 190 (unknown), lane 31 RFH 204 (4), lane 32 
RFH 338 (unknown), lane 33 RFH 266 (unknown), lane 34 RFH 230 (9), lane 35 negative 
control and lane 36 positive control RFH 9 (genomic DNA).
The reproducibility of the CpsAB PCR using boil extracted DNA is 86%, excluding isolate 
RFH 369 which was later confirmed not to be S. pneumoniae.
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4.3.2 Restriction digests of serogroup 6 and 23 PCR amplimers with HinfL and Alul
Single band amplimers from isolates of the same two serogroups were digested with Hinfi 
and Alu\. Serogroup 23 isolates shown in figure 4.3 and serogroup 6 isolates shown in 
figure 4.4.
1 OObp ladder lOObp ladder
Figure 4.3: RFLP digest of serogroup 23 PCR amplimers. (A) shows digestion with Hinfi 
and (B) digestion with AM . For both gels lanes 1 and 7 contain lOObp ladder (Invitrogen), 
lane 2 isolate RFH 6, lane 3 RFH 7, lane 4 RFH 13, lane 5 RFH 59 and lane 6 RFH 329.
1 4 0
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lOObp ladder 
f* ~  1500 bp
lOObp ladder
Figure 4.4: RFLP digest of serotype 6 PCR amplimers. (A) shows digestion with HinfI 
and (B) digestion with Alu\. For both gels lanes 1 and 9 contain lOObp ladder (Invitrogen), 
lane 2 contains isolate RFH 284, lane 3 RFH 10, lane 4 RFH 156, lane 5 RFH 200, lane 6 
RFH 221, lane 7 RFH 224, lane 8 RFH 260.
Since the RFLP for serotype 6 and 23 amplimers did not produce homogenous patterns 
PCR reactions were repeated using freshly prepared genomic target DNA, using the method 
detailed in section 2.6.2.
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4.3.3 PCR Using Genomic DNA
A genomic DNA extraction was used to prepare whole DNA from 51 isolates of mixed 
serotypes, by the method detailed in section 2.6.2 and was used for PCR reactions figures 
4.5, 4.6 and 4.7.
Hyperladder I
Figure 4.5: Lanes 1 and 15 contain Hyperladder I (Bioline), lane 2 isolate RFH 212 (11), 
lane 3 RFH 230 (9), lane 4 RFH 233 (3), lane 5 RFH 18 (9), lane 6 RFH 231 (9), lane 7 
RFH 78 (9), lane 8 RFH 3 (unknown), lane 9 RFH 327 (8), lane 10 RFH 89 (14), lane 11 
RFH 207 (1), lane 12 RFH 150 (12), lane 13 RFH 116 (1), lane 14 RFH 40 (14).
H yperladder I
mm
Figure 4.6: Lanes 1 and 15 contain Hyperladder I (Bioline), lane 2 isolate RFH 51 (7), lane 
3 RFH 360 (unknown), lane 4 RFH 240 (8), lane 5 RFH 81 (7), lane 6 RFH 135 (9), lane 7 
RFH 58 (14), lane 8 RFH 60 (14), lane 9 RFH 43 (11), lane 10 RFH 164 (7), lane 11 RFH 
248 (14), lane 12 RFH 302 (11), lane 13 RFH 27 (3), lane 14 RFH 45 (3).
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H yperladder I
1.5kbp
2kbp^^
1.75 kbp
Figure 4.7: Lanes 1 and 15 contain Hyperladder I (Bioline), lane 2 isolate RFH 216 
(unknown), lane 3 RFH 308 (unknown), lane 4 RFH 261 (1), lane 5 RFH 75 (3), lane 6 
RFH 321 (14), lane 7 RFH 204 (4), lane 8 RFH 250 (unknown), lane 9 RFH (unknown), 
lane 10 RFH 14 (8), lane 11 RFH 208 (14), lane 12 RFH 262 (14), lane 13 RFH 226 (9) and 
lane 14 RFH 292(12).
The reproducibility using genomic DNA was much lower than expected with 15/39 (38%) 
reactions shown producing an amplimer band. A Progene thermocycler with a cooling 
block was used (Techne, Cambrige, UK).
1 4 3
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2kbp-^
1.5kbp^
4.3.4 PCR Using a new thermocycler
The PCR was repeated using the same DNA as PCRs shown in figure 4.4 -4.8, stored at 
4°C overnight, but using the Progene thermocycler (Techne, Cambridge, UK). A mixture 
of samples which had previously either produced or not produced an amplimer are shown 
in figures 4.8 and 4.9.
H yperladder I
2 k b p - 
1.5kbp
Figure 4.8: Lanes 1 and 12 contain Hyperladder I (Bioline), lane 2 is empty, lane 3 isolate 
RFH 242 (3), lane 4 RFH 233 (3), lane 5 RFH 262 (14), lane 6 RFH 180 (14), lane 7 RFH 
60 (14), lane 8 RFH 58 (14), lane 9 RFH 298 (14), lane 10 RFH 16 (14), lane 11 RFH 75 
(3), lane 13 is empty, lane 14 RFH 321 (14), lane 15 RFH 89 (14), lane 16 RFH 208 (14), 
lane 17 RFH 27 (3), lane 18 RFH 40 (14), lane 19 RFH 248 (14), lane 20 RFH 45 (3), lane 
21 negative control, lane 22 RFH 9 (genomic DNA).
1 4 4
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H yperladder I
...... . .
Figure 4.9: Lanes 1 and 18 contain Hyperladder I (Bioline), lane 2 isolate RFH 16 (14), 
lane 3 RFH 40 (14), lane 4 RFH 43 (11), lane 5 RFH 48 (9), lane 6 RFH 54 (4), lane 7 RFH 
58 (14), lane 8 RFH 60 (14), lane 9 RFH 74 (11), lane 10 RFH 74 (11), lane 11 RFH 89 
(14), lane 12 RFH 105 (8), lane 13 RFH 135 (9), lane 14 RFH 150 (12), lane 15 RFH 164 
(7), lane 16 RFH 180 (14), lane 17 RFH 204 (4), lane 19 RFH 204 (4), lane 20 RFH 208 
(14), lane 21 RFH 219 (7), lane 22 RFH 231 (9), lane 23 RFH 248 (14), lane 24 RFH 250 
(unknown), lane 25 RFH 261 (1), lane 26 RFH 262 (14), lane 27 RFH 298 (14), lane 28 
RFH 308 (unknown), lane 29 RFH 321 (14), lane 30 RFH 360 (unknown) and lane 31 
negative control.
23/44 (52%) of reactions shown produced an amplimer using the Progene thermocycler.
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4.3.5 PCR using diluted DNA
To ensure that the low reproducibility of the PCR using genomic DNA was not as a result 
of too much DNA in the reaction, a PCR was performed using Vi0 dilutions of target DNA. 
Figure 4.10 shows a PCR of serotype 9 isolates was performed using neat and a ’/io dilution 
of the DNA. 5/7 reactions were positive using neat DNA and 2/3 reactions using DNA 
diluted Vio- This suggested that failed reactions were not due to the addition of excess 
DNA.
H yper ladder 1
Figure 4.10: Lane 1 contains Hyperladder I (Bioline), lane 2 is empty, lane 3 isolate RFH 9 
(18), lane 4 RFH 19 (34), lane 5 RFH 33 (22), lane 6 RFH 43 (11), lane 7 RFH 51 (7), lane 
8 RFH 52 (38), lane 9 RFH 19 (V 10), lane 10 RFH 33 ( 7 i 0), lane 11 RFH 52 (V i0) and lane 
12 negative control.
4.3.6 Reproducibility
The reproducibility is highest using boil extracted DNA, see table 4.1. However, RFLP 
digestions of PCR amplimers were more homogenous for isolates of the same serotype 
when genomic target DNA and the Progene thermocycler were used. Therefore, RFLP 
digestions were generated by these means and repeating the PCRs where necessary.
Table 4.1 Reproducibility for CpsAB PCR.
Boil extracted Genomic DNA Genomic DNA
DNA Omnigne Progene
Reproducibility 86% 38% 52%
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4.3.7 Digestion of PCR Amplimers
Since the reproducibility for crude DNA preparations was higher than for genomic DNA, it 
was decided to generate RFLP patterns from PCR amplimers generated using genomic 
DNA and then to use crude preparation to process specimens. PCR reaction were repeated 
for different serotypes and the amplimers digested. The PCR amplimers obtained digested 
with three enzymes: Hinfi, Alul and Rsal according to (Lawrence et al. 2000). Each 
serotype produced a unique RFLP pattern, for example serotype 3 in figure 4.11. Patterns 
were generated for serotypes or groups 1, 3,4, 6 , 8 , 9, 12, 18, 19 and 23 (data not shown for 
all types).
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Figure 4.11. Restriction digests of serotype 3 amplimers with enzymes (3A) Hinfl, (3B) Alu\ and (3C) /tori. Lanes 1 and 6 contain 
DNA size marker 100 bp ladder (Invitrogen, Paisley, UK). Lane 2 isolate number RFH 27, lane 3 RFH 45, lane 4 RFH 242 and lane 5 
RFH 283.
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Section  Tw o: A d ap tin g  the PC R  for direct use on clin ical specim ens
4.3.8 Using CpsAB PCR/RFLP to Identify Mixed Serotypes
The PCR was performed using target DNA from isolates of two serotypes that had been 
mixed. This was done to investigate whether the method could be adapted for clinical 
samples that may contain more than one strain. Figure 4.12 shows that digestion of PCR 
amplimers produced from mixed DNA samples (in the same reaction) produce RFLP 
patterns that do not match those of any serotype seen so far. This suggests that if more than 
one serotype of pneumococci were present in a clinical specimen e.g. throat swab, the 
CpsAB PCR should detect it i.e. by producing an RFLP pattern not associated with any one 
type. Any such sample should then be examined by culture for the different serotypes to be 
separated and identified.
100 bp ladder
Serotypes 9 3 9 9 3 9
14 14 3 14 14 3
Digestion Hinfi Alul
Figure 4.12: RFLP digest with Hinfi and Alul of CpsAB PCR amplimers from reaction 
mixtures that contained DNA from isolates of two serotypes. Lanes 1 and 8 contain 100 bp 
ladder (Invitrogen). Lane 2 contains a Hinfi digest of serotypes 9 (RFH 18) and 14 (RFH 
16). Lane 3 contains a Hinfi digest of serotype 3 (RFH 27) and 14. Lane 4 contains a Hinfi 
digest of serotype 9 and 3. Lane 5 contains an Alul digest of serotype 9 and 14. Lane 6 
contains an Alul digest of serotype 3 and 14. Lane 7 contains an Alul digest of a mixture of 
serotype 9 and 3.
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4.3.9 Performing CpsAB PCR on primary clinical samples
A method was established for using the CpsAB PCR on primary clinical samples.
Method 1:
Two throat swab samples were taken from my throat and immersed in lmL aliquots of 
STGG media. lOpL of each STGG sample was streaked onto a blood agar plate and 
incubated in 5% CO2 overnight. No colonies with typical pneumococcal morphology were 
seen, confirming that the samples did not contain pneumococci. A colony pick of S. 
pneumoniae from a fresh overnight culture was transferred to one aliquot of STGG media, 
referred to as the spiked sample, the other being the negative sample. A lOOpL aliquot 
each o f the spiked and negative STGG samples were then heated to 95°C for 5 minutes and 
spun at 16000g for 5 minutes and lpL of the supernatant used in a PCR. The PCR yielded 
no amplimer.
Method 2:
The DNA extraction was modified to include a phenol-chloroform and chloroform 
extraction step after heating at 95°C for 5 minutes and the PCR repeated. This PCR 
produced no amplimer. 10 pL o f the spiked and negative samples of STGG media were 
transferred to 25mL of BHI broth in universal containers, which were incubated at 37°C 
until turbid, ~ 8  hours. The universals containing the turbid broth were centrifuged at 
4000g for 5 minutes and the supernatant discarded. The cells were re-suspended in lmL 
sterile distilled water, transferred to an eppendorf tube and spun at 13000g for five minutes. 
The supernatant was discarded and the cells re-suspended in lmL sterile distilled water, 
lOOpL of this cell suspension was transferred to a 0.5mL eppendorf and heated to 95°C for 
five minutes. Cooled samples were spun at 16000g for five minutes and lpL of the 
supernatant was used in the PCR. The resulting PCR yielded no amplimer.
Method 3:
10 pL each of the spiked and negative samples were spread onto blood agar plates and 
incubated at 37°C in 5% CO2 overnight. Cells from both plates were harvested using a 
sterile disposable loop (Nunc, supplied by Western Laboratory Services, Hampshire, UK) 
by sweeping three times across the width of the plate at an angle of around 60°. The cells
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were suspended in lOOmL of sterile distilled water and heated to 95°C for five minutes and 
centrifuged at 16000g for five minutes. lpL of the resulting supernatants were used in the 
PCR. The spiked sample produced an amplimer whereas the negative one did not, figure 
4.13.
H yperladder I
Figure 4.13. CpsAB PCR amplimers from spiked throat swab. Throat swabs cultured on 
blood agar overnight in 5% CO2 at 37°C. Cells were harvested from plates using a sterile 
loop and a PCR was performed on boil extracted DNA from both samples. DNA was used 
neat in the PCR. Lane 1 contains DNA Hyperladder I (Bioline), lane 2 negative STGG 
sample, lane 3 spiked STGG sample. Lanes 4 and 5 contain RFH 6 and 9 (genomic DNA) 
and lane 6 negative control.
4.3.10 Nasopharyngeal Swabs
lOpL each of eight nasopharyngeal swabs that were collected from children at the TPC 
hospital in Tanzania, were streaked onto blood agar plates containing 4pg/mL gentamicin 
and incubated at 37°C in 5% CO2 overnight. DNA extraction method 3 (section 4.3.9) was 
followed and amplimers were produced for 5/8 samples. There was complete agreement 
between culture identification of S. pneumoniae and amplimers from the PCR in all but one 
sample where the culture was negative, but an amplimer was seen (details of culture data 
not shown here).
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4.3.11 Quality control
In addition to the quality control detailed in Lawrence et al., 35 strains of mixed 
streptococcal species (clinical isolates, except the NCTC strain) were cultured over night on 
blood agar and DNA was boil extracted and used in the PCR, as before (Lawrence, Arias, 
Duke, Beste, Broughton, Efstratiou, George, & Hall 2000). PCR amplimers were seen for 
Streptococcus cristae, which is a nasopharyngeal throat commensal organism. Figure 4.14 
shows 19/35 reactions performed (the remaining reactions were all negative). The two 
positive amplimers correspond to reactions containing S', cristae DNA at 1.5kbp.
H yperladder I
H yperladder I
Figure 4.14: Lanes 1 and 22 contains Hyperladder I (Bioline), lane 2 contains target DNA 
from S. parasanguis (85-81), lane 3 S. mutans (KPSK2), lane 4 S. sobrinas (OM2176), lane 
5 S. sobrinas (TM62), lane 6 S. salivarius (A385), lane 7 S. sobrinas (SL-1T), lane 8 S. 
mutans (161), lane 9 S. parasanguis (UC4989), lane 10 S. cristae (CR311), lane 11 S. mitis 
(K208), lane 12 S. vestibules (LV71), lane 13 S. cristae (CR3), lane 14 S. parasanguis 
(SS895), lane 15 S. salivarius (NCTC 8606), lane 16 S. parasanguis (MaM143), lane 17 S. 
sobrinas (OM265), lane 18 S. sobrinas (TM21), lane 19 duplicate of lane 18, lane 20 S. 
pneumoniae RFH 9 (genomic DNA), lane 21 negative control and lane 23 irrelevant 
sample.
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The PCR amplimer for S. cristae it is smaller than for S. pneumoniae and therefore 
discrimination could be made between the two bands on the basis of size. In an attempt to 
eliminate the possibility of the amplification from S. cristae, the annealing temperature was 
raised. The PCR was repeated with DNA from S. cristae and S. pneumoniae. No PCR 
amplimer was seen at 55°C or 53°C for either S. pneumoniae or S. cristae.
4.3.12 Testing of the CpsAB PCR using clinical samples containing S. pneumoniae
29 nasopharyngeal swabs, collected from the hospital at TPC, known to be contain S. 
pneumoniae were subcultured on blood agar plates and incubated overnight in 5% CO2 at 
37°C. Harvested cells were transferred into lOOpL sterile distilled water and heated at 95°C 
for five minutes. The samples were centrifuged at 16000g for five minutes and lpl of the 
supernatant was used in the PCR, see figures 4.15-4.17.
H yperladder I
2000bp
1500bp
Figure 4.15: CpsAB PCR amplimers. Lane 1 contains Hyperladder I (Bioline), lane 2 
isolate TPC 22, lane 3 TPC 23, lane 4 TPC 26, lane 5 TPC 31, lane 6 TPC 292, lane 7 TPC 
294, lane 8 TPC 296, lane 9 TPC 297, lane 10 TPC 307, lane 11 TPC 4861.
1 5 3
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H yperladder I
2 0 0 0 b p ___^
1 5 0 0 b p — ►
Figure 4.16: CpsAB PCR amplimers. Lane 1 contains Hyperladder I (Bioline), lane 2 TPC 
92, lane 3 TPC 155, lane 4 TPC 171, lane 5 TPC 184, lane 6 TPC 188, lane 7 TPC 193, 
lane 8 TPC 234, lane 9 TPC 238, lane 10 TPC 255, lane 11 TPC 256 and lane 12 TPC 309.
H yperladder I
2 0 0 0 b p ^
1500bp
tjp
1.75 kbp
Figure 4.17: CpsAB PCR amplimers. Lane 1 contains Hyperladder I (Bioline), lane 2 TPC 
262, lane 3 TPC 272, lane 4 TPC 279, lane 5 TPC 281, lane 6 TPC 282, lane 7 TPC 284, 
lane 8 TPC 288, lane 9 TPC 289, lane 10 TPC 290, lane 11 RFH 9 (genomic DNA), lane 12 
negative control.
12/30 (40%) of samples yielded a PCR amplimer. The serotypes of the TPC isolates were 
not known. The primer sequences were aligned cpsA and cpsB genes to attempt to 
ascertain a reason for this lower than expected reproducibility.
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4.3.13 PCR primer sequences
Sequences with the following accession numbers were obtained from the NCBI database: 
cpsl4A X85787, cps37 AJ131984, cps8  AJ239004, cps2 AF026471, cps33F AJ006986, 
cps23F AF057294, cpsl9A AF094575. The cpsA and cpsB primers sequences were 
aligned to relevant sequences within the cpsA and cpsB genes using the Human Genome 
Mapping Project Computing Services http://www.hgmp.mrc.ac.uk/ GCG10 program “pile 
up” function.
For CpsA primer the sequence alignment is 100%. The cpsB primer for which the 
alignment is 100 % for serotype 14 cspB sequence and is different at two base pairs for 
serotype 2 and 8 , see figure 4.19.
cps33fA 5 ’ - TCTGTTGCTG TTCTCTATCC TTGTCAGCTC TGTGTCGCTC TTTGCAGTAC 
cps3 7fA 5 ’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC TGTGTCGCTC TTTGC AGTAC 
cps2fA 5 ’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC TGTGTCGCTC TTTGCAGTCC 
cpsA_primer 5 ’ - ATCC TTGTCAGCTC TGTGTC
cpsl4A  5 ’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC TGTGTCGCTC TTTGC AGTAC 
cps23fA 5 ’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC TGTGTCGCTC TTTGC AGTAC 
cps8A 5 ’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC AGTGTCGCTC TTTGC AGTAC 
cpsl9aA  5’ - TCTGTTGGTG TTCTCTATCC TTGTCAGCTC TGTGTCGC TCTTTGCAGT
Figure 4.18: Sequence alignments of cpsA primer with cpsA gene sequences.
cpsl4B  5’ - GAACGTGATT TAGTTCATGT AGTTGCAAGT GACATGCACA ATTTAGACAG 
cpsB primer 5 ’ - GTTCATGT AGTTGCAAGT GA
cps2B 5’ - GAGCAGGATT TGGTTCATGT CATTGCAAGT GATATGCACA ATTTAGACGG 
cps8B 5’ - GAGCAGACTT TGGTTCATGT CATTGCAAGT GACATGCACA ATCTAGACGG
Figure 4.19: Sequence alignments of cpsB primer with cpsB gene sequences. The
nucleotides that are not homologous are underlined.
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4.4 Discussion
Amplimers were produced from boil extracted DNA from serogroup or type 6 , 11, 14, 19 
and 23 isolates, however, for some of the isolates the RFLP digests were not conserved 
among the serogroup, see figures 4.3 and 4.4. Genomic DNA was used in amplification 
reactions and subsequent RFLP digests were homogeneous.
The PCR does not produce an amplimer for every reaction, this does not appear to be 
serotype specific since isolates from which no amplimer was produced were not of the 
same serotype (data not shown). Neither were the reactions overloaded with DNA, which 
is a common cause of failed PCR reactions, since a Vio dilution did not show amplimers in 
all lanes, see figure 4.10.
An advantage of the CpsAB PCR is that amplimers can be produced using crudely 
extracted pneumococcal target DNA from a mixed culture. This is a major advantage for a 
PCR designed for use in a routine diagnostic laboratory, however, conditions would need to 
be optimised for such use so that amplimers were produced for every reaction.
Examination o f the primers published in Lawrence et al. 2000, show that the sequence 
alignment with some serotypes is good. Redesigning the primers may increase the 
reproducibility o f the PCR but it is likely that the published work involved steps to improve 
the primers.
The target of the CpsAB PCR is within two genes of highly conserved sequences that are 
present in all serotypes. Since the two genes are common to all types and are not among 
those required for serotype specific capsule synthesis, then the sequence variation between 
subtypes of the same serogroup is likely to be limited. Since the cpsA and cpsB genes are 
not involved in the production of serotype specific capsular polysaccharide it is 
coincidental that each RFLP pattern is individual to a serotype. Should mutations occur in 
these genes, that are unrelated to the evolution of novel serotypes then the patterns assigned 
to serotypes would need to be updated, but sera would be needed to identify the serotype of 
a novel pattern. In addition, mutations could occur in serotype specific genes, with no
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change in the cpsA and cpsB genes, which may evolve a new serotype that may not be 
identified by this method.
In conclusion the cpsA and cpsB genes are of limited use, since only serogroups can be 
recognised as serotype specific genes are not targeted by the CpsAB PCR. A PCR which 
targets the whole capsulation locus may provide serotype specific data. Long range PCR 
that targets the whole capsulation locus is described in chapter five.
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Chapter Five 
Design of a Molecular Technique for Serotyping 
Streptococcus pneumoniae
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5.1 Introduction
5.1.1 The need for a molecular serotyping method
The high cost o f pneumococcal antisera prohibits many laboratories from performing 
serotyping, especially in developing countries (Lalitha et al. 1999). The “chess board” 
method using pooled sera makes the application more affordable, but does not offer 
subtype data or type strains not included in the 23-valent vaccine (Lalitha, Thomas, 
Kumar, & Steinhoff 1999). A combination of homology and diversity at the capsulation 
locus makes it an attractive target for a molecular based typing method using PCR and 
RFLP.
It is clear from the literature that all the genetic elements contributing to serotype are 
contained within the locus, and that the rest of the genome need not be considered. A 
second vital piece of information is that the entire locus is flanked by dexB and aliA 
genes, which are highly conserved among different serotypes, see introduction to 
chapter four. These genes are therefore ideal for targeting primers. It was here that a 
crucial decision presented: whether to amplify the whole locus using long range PCR, 
which would require target DNA of a high quality, or to design a multiplex PCR which 
would amplify portions of the locus so that a combination of amplimers produced and / 
or RFLP of some products would distinguish serotypes. It was decided that should the 
long range PCR be successful, this would provide a simpler technique. Both solutions 
had advantages and disadvantages. A multiplex PCR would involve designing many 
primer pairs to accommodate the many different sequences, and to make this more 
complicated, there are not published sequences for the capsulation loci from 
infrequently isolated serotypes. But the size of the target amplimer would make a long 
range approach lengthy in terms o f optimisation. However a major advantage o f the 
long range PCR is that, since the primers are outside o f the coding genes o f the locus 
primer design would not be restricted by knowledge o f serotype specific sequences. 
Additionally non-typeable strains may become typeable by this method, and in the same 
way novel types may be recognised more quickly as the PCR is not dependent on the 
homology of genes for which the diversity of the CPS is dependent.
5.1.2 The work in this chapter
The aim of the work in this chapter was to design and optimise a long range PCR to 
amplify the whole o f the pneumococcal capsulation locus and to show that digestion of 
this PCR product would generate serotype specific patterns.
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5.1.3 Aim
To design a long range PCR/RFLP technique for serotyping S. pneumoniae by 
amplification of the whole capsulation locus and digestion with one enzyme to produce 
serotype specific patterns.
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5.2 Materials and Methods
5.2.1 Long range PCR -  optimised cycle
Oligonucleotide primers of the following sequences were used: aliA2 5’-ATG CAG 
CTA AAG TAG TCG CC-3’ and dexB2 5’-GAC CGT CGC TTC CTA GTT GT-3\ 
The PCR reaction mixture consisted of 2pL REDAccutaq Long Amplification DNA 
Polymerase (Sigma, Poole, UK), 5pL buffer (supplied with Taq), 2mM dNTPs 
(Promega, Southampton, UK), 0.6pM HPLC primers (Sigma Genosys, Poole, UK) and 
the reaction mixture was made up to 50pL with PCR grade water (RFH pharmacy). 
The PCR reaction cycle consisted of 93°C for 2 minutes, followed by 30 cycles o f 93°C 
for 20 seconds, 50°C for 1 minute and 6 8 °C for 20 minutes and a final elongation at 
6 8 °C for 30 minutes.
5.2.2 Visualisation
5pL PCR products were electrophoresed through a 0.7% agarose gel using Hyperladder 
II (Bioline, London, UK) to estimate molecular size, as described in materials and 
methods section 2.6.5.
5.2.3 RFLP
RFLP were performed as described in materials and methods section 2.2.13. Briefly, 
20pL PCR product was mixed with lpL Hinfi enzyme (Promega, Southampton, UK), 
0.2pL BSA and 5pL buffer. The digests were incubated at 37°C for four hours using a 
Progene thermocycler in 0.2pL tubes (Alpha laboratories, Hampshire, UK), and then 
held at 4°C until being electrophoresed through a 3% agarose gel and visualised 
according to materials and methods sections 2.6.4 and 2.6.5.
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5.3 R esults
5.3.1 Optimisation of the long range PCR
Optimisation steps have not been described in detail but a brief discussion of steps and 
conditions which were crucial in the design are outlined.
5.3.1.1 Primer design
The first primers were designed within the homologous dexB and aliA regions that flank 
the locus, illustration 5.1. The target amplimer is 23 kbp and it includes all genes 
required for serotype specific carbohydrate synthesis. A serotype 23 capsulation locus 
sequence were used to design a primer pair with the following criteria: GC1 content 
>50%, 20 nucleotides in length, 3’ GC rich end and containing no palindromic 
sequences longer than 5bp.
dexB gene capsulation locus aliA gene
■■►
Primers: dexB aliA
Illustration 5.1: Diagram of long-range PCR primer positions within the capsulation 
locus. DexB is the forward primer aliA is the reverse primer.
However, with these primers the PCR was not reproducible for other serotypes so 
primers were redesigned following the same criteria but using piled up sequences of 
dexB and aliA genes from different serotypes, obtained from the 
http://www.ncbi.nlm.nih.gov/entrez/Nuc 1 eotide site.
Capsulation locus sequences, accession numbers: cpsl4A X85787, cps37 AJ131984, 
cps8 AJ239004, cps2 AF026471, cps33F AJ006986, cps23F AF057294, cpsl9A 
AF094575, were used in sequence alignments that were performed using the Human 
Genome Mapping Project Computing Services http://www.hgmp.mrc.ac.uk/ GCG10 
program “pile up” function.
1 T he h igher the  GC con ten t the tigh ter the p rim er : target b inding as G :C  bond  is stronger then  A :T
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Homologous sequences were chosen from the alignments, and “Oligo” software (Primer 
analysis software version 4, Wojciech Rychlik 89-91)  was used to confirm that primer 
dimer formations would not have a 3’ overlap. The forward sequence matches the 
target sequence coding strand, and the reverse primer is the mirrored complementary 
sequence to the target DNA. The chosen primer sites are shown in figures 5.1 and 5.2.
Additional forward and reverse primers were designed to target the cpsD gene, but more 
than one was required as the cpsD  gene sequences were not found to be homolgous for 
different serotypes. Multiple bands were seen using the cpsD primers as a result of 
which the use of these primers was discontinued.
Amplimers with multiple bands wee frequently seen and HPLC purified primers, of the 
same sequences, were found to reduce multiple amplimers seen for many reactions.
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cps37_dexB AAAGGTGTTC CGATTGAAGA AATCATGGAC AGTATCCGTG TTATTGGACG
cps3_dexB AAAGGTGTTC CGATTGAAGA AATCATGGAC AGTATCCGTG TTATTGGACG
cpsl_dexB AAAGGTGTTC CGATTGAAGA AATCATGGAC AGTATCCGTG TTATTGGACG
cps8_dexB AAAGGTGTTC CGATGCAAGA AATCATGGAC AGTATCCGTG TTATTGGACG
cpsl4_dexB ---------- -------- - ------------- ---------------------- -
cps33F_dexB  GGTGTTC CGATTGAAGA AATCATGGAC AGTATCCGTG TTATTGGACG
cps37_dexB 
cps3_dexB 
cpsl_dexB 
cps8_dexB 
cpsl4_dexB
351
TGACAATGCC
TGACAATGCC
TGACAATGCC
TGACAATGCC
CGTACCCCTA
CGTACCCCTA
CGTACCCCTA
CGTACCCCTA
TGCAATGGGA
TGCAATGGGA
TGCAATGGGA
TGCAATGGGA
CGAGAGCAAA
CGAGAGCAAA
CGAGAGCAAA
CGAGAGCAAA
400
AACGCTGGTT
AACGCTGGTT
AACGCTGGTT
AACGCTGGTT
cps33F dexB TGACAATGCC CGTACCCCTA
401
cps37_ dexB TCTCAACAGG TCAACCTTGG
cps3_ dexB TCTCAACAGG TCAACCTTGG
cpsl_ dexB TCTCAACAGG TCAACCTTGG
cps8_ dexB TCTCAACAGG TCAACCTTGG
cpsl4 dexB ---------------- — AACCTTGG
cps33F_dexB TCTCAACAGG TCAACCTTGG
451
cps37_ dexB AACGTCCAAG AAGCGCTGGC
cps3_ dexB AACGTACAAG AAGCGCTGGC
cpsl_ dexB AATGTCCAAG AAGCGCTGGC
cps8_ dexB AACGTCCAAG AAGCGCTGGC
cpsl4 dexB AATGTCCAAG AAGCGCTGGC
cps33F dexB AACGTCCAAG AAGCGCTGGC
501
cps37_ dexB GAAACTGGTC CAAATTCGCA
cps3_ dexB GAAACTGGTC CAAATTCGCA
cpsl_ dexB GAAACTGGTC CAAATTCGCA
cps8_ dexB GAAACTGGTC CAAATTCGCA
cpsl4_ dexB GAAACTGGTC CAAATTCGCA
cps33F_ dexB GAAACTGGTC CAAATTCGCA
551
cps37_ dexB TTGAATTGCT TGATACGGCT
cps3_ dexB TTGAATTGCT TGATACGGCT
cpsl_ dexB TTGAATTGCT TGATACGGCT
cps8__dexB TTGAATTGCT TGATACGGCT
cpsl4 dexB TTGAATTGCT TGATACGGCT
cps33F_dexB TTGAATTGCT TGATACGGCT
651
cps37_dexB CTTGACAGTA GAAGGAAAAG 
cps3_dexB CTTGACAGTA GAAGGAAAAG 
cpsl_dexB CTTGACAGTA GAAGGAAAAG 
cps8_dexB CTTGACAGTA GAAGGAAAAG 
cpsl4_dexB CTTGACAGTA GAAGGAAAAG 
cps33F_dexB CTTGACAGTA GAAGGAAAAG
TGCAATGGGA CGAGAGCAAA AACGCTGGTT
450
TTGGCGGTTA ATCCAAATTA CGAGATGATC 
TTGGCGGTTA ATCCAAATTA CGAGATGATC 
TTGGCGGTTA ATCCAAATTA CGAGATGATC 
TTGGCAGTTA ATCCAAATTA CGAGATGATC 
TTGGCGGTTA ATCCAAATTA CGAGATGATC 
TTGGCGGTTA ATCCAAATTA CGAGATGATC
500
AAATCCAGAT TCTATTTTCT ATACCTATCA 
AAATCCAGAT TCTATTTTCT ATACCTATCA 
AAATCCAGAT TCTATTTTCT ATACCTATCA 
AAATCCAGAT TCTATTTTCT ATACCTATCA 
AAATCCAGAT TCTATTTTCT ATACCTATCA 
AAATCCAGAT TCTATTTTCT ATACCTATCA
550
AGGAGAATAG TTGGCTAATT CGAGCTGACT 
AGGAGAATAG CTGGCTAATT CGAGCTGACT 
AGGAGAATAG CTGGCTAGTT CGAGCTGACT 
AGGAGAATAG CTGGCTAATT CGAGCTGACT 
AGGAGAATAG CTGGCTAGTT CGAGCTGACT 
AGGAGAATAG TTGGCTAATT CGAGCTGACT
600
GATAAGGTCT TTGCTTATAT ACGTAAGGAT 
GATAAGGTCT TTGCTTATAT ACGTAAGGAT 
GATAAGGTCT TTGCTTATAT ACGTAAGGAT 
GATAAGGTCT TTGCTTATAT ACGTAAGGAT 
GATAAGGTCT TTGCTTATAT ACGTAAGGAT 
GATAAGGTCT TTGCTTATAT ACGTAAGGAT
650
AAGAGCAAGA 
AAGAGCAAGA 
AAGAGCAAGA 
AAGAGCAAGA 
AAGAGCAAGA 
AAGAGCAAGA
700
TCAAATCTGT CTTGATTGAA AACACCCTAG 
TCAAATCTGT CTTGATTGAA AACACCCTAG 
TCAAATCTGT CTTGATTGAA AACACCCTAG 
TCAAATCTGT CTTGATTGAA AACACCCTAG 
TCAAATCTGT CTTGATTGAA AACACTGCGG 
TCAAATCTGT CTTGATTGAA AACACCCTAG
60
cps37 _dexB GG
cps3_ dexB GG
cpsl_ dexB GG
cps8_ dexB GG
cpsl4 _dexB GG
cps33F_ dexB GG
;g a c c g t c
:g a c c g t c
:g a c c g t c
:g a c c g t c
:g a c c g t c
3£AGCGTC
GCTTCCTAGT
GCTTCCTAGT
GCTTCCTAGT
GCTTCCTAGT
GCTTCCTAGT
GCTBfcCTlAGT
TGI
TGI
TGI
TGI
TGI
TGI
GGCTAAC
GGCTAAC
GGCTAAC
GGCTAAC
GGCTAAC
GGCTAAJC
TTGTCCAATG
TTGTCCAATG
TTGTCCAATG
TTGTCCAATG
TTGTCCAATG
TTGTCCAATG
Figure 5.1 Sequence alignments for dexB gene.
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cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
cpsl9A_aliA
cps8aliA
cps37_aliA
cps23F_aliA
cps33f_aliA
50
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - —  - - - - - - - - - - - - - - -   G A A A G T T T T A A
A T T C T G T T G A  C A A C T T T C T G  A A A A G A G T C T  A T A A T G G A G A  G A A A G T T T T A
51 100
- - - - - - - - - - - - - ~ T G ATG A AA A G T T C A A G A C T A T  T T G C C C T T G C  G G G C G TG A C A
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TTATTGG 
TTATTGG 
TTATTGG 
TTATTGG 
T'TAl IGQ
GG C G A C T A C T T T  
GG C G A C T A C T T T  
GG C G A C T A C T T T  
GG C G A C T A C T T T  
GrG CGA|CTA)3TTjr
A G C T G C A 1 
A G C TG C A 1 
A G C T G C A 1 
AGCTGCA' 
AGbTCtAJ3
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GC T C T G G A T C A G  G T T C A A G C A C  
C T C T G G A T C A G  G T T C A A G C G C  
C T C T G G A T C A G  G T T C A A G C A C  
C T C T G G A T C A G  G T T C A A G C A C  
C  ------------------- -
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T AA A G G T G A G  A A A A C A T T C T  C A T A C A T T T A  T G A G A C A G A C  C C T G A T A A C C  
TAA A G G T G A G  A A G A C A T T C T  C A T A C A T T T A  T G A G A C A G A C  C C T G A T A A C C  
T A A A G G T G A G  A A G A C A T T C T  C A T A T A T T T A  T G A G A C A G A C  C C T G A T A A C C  
TA A A G G T G A G  A A G A C A T T C T  C A T A C A T T T A  T G A G A C A G A C  C C T G A T A A C C
201
T C A A C T A T T T
T C A A C T A T T T
T T A A C T A T T T
T C A A C T A T T T
G A C A A C T G C T  
G A C A A C T G C T  
G A C A A C T G C T  
GGGG ~ ~
AAG G C TG C G A
AAG G C TG C G A
A AG G C TG C G A
C A G C A A A T A T
C A G C A A A T A T
C A G C A A A T A T
250
T A C C A G T A A C
T A C C A G T A A C
T A C C A G T A A C
251
G TG G T T G A TG
G TG G T T G A TG
G TG G T T G A TG
G T T T G C T A G A
G T T T G C T A G A
G T T T G C T A G A
A A A TG A T C G C
A A A TG A T C G C
A A A TG A T C G C
T A C G G G A A C T
T A C G G G A A C T
TA C G G G A A C T
300
T T G T G C C G T C
T T G T G C C G T C
T T G T G C C G T C
301
T A T G G C T G A G
T A T G G C T G A G
T A T G G C T G A G
G A T TG G T C TG
G A T TG G T C TG
G A T TG G T C TG
T A T C C A A G G A
T A T C C A A G G A
T A T C C A A G G A
T G G A T T G A C T
T G G A T T G A C T
T G G A T T G A C T
350
T A C A C T T A T A
T A C A C T T A T A
T A C A C T T A T A
Figure 5.2 Sequence alignments for aliA gene.
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5.3.1.2 Template DNA
Only whole genomic template DNA was used for the long range PCR. The phenol 
chloroform genomic DNA preparation method, section 2.6.2, was initially used to 
prepare DNA, but the Promega kit (Southampton, UK) method was found to give more 
reliable DNA and reduce multiple amplimers.
5.3.1.3 Amplification Enzyme
The Expand Long Template PCR system was purchased from Roche (formerly 
Boehringer-Mannheim, Sussex, UK) as it was used for a similar but shorter PCR 
described by Morona et al in (Morona et al. 1999). The kit consisted of a Taq and Pwo 
enzyme mixture and three buffers. The buffers contained different concentrations of 
MgCL, one with the lowest, and three with the highest. Buffer three was recommended 
for PCR products larger than lOkbp and in the final reaction mixture provides 2.25mM 
concentration MgCL. However, amplification was not reproducible with the Roche kit 
and double the concentration of this enzyme was needed to obtain amplimers.
A new kit was bought REDAccutaq (Sigma, Poole, UK). The reaction mixture was 
prepared following the manufacturers’ guidelines, see methods section 5.2.2, but the 
cycling conditions were kept the same. The PCR was successful first time, using only 
the recommended amount of enzyme, and the REDAccutaq kit was used hereafter.
5.3.1.4 Magnesium chloride
Magnesium chloride titrations were performed on many occasions, e.g. with different 
primers, Taq, DNA and cycles. Experiments showed that the optimal amount of MgCl2 
is provided in the enzyme buffer for the REDAccutaq (Sigma, Poole, UK).
5.3.1.5 Cycle
A touchdown cycle was used initially since this approach had been shown to be 
successful for producing long range PCR amplimers (Morona, Miller, Coffey, 
Vindurampulle, Spratt, Morona, & Paton 1999). The cycle was modified to suit 
programming o f the Progene thermocycler (Techne, Cambridge, UK) and the melting 
temperatures o f the primers (annealing temperature being approximately 10°C below the 
melting temperature o f the primers1).
1 Information supplied by manufacuturer
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A few single band amplimers were seen for initial expteriments but multiple bands were 
repeatedly seen until a single annealing temperature wais used, the appropriate annealing 
temperature was found to be 50°C. At temperatures above 50°C no amplification is 
seen, and below amplification of additional bands is seen.
5.3.2 How Many Serotypes Does The PCR Work Foir?
Amplimers have been produced for the following seroty/pes: 1, 3, 4, 5, 6A, 6B, 7, 8, 9N 
and 9V, 12, 14, 15, 17, 18, 19A, 19F, 20, 23. Examples of which are seen in figures 5.3 
-5 .5 .
Hyperladder II
Figure 5.3: Long range amplimers of PCR of S. pnieumoniae serotype 14. Lane 1 
contains Hyperladder II, lane 2 contains amplimer produced with DNA from isolate 
RFH 16, lane 3 RFH 34, and lane 4 RFH 40.
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Hyperladder II
Figure 5.4: Long range PCR serogroup 19 isolates. Lane 1 Hyperladder II (Bioline), 
lane 2 isolate RFH 5 (serogroup 19), lane 3 RFH 25 (serogroup 19), lane 4 RFH 32 
(serotype 19F), lane 5 RFH 232 (serotype 19A), lane 6 RFH 244 (serotype 19A), lane 7 
RFH 325 (serotype 19F), lane 8 Tz 2412.3 (serogroup 19), lane 9 Tz 2701.2 (serogroup 
19), lane 10 RFH Tz 2710.1 (serogroup 19), lane 11 Tz 3213.1 (serogroup 19) and lane 
12 negative control.
Hyperladder II
Figure 5.5: Long range PCR for serogroups 6 and 19. Lane 1 Hyperladder II (Bioline), 
lane 2 isolate Tz 1701.3 (serogroup 19), lane 3 Tz 1804.1 (serogroup 19), lane 4 Tz 
2401.2 (serogroup 19), lane 5 Tz 2604.2 (serogroup 19), lane 6 Tz 0801.1b (serogroup 
19), lane 7 Tz 1402.1 (serogroup 19), lane 8 Tz 2702.1 (serogroup 19), lane 9 Tz 2902.1 
(serogroup 19), lane 10 RFH 10 (serogroup 6), lane 11 RFH 200 (serogroup 6), lane 12 
RFH number 221 (serotype 6B) and lane 13 RFH number 260 (serotype 6A).
5.3.3 Reproducibility
Out of 100 reactions 90 (90%) were positive, 4 (4%) were positive but with an 
additional band and 6 (6%) were negative.
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5.3.4 RFLP -  Choosing a restriction enzyme
Mapsort software (Human Genome Mapping Project Computing Services 
http://www.hgmp.mrc.ac. uk/) was used to choose a frequent (>20 times) and a not- 
frequent (<20 times) cutting enzyme. Hinfl (frequent) and HindlU (not frequent) were 
chosen.
PCR amplimers of serotype 14 isolates, figure 5.3, were digested with Hinfl and HindlU 
for 4 hours at 37°C, see section 2.6.6. Identical patterns were seen for serotype 14 
samples digested with Hinfl, and patterns which differed very slightly were seen for 
HindlU digests, see figure 5.6. Hinfl produced more than 12 bands, which were spread 
over the length of the gel. This enzyme was chosen as being suitable for the RFLP step, 
and was used henceforth.
I
Figure 5.6: RFLP digestion of long range PCR products with hinfl and hindlU for 
serotype 14 isolates. Lane 1 contains hinfl digest for isolate RFH 16, lane 2 hinfl 
digest for RFH 34 and lane 3 hinfl digests for RFH 40. Lane 4 contains Hyperladder I 
(Bioline). Lane 5 contains HindlU digest for RFH 16, lane 6 HindlU digest for RFH 34 
and lane 7 HindlU digest for RFH 40.
[yperladder
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5.3.5 Comparison of invasive (RFH) and carriage strains (Tanzania)
Four isolates of serogroup 6 of known subtype (RFH) were used for DNA extraction, 
PCR and RFLP and compared to seven carriage isolates (Tanzania). The restriction 
digests are shown in figures 5.19 and 5.20 and suggest that the two types of pattern seen 
are the same for the carriage and invasive strains from the two collections and represent 
subtypes 6A and 6B.
Hyperladder I
Figure 5.7: RFLP digestion with Hinfl of long range PCR products from blood culture 
isolates. Lanes 1 and 6 contain Hyperladder I (Bioline). Lane 2 RFH 221 (serotype 
6B), lane 3 RFH 200 (serogroup 6), lane 4 RFH 10 (serogroup 6), lane 5 RFH 260 
(serotype 6A).
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Hyperladder I
Figure 5.8: RFLP with Hinfl of long range PCR products of serogroup 6 carriage 
strains. Lanes 1, 6 and 10 contain Hyperladder I (Bioline). Lane 2 isolates Tz 5303-2, 
lane 3 Tz 7712-2b, lane 4 Tz 4613.3, lane 5 Tz 4202-1, lane 7 Tz 1003-2, lane 8 Tz 
1003-3 lane 9 Tz 8509-2
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PCR products were then produced for isolates of different serotypes that were available 
from blood culture and carriage isolates, and then digested using Hinfl. The digests 
were all electrophoresed through 30mL 3% gels. Running conditions were set as 
standard and are as follows: the current was set at 100 volts and run until the loading 
dye was at the very bottom of the gel and just starting to run off.
Some subtypes were assigned on the basis of the Royal Free strain patterns, and a very 
high degree of consistency was seen between patterns of known serotype from the 
Royal Free / invasive isolates. These patterns corresponded to those of the same 
serogroup but unknown subtype representing Tanzanian / carriage isolates. However, 
for some serotypes there is only one representative isolate. For other serogroups, such 
as 7, more than one pattern has been produced but without subtype data, the patterns 
cannot be assigned to a subtype, these patterns are arbitrarily given numerical subtypes 
e.g. 7.1 and 7.2.
5.3.6 Good agreement between patterns of the same serotype
Multiple isolates of the same serotype were used to show that there is good agreement 
of the restriction digests, see figures 5.9 and 5.10.
5.3.7 Patterns from multiple serotypes
Patterns were then generated for different serotypes using standardised electrophoresis 
conditions, see section 5.3.5, figures 5.11 to 5.26.
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Hyperladder I
Figure 5.9: RFLP digests of long range PCR products from serotype 19F isolates 
digested with hinfl. Lanes 1 and 6 contain 5pi Hyperladder I (Bioline), lane 2 isolate 
RFH 5 (serogroup 19), lane 3 RFH 32 (serotype 19F), lane 4 Tz 2701-2 (serogroup 19) 
and lane 5 Tz 2710-1 (serogroup 19).
1 7 3
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Hyperladder I 
2 kbp -  
1 kbp -
400 bp
Figure 5.10: RFLP digests of long range PCR products from serogroup 6A isolates 
digested with hinfl. Lanes 1 and 8 contain 5pi Hyperladder I (Bioline), lane 2 isolate 
RFH 10 (serogroup 6), lane 3 RFH 260 (serotype 6A), lane 4 Tz 4613-3 (serogroup 6), 
lane 5 Tz 4202.1 (serogroup 6), lane 6 Tz 1003-2 (serogroup 6), lane 7 isolate number 
1003-3 (serogroup 6).
1 7 4
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5.3.8 Patterns of all serotypes available
Figure 5.11: Serotype 1. Lane 1 
Hyperladder I, lane 2 isolate RFH 116 
and lane 3 RFH 206
Figure 5.13: Serotype 4. Lane 1 
Hyperladder I, lane 2 contains isolate 
Tz 1104-2, lane 3 Tz 368-2 and lane 4 
Tz 2706-1
Figure 5.12: Serotype 3. Lane 1 
Hyperladder I, lane 2 isolate Tz 8810- 
1, lane 3 Tz 2604-2.
Figure 5.14: Serotype 5. Lane
contains isolate Tz 7310-1 and lane 2 
Hyperladder I
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Figure 5.15: Serotype 6A. Lane I 
Hyperladder I, lane 2 contains isolates 
RFH 260, lane 3 Tz 4613-3, lane 4 Tz 
4202-1
Figure 5.16: Serotype 6B. Lane 1 
Hyperladder I, lane 2 Tz 5303-2 and 
lane 3 RFH 200
Figure 5.17: Serogroup 7. Lane 1 
Hyperladder I, lane 2 contains isolate 
RFH 18 and lane 3 RFH 51 (demoted 
type 7.1). Lane 4 contains Tz 2514-1, 
lane 5 Tz 4711-1 and lane 7 Tz 5301-2 
(denoted 7.2)
Figure 5.18: Serogroup 9. Lane 1 
Hyperladder I, lane 2 contains isolate 
RFH 18, lane 3 RFH 48, lane 4 RFH 
93 (9V). Lane 5 RFH 78, lane 6 RFH 
98 and lane 7 RFH 120 (9N).
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Figure 5.19: Serotype 11. Lane 1 
Hyperladder I, lane 2 contains isolate Tz
1101-2, lane 3 Tz 3912-1, lane 4 Tz
1102-1 and lane 6 5907-1
Figure 5.21: Serotype 19A. Lane 1 
Hyperladder I, lane 2 contains isolate 
RFH 25, lane 3 RFH 232 and lane 4 
RFH 244
Figure 5.20: Serotype 14. Lane 1 
Hypperladder I, lane 2 contains isolate 
RFH 16, lane 3 RFH 34 and lane 4 
RFH 40
ss
mmrn
.
Figure 5.22: Serotype 19F. Lane 1 
Hyperladder I, lane 2 contains isolate 
RFH 5, lane 3 RFH 32, lane 4 Tz 
2701-2 and lane 5 Tz 2710.1
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.
Figure 5.23: Serotype 22. Lane 1 
Hyperladder I, lane 2 contains isolate 
RFH 33
Figure 5.25: Mixed serotypes. Lane 1 
Hyperladder I, lane 2 contains isolate Tz 
5808-1 (serotype 18.1), lane 3 Tz 8715-1 
(serotype 18.2), lane 4 Tz 1103-1 
(serotype 20), lane 5 6614-1 (serotype 
17), lane 5 Tz 4119-2 (serotype 15) and 
lane 7 Tz 7310-1 (5)
Figure 5.24: Serotype 23. Lane 1 
contains RFH 13, lane 2 RFH 329 and 
lane 3 Hyperladder I
H'M
Figure 5.26: Mixed serotypes. Lanes 
1, 4 and 6 Hyperladder I, lane 2 
contains isolate Tz 3407-1 (serotype 
12), lane 3 Tz 8103-2 (serogroup 12) 
and lane 5 Tz 4603-3 (serotype 8)
1 7 8
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5.4 Discussion
The long range PCR strategy was chosen so that the resulting PCR would be capable of 
serotype differentiation. It was decided that the advantages o f having a PCR that 
included all o f the capsular genes outweighed the disadvantages; the disadvantage being 
the requirement for high quality DNA. No published PCR could be found that 
described such a large PCR with high reproducibility from the bacteriology literature on 
the capsulation locus. The largest published PCR at the outset of this project that 
focused capsulation o f genes was detailed in (Morona, Miller, Coffey, Vindurampulle, 
Spratt, Morona, & Paton 1999). Since this PCR could not be reproduced, primers were 
designed to target conserved dexB and aliA genes that flank the locus at either end and 
are outside the coding sequences. The loci between these positions are large; in excess 
of 2 2  0 0 0  base pairs in most serotypes.
It was thought that this approach would be robust for any serotype so an appropriate 
enzyme with proof reading activity was purchased. Initial experiments, with the first 
primers, were encouraging and indicated that the PCR would be successful. However, 
amplimers could not be generated for other serotypes and pile-ups of dexB and aliA 
sequences showed the primers were unlikely to work for other serotypes, so were 
abandoned. New primers were designed using piled up dexB and aliA sequences and 
the same criteria. However, using the same reaction conditions with the new primers it 
was not possible to produce amplimers. Due to initial success with the touchdown cycle 
for the original primers, the cycle was modified only slightly i.e. changes of the 
temperature increment and the initial annealing temperature. Titrations of nucleotides, 
MgCl2 , enzyme and primers were performed with the touchdown cycle. Using 
additional primers to shorten the target did not reduce the number o f additional bands 
being amplified. Changing to a single annealing temperature was critical and produced 
the first amplimer seen with primers dexB2 and aliA2 . Multiple bands were seen using 
these primers and many attempts were made to reduce non-specific binding. These 
include additional primers targeted to the cpsD gene to shorten the PCR, increasing the 
annealing temperature and titrations o f MgCb. A PCR performed using primers 
individually showed multiple amplimers so HPLC pure primers were purchased.
It is clear from the lengthy optimisation of this PCR that the crucial factors to optimise 
for a long range PCR are the cycle, in particular the annealing temperature, DNA 
quality and the right Taq polymerase. Furthermore, that changing the primer sequences
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changes other requirements e.g. the cycle. The annealing temperature is so critical that 
once optimised, an experiment using larger PCR tubes (on the same machine with a 
different heating block) induced multiple bands (data not shown). The Promega DNA 
extraction kit is quicker and easier to use than the phenyl chloroform method and pellets 
were consistently seen.
Unlike a project which sequences a gene, when the PCR may only be required to work a 
few times, a PCR for a serotyping technique should work every time. Repetitions o f the 
PCR before the new Taq was introduced showed some failed reactions (data not 
shown). This highlights the importance of choosing the appropriate Taq for the PCR 
and sampling from more than one company because repeating PCRs in routine work is 
uneconomical. Papers published since this work was begun, detailing long range PCR 
techniques, such as Jiang et al. and Llull et al. do not discuss how many times the PCR 
worked (Jiang, Wang, & Reeves 2001;Llull et al. 1999). The reproducibility of this 
PCR needs to be increased from 90% to 100% for routine use and it is thought that with 
more experience this is possible.
A unique RFLP pattern exists for each subtype tested thus far. The blood culture 
isolates collected from the Royal Free and carriage isolates from Tanzania o f the same 
serotype produced the same patterns. The origin of the isolate does not seem to affect 
the sequence of the capsulation locus and the method is suitable for isolates from these 
sites.
An evaluation of the method using Bionumerics software to show that patterns of the 
same serotype are significantly similar and that patterns of different serotypes are 
significantly different to base a typing system is detailed in chapter 6 .
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Chapter Six
Evaluation of a Long Range PCR / RFLP 
Serotyping Method
181
Evaluation o f  long ranee PCR /  RFLP serotvoing method
6.1 Introduction
6.1.1 Evaluation using a database
To use the long range PCR RFLP method for serotyping S. pneumoniae a database has 
to be established that contains all o f the patterns generated and that are to be used as 
reference patterns. Firstly this has to show that patterns representing the same serotype 
are consistently similar and that patterns representing different serotypes are 
consistently different. Secondly it has to show that patterns from unknown types can be 
serotyped using this database. Bionumerics (Applied Maths, Sint-Martins-Latem, 
Belgium) is a suitable software package for this purpose as it enables the creation of a 
database to which novel patterns can be compared.
6.1.2 Description of Bionumerics
RFLP patterns are normalised during which molecular sizes are assigned to the 
reference lane, DNA size ladder, of the very first image. These molecular sizes are then 
assigned to subsequent images which are stretched or shrunk to the appropriate size so 
that patterns from different gels can be compared. Once images have been normalised 
bands are selected for the test lanes. The band selection can be done manually or using 
the automatics band search tool.
Comparisons are then created for selected lanes using band based co-efficiencies, such 
as Jaccard and Dice, that take into account only the presence or absence o f a band. This 
calculates similarity co-efficiencies for all pairs of patterns on the bases of whether each 
band is present or absent in patterns being compared. The similarity coefficient is used 
to create a dendrograms using the un-weighted pair group method algorithm (UPGMA). 
This finds the two best matched patterns and averages both their coefficients. Then the 
next closely matched and averages the pair against the third pattern. This is repeated for 
all patterns. The dendrograms shows the average similarity co-efficient as a percentage 
similarity by clicking on the branch.
6.1.4 Aim
To evaluate the long range PCR/RFLP method described in chapter five using 
Bionumerics (Applied Maths, Sint-Martens-Latem, Belgium) and epidemiologically 
unrelated strains collected during fields studies in northern Tanzania.
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6.2 Materials and Methods
Bionumerics software version 2.0 (Applied Maths, Sint-Martes-Latem, Belgium) was 
used to perform similarity clustering o f restriction digests for each serotype using the 
manufacturers manual. During the course of this thesis the Bionumerics version was 
updated to 3.0. Dendrograms drawn using version 2.0 do not show percentages, which 
have been added for presentation. Dendrograms drawn using version 3.0 show 
percentage similarities.
6.2.1 Entering patterns into Bionumerics
The RFLP patterns were entered into Bionumerics Applied Maths, (Sint-Martes-Latem, 
Belgium) 2.0 and saved into a single database. The gels were all normalised by 
assigning bands sizes to the Hyperladder I (Bioline, London, UK). Since the largest 
bands did not resolve, the top band observed was assigned 2kbp. It was not necessary 
to alter the background colour, since it did not make the gels much clearer; hence why 
some o f the lanes appear darker than others. The bands were chosen using the search 
band tool, and adjusted by hand, for example, the band in the well at the top o f the gel 
was always marked, so this was deleted, and any shadows that were marked were also 
deleted. Bands were selected which could be seen on the image of the gel, by eye, that 
also had a corresponding peak on the graph to the right o f the screen. If a band did not 
have a corresponding peak, or there was a peak but no visible band, no band was 
selected. This criteria was used for every gel, and reconfirmed on a separate occasion.
6.2.2 Cluster Analysis
The Dice coefficient was chosen for the calculation of the similarity. The Dice 
coefficient is a band-based similarity coefficient which gives more weight to matching 
bands. Dendrograms were drawn using the un-weighted pair group method (UPGMA) 
clustering algorithm. The position tolerance was set to 1.5% and optimisation 1%, 
being the value that gave the best agreement between very similar patterns. 1 0 0 % 
similarity was seen for Hyperladder I lanes.
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6.3  R esu lts
6.3.1 Band selection
Bands were initially selected including bands with the following criteria: the top band of 
the RFLP digest and all subsequent bands down to the 200 bp marker. This showed that 
all patterns from different serotypes tested had less than 90% similarity, see figure 6.1. 
The least homologous patterns is for serotype 38 (30%) and the closest for serotypes 
18.2 and 6B (84%), figure 6.1.
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Figure 6.1: Patterns of different serotype showing less than 90%.
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6.3.1 Dendrograms of isolates of the same serotype or serogroup show agreement 
greater than 90%
Multiple patterns for each serotype were then included in a cluster analysis. It was 
noticed that for some serotypes the resolution of the bands was less clear after 3kpb. 
Bands were then deleted between 400bp and 200bp and clustering repeated. Patterns of 
different serotype showed a higher degree of similarity and those of different types 
remained below 90%.
6.3.1.a Position tolerance and optimisation settings
Different combinations of position tolerance and optimisation settings were tried until 
the appropriate combination was found that gave agreement above 90% for patterns 
from isolates that were known to be the same serotype and below 90% for patterns that 
were different. These settings are tolerant of single band differences, for example 
serotype 19F and 19A patterns, see figure 6.4.
For some serotypes the agreement is 100% such as serotype 14, figure 6.2, whereas 
most agree between 90 and 100%, such as serogroup 19 isolates, figure 6.3.
Figure 6.2: Dendrogram of serotype 14 patterns 
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Figure 6.3: Dendrogram of serogroup 19 patterns
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Figure6.4: Dendrogram showing greater than 90% similarity for patterns which were 
not labelled with the serotype. One lane for each representative pattern was used for 
comparison.
6.3.4 Patterns of unknown serotype
To test that isolates could be typed by this method, DNA was extracted from 5 strains of 
known serotype and used as template DNA in the long range PCR. The amplimers 
were digested. Patterns generated were entered into Bionumers 2.0 following the band 
selection criteria and compared to all patterns in the database using the cluster analysis. 
The test patterns were entered blind i.e. the pattern was not labelled with the serotype. 
All of the isolates were aligned with greater than 90% to another pattern representing 
the same serotype, figure 6.4.
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6.3.5 Non-typeable strains
In order to ensure that patterns which had not reacted with the pneumococcal antisera, 
or had given equivocal results would produce PCR products 11 isolates collected in 
Tanzania were subjected to long range PCR and subsequent RFLP. All isolates 
produced a PCR product. The RFLP patterns were entered into Bionumerics and an 
alignment was performed with patterns of known serotypes, figure 6.5. One of the 
strains (9/2B) produced a pattern that aligned to serotype 23F and the others produced 
novel patterns, suggesting that they are either non-vaccine serotypes or they are genuine 
non-typeables.
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Figure 6.5: The following isolates were used to generate serotype specific patterns. 
Serotype 1 RFH 116, RFH 206. Serotype 3 Tz 8810-1, Tz 2604-1. Serotype 4 Tz 
1104-2, Tz 3682-2, Tz 2706-1. Serotype 5 Tz 7310-1. Serotype 6 A RFH 260, RFH 6 , 
Tz 4613-3, Tz 4202-1, Tz 1003-2, Tz 1003-3. Serotype 6 B Tz 5303-2, Tz 7712-2b. 
Serotype 7.1 RFH 18, RFH 51. Serotype 7.2 Tz 2514-1, Tz 4711-1, Tz 5310-2. 
Serotype 8  Tz 4603-3. Serotype 9V RFH 18, RFH 48, RFH 93. Serotype 9N RFH 78, 
RFH 98, RFH 120. Serotype 11 Tz 1101-2, Tz 3912-1, Tz 1102-1, Tz 5907-1. 
Serotype 12 Tz 3407-1, Tz 8103-2. Serotype 14 RFH 16, RFH 34, RFH 40. Serotype 
15 Tz 2810-1, Tz 4119-2. Serotype 17 Tz 3708-2, Tz 6614-1. Serotype 18.1 Tz 5808- 
1. Serotype 18.2 Tz 8715-1. Serotype 19A RFH 25. Serotype 19F RFH5, RFH 32, Tz 
2701-2, Tz 2710-1. Serotype 20 Tz 1103-1. Serotype 22 3707-3. Serotype 23 RFH 13, 
RFH 329, RFH 6 , RFH 7. Serotype 38 RFH 52. The following strains were used to 
generate non-typeable patterns: Tz 9/2B, 8/7B, 10/3B, 3/1 A, 19/2A.
189
Evaluation o f  long ranee PCR /  RFLP serotvping method
6.3.6 Summary of Serotype specific patterns
Table 6 .1: Summary of patterns where serotypes are known of assumed
Serotype / Subtypes Subtypes
group assigned assumed
1
3
4
6 6 A & 6 B
7 7.1 & 7.2
8
9 9N & 9V
1 1
1 2
14
15
17
18 18.1 & 18.2
19 19C& 19F
2 0
2 2
23 23F
38
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6.4 Discussion
The PCR described in chapter five has been designed for use in routine microbiology 
practice, thus a single set o f primers and a single restriction digest were chosen. The 
requirement o f good quality DNA is a significant drawback because genomic DNA 
requires more time in preparation than boiling colony picks, however, this is 
compensated by the simplicity of the subsequent steps. A significant advantage o f this 
PCR is that there is no limitation by the availability of antisera and it should be possible 
to identify novel types by this method, provided they share the aliA -  dexB cassette 
arrangement. Importantly, this PCR RFLP method is capable of distinguishing 
subtypes, as shown for serotype 19A and 19F, 6 A and 6 B and 9N and 9V.
Laboratories handling small numbers of S. pneumoniae for whom buying a complete set 
of antisera is not economically viable will be able to use the long range PCR technique 
with the cost reflecting the number o f strains rather than an initial outlay.
There are single band differences between patterns produced from the same subtype, 
however, this was expected as the fragment o f DNA being digested is so large that 
single base pair or short sequence changes are likely to exist. However, entering 
multiple patterns o f the same serotype into Bionumerics, and performing alignments 
with other serotypes, shows that even with an additional band, or one missing, the 
sequences o f the same serotypes are still significantly aligned.
RFLP patterns of the same serotype have a similarity o f 90% or more, many patterns 
have 100%. When comparing a pattern o f unknown serotype to the database, the setting 
should be set at 1 % optimisation and 1.5% position tolerance, which were used to 
perform the alignments with existing patterns. The unknown patterns should appear on 
the screen aligned next to the closest two patterns, the corresponding serotype should 
have the highest similarity. It should be taken into account that minor alterations in the 
DNA sequence of the locus may alter the pattern, as seen in serotype 23F where one 
pattern appears to have one heavy band where the other lanes have two.
Digestion with Hinfl produces a high number o f bands that are evenly spaced along the 
length o f the gel. This gives good resolution of the patterns and is therefore suitable for 
analysis with Bionumerics. If the bands are feint, the peaks on the right hand side o f the 
screen should be used, bearing in mind that shadows in the gel not corresponding to a
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band i.e. uneven ethidium bromide staining should be ignored. If a less frequently 
cutting enzyme were to be used, producing fewer bands, selection of bands would be 
made easier. However, a single alteration in the band position or number would have a 
greater impact on the similarity and make the system more prone to error. The 
maximum number of bands possible will ensure that one or two bands differing from 
the reference pattern will still allow the serotype to be assigned. The alignments show 
that in general there is very good agreement between patterns of the same serotype e.g. 
serotypes 1 1  and 14 having 1 0 0 % agreement for more than two patterns.
This chapter has only dealt with a limited number of serotypes, however, it is likely that 
the patterns generated so far are representative o f all serotypes in that patterns 
representing different serotypes are significantly different. Thus including more 
patterns will not change the conclusion drawn so far, that the RFLP of the capsulation 
locus is capable o f serotyping S. pneumoniae.
Obtaining patterns for all 90 odd serotypes is outside the scope of this project and the 
resources at present, see further work in chapter ten. It may be that as more patterns, of  
serotypes not included at present, are entered into the database that the bands selection 
criteria and tolerance settings may need to be adjusted. As the PCR and RFLP is used, 
more refinements may improve the reproducibility o f the PCR and / or give closer 
alignments of patterns representing the same serotype.
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Chapter Seven
The Impact of Community Wide Distribution of 
Single-Dose Azithromycin on Macrolide 
Resistance in Streptococcus pneumoniae
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7.1 Introduction
7.1.1 Trachoma
Trachoma is the leading cause of preventable blindness and accounts for 15% of all 
blindness worldwide (Dawson et al. 1997). It is a chronic infection of the conjunctiva 
caused by infection by Chlamydia trachomatis. Repeat infection leads to scarring 
trachoma, in which the upper eyelid is shortened and distorted (entropion), turning in 
the eyelashes which then abrade the cornea (trachiasis); blindness results from 
corneal opacification (Fraser-Hurt et al. 2001). Other symptoms include pain and 
photophobia, which add to the disabilities associated with the disease (Frick et al. 
2001). Children are at greater risk of acquiring active trachoma, with incidence 
peaking in pre-school children, and young children are considered to be the major 
vector for C. trachomatis (Emerson et al. 2000b;West et al. 1991a). Blindness results 
from repeat infection over many years, thus, is more commonly seen in adults 
(Mabey & Fraser-Hurt 2001).
7.1.2 Prevalence of trachoma
Trachoma is a disease o f poverty with blinding trachoma prevalent in Africa, the 
Middle East, India, South West Asia and Aboriginal communities in Australia 
(Mabey & Fraser-Hurt 2001). The World Health Organisation (WHO) estimates that 
600 million people live in trachoma endemic areas, 150 million people have active 
trachoma, 1 0  million people need surgery and around 6  million are blind as a result of 
the disease (Schachter et al. 1999).
7.1.3 Risk factors for trachoma
Risk factors associated with trachoma are numerous and are mainly the results o f low 
socio-economic status such as poor hygiene and lack o f face washing, small crowded 
living spaces where families often share a bedroom and siblings share a bed, limited 
access to water, familial ownership of cattle, discharge from eyes and nose and facial 
contact between individuals - often mediated by flies, and sharing o f towels etc. 
(Hsieh et al. 2001;Mabey & Fraser-Hurt 2001;Taylor et al. 1989;West et al. 1996). 
The relationship between water use and trachoma was studied in a Gambian village 
where water use was compared between 18 families ( 6 8  children) with one active 
trachoma case per family and 16 trachoma free families (50 children). Families with 
trachoma were found to use significantly less water than the control group (Bailey et 
al. 1991) although this may reflect more on income and education levels o f the family
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rather than access to water (Emerson, Caimcross, Bailey, & Mabey 2000b). Another 
study in the Gambia showed that Muscid flies (.Musca sorbens -  bazaar fly and 
Musca domestica -  housefly) and trachoma were associated with M. sorbens as the 
principal vector, being responsible for >90% eye contacts (Emerson et al. 2000a). 
Two village communities of similar size, age composition and ethnicity were studied. 
One village, in which a fly intervention program reduced the number of flies, was 
compared to a control village. The village with the fly intervention program had 61% 
fewer cases o f trachoma during the study and the overall risk of becoming a new 
active trachoma case was 75% lower (Emerson et al. 1999).
Women are at greater risk from blinding complications o f trachoma (West et al. 
2 0 0 1 ) with a four-fold increase of trachoma observed in women than in men in a 
study in central Tanzania (West et al. 1991b). Risk factors for women include history 
of trachoma in the individuals mother, living in a room with a fire and in a house 
made from wood and earth, and being a child carer (Turner et al. 1993).
7.1.4 Effects of trachoma on village life
A study in the Kongwa district of Tanzania investigated the disabling effects and 
limitations of active trachoma and blindness resulting from trachoma on the daily 
activities of village life. 3064 individuals were sampled, examined and questioned as 
to impairments on daily activities of village life. The findings were that disability 
from trachoma was greater than previously thought, due to pain and photophobia not 
associated with other causes of visual impairment, and that women were more 
affected by active trachoma than men. Excess functional limitation was seen in men 
and women with visual loss or blindness from trachoma (Frick, Melia, Buhrmann, & 
West 2001).
7.1.5 Treatment of trachoma
Previously topical antibiotics, such as tetracycline, have been used to treat trachoma, 
but in high endemic areas the risk of re-infection is high and such treatment is 
ineffective on a long-term community basis (Schachter, West, Mabey, Dawson, 
Bobo, Bailey, Vitale, Quinn, Sheta, Sallam, Mkocha, Mabey, & Faal 1999). Various 
studies have shown oral antibiotic treatments to be more effective but multiple daily 
doses required for antibiotics such as tetracycline, older macrolides (erythromycin) 
and sulphonamides prove difficult for mass treatment (Dawson, Schachter, Sallam,
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Sheta, Rubinstein, & Washton 1997;Schachter, West, Mabey, Dawson, Bobo, Bailey, 
Vitale, Quinn, Sheta, Sallam, Mkocha, Mabey, & Faal 1999). Oral doxycycline is 
also effective but is contraindicated for children under seven years of age (Dawson, 
Schachter, Sallam, Sheta, Rubinstein, & Washton 1997). However, azithromycin is 
highly active against C. trachomatis (Agacfidan, Moncada, & Schachter 1993) and is 
effective as a single dose because of its unique pharmacokinetic properties, including 
a long half-life and high concentrations reached in local tissue areas (Alvarez-Elcoro 
& Enzler 1999). Azithromycin has been shown to reduce the prevalence o f clinically 
active trachoma and infection 6  months after treatment, both with targeted treatment 
and mass treatment (Holm et al. 2001). Azithromycin is an azalide antibiotic with a 
broader spectrum than erythromycin, including against C. trachomatis, and has 
excellent activity against respiratory pathogens (Chem et al. 1999). After oral dosing, 
tissue specimens from the conjuctiva show azithromycin concentrations 1 0 0  times 
greater than in serum (Tabbara et al. 1998). It, therefore, offers an opportunity for 
controlling blinding trachoma (Schachter, West, Mabey, Dawson, Bobo, Bailey, 
Vitale, Quinn, Sheta, Sallam, Mkocha, Mabey, & Faal 1999).
7.1.6 Intervention Programs
The World Health Organisation has targeted trachoma for eradication by the year 
2020 (Whitty et al. 1999). This Global Eradication o f Trachoma (GET) program 
aims at controlling trachoma by eyelid surgery (S), antibiotic treatment (A), facial 
cleanliness (F) and environmental improvement (E) -  the SAFE strategy (Emerson, 
Lindsay, Walraven, Faal, Bogh, Lowe, & Bailey 1999) although most programs are 
dominated by S and A (Emerson, Caimcross, Bailey, & Mabey 2000b).
A major stumbling block for treatment with azithromycin was the cost. This problem 
was overcome for some countries when in 1998, the Edna McConnell Clark 
Foundation and Pfizer Inc, in collaboration with the WHO, launched a new Trachoma 
initiative which includes a donation program (Mabey & Bailey 1999).
7.1.7 The effect of using azithromycin to control trachoma on carriage and 
macrolide resistance in S. pneumoniae
Three doses of oral azithromycin were found to significantly reduce the carriage of  
oropharyngeal S. pneumoniae in Gambian children, and so is active against S.
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pneumoniae (Adegbola et al. 1995).(Adegbola, Mulholland, Bailey, Secka, Sadiq, 
Glasgow, & Mabey 1995)
Azithromycin is active against respiratory pathogens and consequently the use of 
macrolides for treating respiratory pathogens has increased in the United States and 
Canada. In developing countries it is only available through a drug donation scheme 
and is unlikely to be used to treat LRTIs due to its cost. However, there is some 
concern that the use of azithromycin to treat trachoma, particularly on a community 
basis, may have an impact on the level o f resistance to other macrolides in respiratory 
pathogens, particularly S. pneumoniae (Chem, Shrestha, Cevallos, Dhami, Tiwari, 
Chem, Whitcher, & Lietman 1999). Before azithromycin is used on a large scale in 
this way, the likely impact must be assessed.
7.1.8 Previous studies to assess the impact of azithromycin for the treatment of 
trachoma on a community level on macrolide resistance in S. pneumoniae
A study was conducted among Aboriginal primary school children living 800 
kilometres south west of Darwin, Australia (Leach et al. 1997). Children were 
screened for trachoma, and of those with the disease, a nasopharyngeal sample was 
taken and cultured for S. pneumoniae before azithromycin therapy. 130 children were 
treated with 20mg/kg azithromycin out of 221 children in a population of 750. 
Follow up visits were made 2-3 weeks after treatment and then 2 and 6  months later. 
Ethical approval restricted initial swabbing to 80, and a cohort o f 46 for follow up 
swabbing. The average age of children seen at least twice was 9.0 years. The table
7.1 summarises their data.
High carriage rates were observed initially which were reduced significantly by the 
azithromycin and then rose again afterwards. The increase in carriage was not 
significant between baseline and 2  months but was between baseline and 6  months, 
although this could have been due to seasonal changes. The number of azithromycin 
resistant isolates increased significantly following the azithromycin treatment and 
then fell at six months. An unusual pattern of serotypes was also observed. At 
baseline predominant serotypes were 22F, 6 A, 1 and 13. At 2-3 weeks 10F had been 
introduced and was the most common serotype and at 2 and 6  months 6 A, 23A, 6 B 
10F and 35 were the most frequent. The serotypes found to be resistant were
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serotypes 10F, 23 A (serotype of original resistant strain) and 45, these serotypes are 
not usually found in paediatric patients.
Table 7.1: Data summary from Leach et al. (Leach, Shelby-James, Mayo, Gratten, 
Laming, Currie, & Mathews 1997).
Baseline 2-3 weeks 2 months 6 months
Carriage 6 8 % 29% 78% 87%
Individuals carrying 
Azithromycin resistant strains
1.3% 15.8% 27% 5.1%
Azithromycin resistance as a 
proportion of carriers
Not
calculated
54.5% 34% 5.9%
Predominant serotypes 22F, 6 A, 16, 
1, 13, 11A 
and 33F
10F, 9V, 
22F, 45 
and 23A
23A and 
10F
Azithromycin was found to be successful in treating trachoma but was found to select 
for macrolide resistance in S. pneumoniae, and the authors concluded that the increase 
in resistance was due to the selective pressure exerted on existing but hidden resistant 
strains.
7.1.9 Assessment of the impact of azithromycin for the treatment of trachoma on 
a community level on macrolide resistance in S. pneumoniae
Pfizer has made a philanthropic community-wide donation o f azithromycin to treat 
trachoma in the Huruma villages in the Kilimanjaro region of northern Tanzania. In 
order to assess the impact of community-wide administration of a single dose 
azithromycin on macrolide resistance in S. pneumoniae, we have conducted a cross- 
sectional and longitudinal study of pneumococcal carriage in the Huruma villages. S. 
pneumoniae isolates were obtained by collecting throat swabs from children under 
seven years of age at 0 , 2  and 6  months and were isolated using conventional 
techniques. The isolates were then tested for antibiotic resistance using E-test strips 
for erythromycin.
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7.1.10 Description of study population - Tanzania
Kahe lies on the north-east slopes of Mount Kilimanjaro at an elevation o f 1300 -  
1600 metres above sea level, for map see appendix 1. There are two rainy seasons: 
November and December (short rains) and March through to July (long rains), 
however, rainfall has recently been considerably lower than historical averages. The 
economy is dominated by subsistence farming and some families additionally grow 
coffee and bananas as cash crops. The village is served by one hospital, Huruma 
hospital, which is approximately one hour away by bus. There is a dispensary in 
Kahe village that provides basic medical supplies, and in addition, a variety of 
antibiotics are available over-the-counter in village shops, notably co-trimoxazole is 
the cheapest of these. Trachoma is endemic in the Huruma area.
7.1.11 Trachoma control program in Huruma villages
A trachoma research program was initiated in 1999 and a survey found 1096 active 
trachoma cases in 5527 individuals examined. As part o f this program, all available 
non-pregnant resident individuals over 1 2  months of age were offered a single oral 
dose of 20mg/kg azithromycin (Zithromax™, Pfizer, New York) in August 2000. 
Women who thought they might be pregnant or children under 12 years were given 
tetracycline ointment 1 % with instructions to apply it to the lower conjunctival 
fomices of both eyes, twice daily for six weeks. Treatment coverage was 5001 / 5838 
(85.7%). The trachoma control program was conducted by Dr. Anthony Soloman, 
London School o f Hygiene and Tropical Medicine.
7.1.12 Aim
To assess the impact of using azithromycin to treat trachoma on a community basis 
on macrolide resistance in S. pneumoniae.
199
The im pac t o f  com m unity w ide distribution o f  single-dose Azithromycin on macro! idc resistance in Streptococcus pneumoniae
7.2 Methods
7.2.1 Ethical approval and sample collection
Ethical approval for the trial was established before this PhD was begun, and is 
detailed in section 2 .1 .
7.2.2 Sample Collection
The oropharyngeal sample collection was conducted as described in section 2.1.
7.2.3 Antibiotic Sensitivity Testing
Antibiotic sensitivity testing for erythromycin was performed following the methods 
in Materials and Methods section 2.2.4.
7.2.4 Serotyping using anti-sera -  Slide agglutination
Serotyping was performed for all S. pneumoniae using pneumococcal antisera 
following the method in Materials and Methods section 2.2.5.
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7.3 Results
7.3.1 Carriage rates
A total o f 1315 oropharyngeal swabs were obtained at baseline, 1225 at two months 
and 1402 at six months. The prevalence o f S. pneumoniae carriage was 11 % 
(141/1315), 12 % (149/1225) and 7 % (92/1402) respectively. The distribution has 
no affect on the rate o f carriage of S. pneumoniae at two months post distribution.
7.3.2 Azithromycin resistance
Erythromycin MICs were used as a marker for azithromycin. No background 
resistance was found in the cohort population before azithromycin distribution 
(baseline data). Following drug administration no macrolide resistance was detected 
(2 month data). At 6  months 1 / 92 (1.1%) of isolates had erythromycin resistance the 
MIC being 8  pg/ml, see tables 7.2 and 7.4, this isolate is designated 8802.2a.
Table 7.2. Number of S. pneumoniae strains sensitive, intermediately resistant, and 
resistant to erythromycin. MICs were obtained using e-tests.
0 Month 2 Months 6 Months
Total no. of Isolates 141 149 92
Erythromycin
Sensitive 142 (100%) 149(100%) 89 (98%)
Intermediate 0 0 0
Resistant 0 0 i d% )
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7.3.3 Serotyping of carriage isolates
All isolates were serotyped using pneumococcal antisera (Statens Serum Institut, 
Copenhagen, Denmark) and are summarised in table 7.3.
Table 7.3: Serotypes of isolates collected at baseline, 2 months and 6  months. The 
isolates which could not be typed with the sera are “not typed” since they may not be 
genuinely “non-typeable” but merely not one of the 23 vaccine types.
Baseline
2
Months
6
Months
Total number of isolates 
serotyped 141 % 149 % 92 %
Serogroup
1 2 1.4 1 0.7 0 0
3 8 5.7 9 6 . 0 7 7.6
4 4 2 . 8 3 2 . 0 4 4.3
5 1 0.7 0 0 1 1 . 0
6 2 0 14.2 26 17.4 8 8 . 8
7 6 4.2 4 2.7 2 2 . 2
8 1 0.7 1 0.7 0 0
9 15 1 0 . 6 1 2 8 . 1 6 6.5
11 4 2 . 8 7 4.7 4 4.3
12 1 0.7 0 0 3 3.3
14 1 0.7 1 0.7 0 0
15 8 5.7 3 2 . 0 7 7.7
17 1 0.7 2 1.3 0 0
18 5 3.5 7 4.7 8 8.7
19 29 2 0 . 6 33 2 2 . 1 9 9.8
20 0 0 0 0 1 1 . 1
22 1 0.7 0 0 0 0
23 18 1 2 . 8 1 0 6.7 1 2 13.0
Not typed 16 11.3 30 2 0 . 1 2 0 2 1 . 8
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7.3.4 Affect of azithromycin distribution of serotype prevalence
To assess whether the azithromycin distribution had affected serotype distribution, 
the serotype prevalence before and after distribution was compared. Following 
treatment with azithromycin there is only a small shift in the proportion o f serotypes 
carried. The prevalence of serotypes 6  and 19 have decreased following treatment 
along with an increase in not-typed isolates. The distribution o f other serotypes 
remained unchanged. Using Chi-squared testing the five most prevalent serotypes 6 , 
9, 19, 23 and not typed for baseline, 2 month and 6  month percentage carriage rates 
were found not to be significantly different (P = 0.2184). Chi-squared testing was not 
valid for all serotypes since the percentage carriage values were too small for some 
types. Statistical testing was not done on the affect o f azithromycin on individual 
serotypes as the actual numbers are very small for some types.
7.3.5 Properties of the erythromycin resistant strain
The erythromycin resistant strain 8802.2a is a multiple carriage isolate. It is serotype 
23 and is resistant to all three antibiotics tested (the other multiple carriage isolate 
being serotype 15 and fully sensitive to penicillin, erythromycin and co-trimoxazole), 
table 7.4.
Table 7.4: Properties of the erythromycin resistant strain.
Isolate number 8802.2a
Erythromycin MIC 8  (R)
Penicillin MIC 0.25 (I)
Co-trimoxazole MIC 16 (R)
Serotype 23
Number of siblings 1
Siblings carriers? No
7.3.6 Mechanism of macrolide resistance
The mechanism of macrolide resistance was determined by PCR to be mediated by 
the MefE efflux mechanism.
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7.4 Discussion
This is the largest evaluation to date o f the impact o f an azithromycin distribution 
campaign on S. pneumoniae resistance. The results of this study differ from the small 
study performed among Aboriginals in Australia (Leach, Shelby-James, Mayo, 
Gratten, Laming, Currie, & Mathews 1997) where an increase in macrolide resistance 
was found following treatment with azithromycin. This difference may be due to 
differences in the study populations. The Aboriginal community where Leach’s 
study was performed had background macrolide resistance, albeit only one isolate 
was recovered but the sample population was much smaller. The authors concluded 
that there were resistant-but-hidden isolates, as a result o f only sampling 80 children 
before drug distribution. Thus may have offered a selective advantage during 
treatment, accounting for their observed increase in azithromycin resistance. This 
study involved a much larger cohort, therefore, our observed absence of erythromycin 
resistance is likely to be a true and reliable observation. At baseline 1315 children 
were sampled out of 5538 individuals who received treatment for trachoma, at 2 
months 1225 / 5538 and at 6  months 1402 / 5538 children were sampled, see sections
7.1.11 and 7.3.2. 130 children out of 750 individuals in Leach’s study were treated 
and 46 of these children were sampled on more than one occasion. The carriage rate 
observed in the Aboriginal community was much higher than that in the Tanzanian 
community and this may have facilitated the spread of resistant genes between strains 
(Leach, Shelby-James, Mayo, Gratten, Laming, Currie, & Mathews 1997).
The carriage rate in Kahe was lower than expected; a comparison o f carriage rates 
from another area of northern Tanzania using the same techniques can be found in 
section 8.4. Oropharyngeal swabs were chosen, even though they are associated with 
a lower detection rate then nasopharyngeal swabs (Capeding et al. 1995;Rapola et al. 
1997), because they are better tolerated by young children (Leach et al. 1994). In 
addition local discussions suggested that oropharyngeal swabs would be more 
acceptable to children and thus it was decided that oropharyngeal swabs would result 
in higher recruitment rates. Inefficiencies in specimen collection would only have 
influenced the outcome of the study if resistant isolates were more able to colonise 
the nose than the throat. There is no evidence in the literature to support this. S. 
pneumoniae were recovered from throat swabs using blood agar gentamicin 5mg/L as 
this media has been reported to give good isolation rates (Hendley et al. 1975).
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In a population with antibiotic resistance to a particular drug, the use o f that drug is 
likely to offer a selective advantage to isolates harbouring resistance to that drug. 
Hence, the increase in azithromycin resistant organisms following azithromycin 
donation in the Leach et al study is not surprising, even if  they only isolated one 
resistant strain. In contrast, a single-dose o f a drug administered to a community 
where there is no background resistance to the drug does not offer the same 
opportunity for selection as if  there were already strains harbouring resistance, so our 
results were also expected. Should the azithromycin donation be repeated in our 
study population, with the resistant strain present, the result may mirror the outcome 
of the Leach study.
This investigation found only one strain with erythromycin resistance. It is unknown 
whether this was as a consequence o f the azithromycin distribution, was already in 
the population but not picked up by previous screening, or whether it was introduced 
either from macrolide use aside from the project or brought into the population by a 
carrier from a population where macrolide use may be more common. Since the 
resistant strain was isolated at 6  months, late in the study, the latter two possibilities 
are more likely. It is surprising that only one strain was found, and that the one strain 
had not spread further among the population. Repeat sampling on a later occasion 
may find more strains harbouring macrolide resistance. Since the strain is 
additionally resistant to co-trimoxazole and intermediate to penicillin then a selective 
advantage is offered indirectly via these two antibiotics. Macrolide resistance is 
frequently found to be associated with resistance to other antimicrobials, as discussed 
in section 1.5.6.
The proportion of serotype distribution remained unchanged in this study, which 
differs from the Leach study. This observation could be accounted for by the lack of 
drug resistance; had there been drug resistant strains in the community they would 
have had a selective advantage over sensitive strains and the serotypes of drug 
resistant strains may have become more prevalent. However, in our population, after 
treatment with azithromycin all strains should have had equal chance o f re- 
emergence.
The data in this study suggests that the use of azithromycin is safe in a community 
where there is no background macrolide resistance. Large-scale trachoma
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intervention programs should follow screening for macrolide resistance in S. 
pneumoniae, and the cautious use of azithromycin would be prudent if any macrolide 
resistance is found in a population.
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Chapter Eight
Epidemiology of Streptococcus pneumoniae 
Carriage Organisms in Northern Tanzania
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8.1.1 Local use of antibiotics
The following antibiotics were prescribed over a twelve month period from the 
pharmacy at Huruma Hospital (the number used per year in brackets is to be multiplied 
by 1000, cost for complete course is in Tanzanian shillings (Tsh)1): amoxycillin (240, 
486Tsh), amplox (2.4, 2100Tsh), chloramphenicol (120, 308Tsh), ciprofloxacin (6 , 
1386Tsh), cloxacillin (100, 1232Tsh), co-trimoxazole (6 , 70Tsh), doxycyclin (40, 
160Tsh), erythromycin (60, 1064Tsh), nitrofuratoin (120, 112Tsh), penicillin V (3.6, 
1064Tsh) and tetracycline (60, 252Tsh) (Stronge 2002).
The following antibiotics are available at a village kiosk in Huruma (cost for course in 
Tanzanian shillings): amoxicillin (40Tsh), co-trimoxazole (20Tsh) crystapen for 
injection (700Tsh), doxycyclin (free2), penicillin V for injection (500Tsh) and 
tetracycline (20Tsh) but it was not known how many o f these were used (Stronge 2002).
8.1.2 Co-resistance to penicillin and co-trimoxazole
Co-resistance to penicillin and co-trimoxazole has been documented in South Africa 
and is o f particular concern in a community where use o f these two antibiotics is likely 
to be higher than any other (Adrian & Klugman 1997). Since there are few reports 
detailing antibiotic sensitivity patterns in Africa, where the disease burden from S. 
pneumoniae is very high, it was decided to examine resistance to penicillin and co- 
trimoxazole for the pneumococcal isolates collected for the assessment o f azithromycin 
on the treatment o f trachoma, to see what resistant levels are in northern Tanzania and 
to see if  any increase can be detected over six months, and to see whether the 
azithromycin distribution had affected penicillin and co-trimoxazole resistance.
8.1.3 Molecular typing to ascertain source of resistant isolates
Further to azithromycin resistance typing and serotyping detailed in chapter seven, 
MICs were determined to penicillin and co-trimoxazole. Multi locus sequence typing 
(MLST) 1 was then performed on a small number o f isolates to see whether there were 
any representatives o f internationally spread clones among this population. It is 
important to identify whether resistant strains are indigenous or imported since this has
1 £1 GB is equivalent to 1,7025.01 Tanzanian shillings (14.08.03)
2 Doxycyclin is provided by the government to combat cholera
1 Sequencing of seven housekeeping genes which are then compared to MLST database
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either local or global epidemiological implications. In the context o f the erythromycin 
isolate from chapter seven, this would suggest whether the isolate was imported or was 
a direct result o f the azithromycin distribution. Imported resistant strains must be being 
moving from one location to another by infected or colonised individuals. This may be 
a two step process for example by someone moving from Europe to a major African 
city, then by another person from the city to Huruma, or directly from abroad (within 
Africa or further) to Huruma, which indeed could have been via somebody involved 
with this study. Alternatively a locally derived resistant isolate could have acquired 
resistance from local selective pressure.
8.1.5 Aim
To describe the epidemiology o f the carriage strains collected in Tanzania using MIC to 
penicillin and co-trimoxazole, serotype and MLST with reference to resistance to these 
commonly used antibiotics, multiple colonisation, carriage within families and carriage 
over time.
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8.2 Methods
8.1 Antibiotic sensitivity testing and serotyping
Antibiotic sensitivity testing for penicillin and co-trimoxazole was performed following 
the methods in section 2.4. Serotyping data was common for this and chapter seven, 
and was performed following the method in section 2.5.
8.2 Age data
Consent forms, that were used to gain written consent from carers o f children who were 
sampled, were used as a source for the individual’s date o f birth and demographic 
numbers. A database was generated in EXCEL (Microsoft, California, USA) o f the 
numbers and dates o f birth. This was used to calculate ages o f all o f the children at each 
of the sampling periods using. Ages were recorded as 0 -  1 year.
8.3 Carriage over time data
Once the spreadsheet was complete for all o f the carriers EXCEL (Microsoft, 
California, USA) functions were used to create a master list that had all children who 
were sampled (and carriers) at any time so that one line represented one child. Multiple 
colonisation data and carriers on more than one occasion data was extrapolated from 
this list.
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8.3 Results
8.3.1 Carriage Rates
A total of 2012 children were sampled, of these 465 children were sampled three times. 
There were 138, 145 and 8 8  carriers at baseline, 2 and 6  months respectively. Overall 
carriage rates were 11%, 12% and 7% at baseline 2 months and 6  months respectively. 
Carriage rates for children sampled three times were 11%, 11% and 9% at baseline, 2 
months and 6  months respectively.
8.3.2 Age of Carriers
The age or date o f birth (if known) was taken for each child and ages for all of the 
children sampled were calculated to ensure that there was an even sampling of children 
of all ages. The ages of all children sampled is shown in graph 8.1, and demonstrates 
that in sample size by age. The ages for the pneumococcal carriers were pooled for the 
three sampling periods and is shown in graph 8 .2 , with the mean and standard 
deviations of carriers. The highest carriage rates are seen for 0, 1 and 5 year age groups. 
Since ages taken were approximate in many cases no further analysis has been 
performed for age data.
Ages of children sampled
250 
1 200
I  150</>
1 100 
E
i50 
0
0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9+
Age in years
Figure 8 .1: Ages o f all children sampled.
■  Baseline
■  2 month 
□  6 month
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Figure 8.2: Mean and standard deviation of ages of the carriers o f S. pneumoniae as a
percentage o f all children sampled.
8.3.3 Penicillin and co-trimoxazole resistance
The rates o f penicillin intermediate resistance, 0.1 -  1.0pg/ml, are 21% at baseline, 17% 
at 2 months and 16% at 6  months. All other isolates are sensitive <0.1pg/ml. There 
were no penicillin fully resistant isolates. 59% of baseline isolates are fully sensitive to 
co-trimoxazole <0.5pg/ml, 14% have intermediate resistance and 27% are resistant 
>4pg/ml. At 2 months 57% are fully sensitive, 17% have intermediate resistance and 
26% are resistant. At 6  months 53% are fully sensitive, 22% have intermediate 
resistance and 25% have full resistance. This data is summarised in table 8.1.
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8.3.4 Penicillin and co-trimoxazole resistance are significantly associated
Isolates resistant to penicillin are more likely to have some resistance to co-trimoxazole 
than be sensitive. At 0 months 67% of penicillin resistance was associated with co- 
trimoxazole resistance, at 2 months 85% of penicillin resistance was associated with co- 
trimoxazole resistance and at 6  months 73% of penicillin resistance was associated with 
co-trimoxazole resistance, this data is summarised in table 8.2. This association is 
highly statistically significant (Fisher’s exact pO.OOOl), see table 8.3.
Penicillin and Co-trimoxazole Resistance 
Table 8.1. Table o f sensitivities to penicillin and co-trimoxazole at baseline, 2 months 
and 6  months. MIC values were determined by E test.
Baseline 2 Month 6  Month
Total no. of Isolates 141 149 92
Penicillin
Sensitive
Intermediate
Resistant
112(79%) 
30 (21%) 
0
125 (83%) 
24 (17%) 
0
76 (84%) 
15 (16%) 
0
Co-trimoxazole
Sensitive
Intermediate
Resistant
82 (59%) 
20 (14%) 
39 (27%)
85 (57%) 
25 (17%) 
39 (26%)
49 (53%) 
2 0  (2 2 %) 
23 (25%)
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Penicillin and Co-trimoxazole Resistance Are Significantly Associated
Table 8.2. Penicillin resistant isolates with or without co-trimoxazole resistance.
Month 0 Month 2 Month 6
Isolates N (%) N (%) N (%)
Penicillin intermediate 
resistance with co-trimoxazole 
resistance
11 (37) 10(39) 5(33)
Penicillin intermediate 
resistance with co-trimoxazole 
intermediate resistance
9(30) 12 (46) 6(40)
Penicillin intermediate 10(33) 4(15) 4(27)
resistance no co-trimoxazole 
resistance
Table 8.3: Relationship between penicillin and co-trimoxazole resistance. Fischer’s 
exact test, the numbers o f isolates with co-trimoxazole intermediate and full resistance 
were pooled, as were the numbers from 0 , 2  and 6  months.
Penicillin R Penicillin S Total
Co-trimoxazole R 53 113 166
Co-trimoxazole S 18 198 126
Total 71 311 382
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8.3.5 The azithromycin distribution did not affect the risk of acquiring an 
antibiotic resistant strain
Baseline and 2 month isolates were compared to see whether the azithromycin treatment 
had changed the rate o f carriage of penicillin or co-trimoxazole resistant isolates. The 
number o f penicillin resistant isolates decreased from 30/141 (21%) before treatment to 
24/149 (17%) 2 months after treatment, table 8.4. The number o f co-trimoxazole 
resistant isolates increased from 59/141 (41%) before treatment to 64/149 (43%) after 
treatment, table 8.5. A Fischer’s exact test was performed on baseline and 2 month data 
and showed there was no significant change in the rate o f carriage o f penicillin or co- 
trimoxazole resistant strains before versus after the azithromycin treatment, see tables
8.4 and 8.5.
Table 8.4: Fischer’s exact test shows no significant difference in penicillin resistant 
isolates recovered before and after azithromycin distribution (P = 0.2921).
Number of isolates recovered (%)
Penicillin S Penicillin IR Total
Before treatment 1 1 1 30 141
(38%) ( 1 0 %) (49%)
After treatment 125 24 141
(43%) (8 %) (51%)
Total 236 54 290
(81%) (19%) ( 1 0 0 %)
Table 8.5: Fischer’s exact test shows no significant difference in co-trimoxazole
resistant isolates recovered before and after azithromycin distribution (P = 0.9055).
Number of isolates recovered (%)
Co-trimoxazole S Co-trimoxazole R Total
Before 82 59 141
treatment (28%) (2 0 %) (49%)
After 85 64 149
treatment (29%) (2 2 %) (51%)
Total 167 123 290
(58%) (42%) ( 1 0 0 %)
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8.3.6 Relationship between serotype and antibiotic resistance
Resistant isolates are mostly represented by serotypes 3, 6, 9, 19, 23 and not-typed. Of 
isolates resistant to both penicillin and co-trimoxazole, the majority are accounted for 
by serotypes 3, 6, 9, 19, 23 and not-typed. Serogroup 19 is the most prevalent among 
antibiotic resistant isolates with 10/20 (50%) at baseline, 7/22 (32%) at month 2 and 
3/11 (27%) at month 6. The second most common group was not-typed followed by 
serogroup 6.
Data from baseline, 2 and 6 months were pooled since in chapter 7 it was show that 
there was no significant change, with respect to frequency of serotype, during the course 
of the six months. Levels of resistance to penicillin and co-trimoxazole among different 
serotypes is shown in figures 8.3 and 8.4.
Relationship between serotype and penicillin resistance
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Figure 8.3: Serotypes of penicillin sensitive and intermediate resistant isolates
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Relationship between serotype and co-trimoxazole resistance
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8.3.7 Serotypes of isolates resistant to both penicillin and co-trimoxazole
Resistance to both antibiotics is shown in table 8 .6 . The percent o f isolates resistant to 
both antibiotics out o f the total number o f isolates o f that serotype has been calculated.
Table 8 .6 : Frequency and percentage o f isolates resistant to both penicillin and co- 
trimoxazole
Serotype
Isolates resistant to both penicillin and co-trimoxazole
Frequency % of each serotype 
resistant
3 5 21
6 7 13
9 4 12
12 1 25
14 1 50
15 1 6
18 1 5
19 20 28
22 1 100
23 3 7.5
NT 9 14
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8.3.8 Carriage over time
There were 465 children sampled three times. Of these 11 individuals carried isolates at 
two consecutive periods. Two children were carriers at baseline and 6  months and one 
child was a carrier at all three sampling periods. Only one child carried an isolate o f the 
same serotype on more than one occasion, it was a serotype 19 strain that was resistant 
to co-trimoxazole and sensitive to penicillin and erythromycin, see table 8.7 (green 
text).
Child 8715.1 was a carrier at all three sampling periods, each o f which yielded different 
serotypes. This child was also a multiple colonisation case, see section 8.3.9. A  sibling, 
child number 8715.2 was a carrier at baseline and 6  months, see table 8.7 (orange text).
Table 8.7: Serotypes and sensitivities o f strains carried by children sampled three times, 
that were colonised more that once. Penicillin and co-trimoxazole only are included 
since all strains were sensitive to erythromycin.
Baseline 2 month 6 month
PEN CTX ST PEN CTX ST PEN CTX ST
1103.2 S s 19 1103.2 S I 6
1104.1 S R 1 1104.1 s R 6
1804.1 s S 18 1804.1 s s 19
2401.2 s s 19 2401.2 s I 3
2902.1 s S 9 2902.1 I I 19
4801.2 s s NT 4801.2 s s 23
4916.1 s s NT 4916.1 s s 19
5303.2 s R 23 5303.2 s s NT
5907.2 I I 6 5907.2 s R NT
6010.1 s I NT 6010.1 s I 5
6901.2 s R 19 6901.2 s R 19
8603.2 s S NT 8603.2 I I NT
8715.1 s S 18 8715.1 s R 11 8715.1 s I 3
8715.2 s s 6 8715.2 s I 9
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8.3.9 Multiple carriage
Of the children sampled three times, there were nine individuals from whom two 
isolates o f different serotypes were isolated, summarised in table 8 .8 . In one household 
there were two children both colonised with serotype 3 and 19 strains, these strains were 
subjected to MLST, see section 8.3.11. The children carrying more then one serotype at 
month 0  were aged two and three years, at month 2  are aged two, seven, five and five 
years, and at month 6  are aged eight months, eight months and seven years.
Table 8 .8 : Serotypes and sensitivities of multiple carriage strains carried by children 
sampled three times.
Baseline 2 month 6 month
PEN CTX ST PEN CTX ST PEN CTX ST
0606.1a S R 6
0606.1b S I NT
0801.1a S S 15
0801.1b S S 19
1108.3a S R 23
1108.3b S S 3
2604.1a I S 19
2604.1b S S 3
2604.2a S S 19
2604.2b S S 3
4915.1a S I 4
4915.1b S s 3
4212.3a S S 9
4212.3b S S 6
7310.1a S S 6
7310.1b S I 5
8802.2a I R 23
8802.2b S S 15
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8.3.10 Congruent carriage
Congruent carriage means more than two carriers in one household. Overall there were 
43 households in which more than one child was a carrier. At baseline there were 50 
congruent carriers out o f a total o f 138 carriers, 26 out o f 145 at 2 month and 14 out o f  
8 8  at 6  months. The mean rate o f congruent carriage by isolates o f the same serotype is 
20%, see table 5.8, since half o f these isolates are likely to have been transmitted from 
one individual to another, the average transmission of isolates between siblings is 1 0 %.
Table 8.9: Congruent carriers as a proportion o f total carriers -  summary o f data.
Collection
period
Same serotype
Congruent Y N
Baseline 50 8 42
(16%) (84%)
2 Months 26 8 18
(31%) (69%)
6  Months 14 2 1 2
(14%) (76%)
Mean 30 6 24
(2 0 %) (80%)
At baseline there were 24 households from which more than one sibling was a carrier at 
baseline. Two o f these households had three children all carrying pneumococci, data is 
summarised in table 8.10. At month 2 there were 12 households in which more than 
one sibling was a carrier, all o f which only included two children, data is summarised in 
table 8.11. At month 6  there were seven households, one o f which had three carriers 
and the others all had two, data is summarised in table 8 .1 2 .
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Table 8.10: MIC and serotype o f congruent carriage strains at baseline. Red = isolates 
of the same serotype and MIC value. Blue = the same serotype and different MIC 
values.
Number Penicillin Erythromycin Co-trimoxazole Serotype
1104.1 0.016 0.064 1 2 1
1104.2 0.006 0.094 0.125 4
2503.1 0.38 0.125 >32 6
2503.2 0.19 0.125 32 23
2810.1 0.016 0.094 6 15
2810.2 0.016 0.064 0.125 1 1
3005.1 0.032 0.064 0.38 19
3005.2 0.016 0.094 0.19 1 1
3205.1 0.016 0.064 0.19 23
3205.2 0.25 0.094 0.75 NR
3208.2 0.032 0.094 0.38 9
3208.3 0.047 0.094 0.19 NR
3212.2 0.016 0.094 0.19 18
3212.3 0.38 0.094 0.125 1 2
3213.1 0.25 0.125 1 19
3213.3 0.016 0.094 0.75 3
3305.2 0.25 0.125 0.25 9
3305.3 0.047 0.064 0.25 23
3311.1 0.016 0.094 0.38 15
3311.2 0.125 0.094 0.38 19
3601.1 0.023 0.064 0.19 9
3601.2 0.032 0.094 0.19 NR
3612.2 0.016 0.094 0.19 9
3612.3 0.016 0.094 0.125 15
3912.1 0.016 0.094 >32 1 1
3912.2 0.023 0.047 0.25 3
4119.1 0.016 0.064 0.094 NR
4119.2 0.19 0.064 0.25 15
4307.1 0.016 0.047 0.25 NR
4307.3a 0 . 0 1 2 0.094 0.125 NR
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4307.3b 0.016 0.064 0.125 14
5605.1 0.38 0.094 0.5 19
5605.2 0.016 0.094 0.25 6
5608.1 0.19 0.064 0.094 23
5608.2 0.016 0.064 12 23
5609.1 0.032 0.064 0.19 9
5609.2 0.016 0.094 0.19 6
5609.3 0.016 0.064 0.19 6
5701.3 0.19 0.094 0.19 19
5701.4 0.016 0.094 6 23
5701.5 0.016 0.094 0.025 9
5803.1 0.016 0.094 >32 23
5803.3 0.016 0.094 4 23
5805.1 0.016 0.094 6 23
5805.2 0.016 0.094 6 23
5907.2 0.25 0.094 0.75 6
5907.3 0.023 0.047 >32 9
7305.1 0.016 0.125 2 19
7305.2a 0.008 0.047 0.5 6
7305.2b 0.064 0.094 3 6
8715.1 0.032 0.125 0.19 18
8715.2 0.016 0.064 0.19 6
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Table 8.11: MIC and serotype of congruent carriage strains at month 2. Red = isolates 
of the same serotype and the same MIC value. Blue = the same serotype and different 
MIC values.
Number Penicillin Erythromycin Co-trimoxazole Serotype
1003.2 0.38 0.125 >32 6
1003.3 0.19 0.047 >32 6
2703.2 0.023 0.094 0.19 NT
2703.3 0.032 0.016 0.75 NT
3401.1 0.125 0.032 0.75 19
3401.2 0.023 0.064 0.25 NT
5102.1 0.016 0.094 0.25 18
5102.2 0.016 0.047 0.19 NT
5712.1 0.016 0.064 0.19 9
5712.2 0.016 0.094 0.38 6
5805.1 0.016 0.125 12 23
5805.2 0.016 0.094 >32 1
5907.1 0.016 0.064 8 11
5907.2 0.016 0.125 12 NT
6614.1 0.016 0.094 0.19 17
6614.3 0.016 0.094 4 6
7201.2 0.016 0.094 0.125 6
7201.4 0.016 0.094 >32 NT
7908.1 0.094 0.094 >32 19
7908.2 0.125 0.125 >32 3
7916.1 0.016 0.125 1 19
7916.2 0.016 0.125 1.5 19
0509.1 0.125 0.094 >32 19
0509.3 0.5 0.094 24 19
2604.1a 0.19 0.094 0.5 19
2604.1b 0.023 0.094 0.25 3
2604.2a 0.023 0.094 0.19 19
2604.2b 0.023 0.094 0.125 3
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Table 8.12: MIC and serotypes of congruent carriage strains at month 6 . Red = isolates 
o f the same serotype and the same MIC value. Blue = the same serotype and different 
MIC values.
Number Penicillin Erythromycin Co-trimoxazole Serotype
0210.1 0.016 0.094 6 23
0210.2 0.016 0.125 16 23
0210.3 0.19 0.125 24 NT
1103.1 0.016 0.094 0.5 20
1103.2 0.016 0.064 0.5 6
1603.1 0.023 0.064 0.25 6
1603.2 0.016 0.064 3 11
1811.1 0.016 0.094 0.19 NT
1811.2 0.016 0.125 0.75 NT
3212.2 0.19 0.047 0.5 3
3213.4 0.25 0.064 0.5 3
8715.1 0.016 0.023 0.75 3
8715.2 0.016 0.023 1 9
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8.3.11 Multilocus sequence typing
Multilocus sequence typing was performed on 11 isolates, for allelic profiles see figure 
8.13. The profile o f each organism was compared at http://www.MLST.net selecting 
database, S. pneumoniae and allelic profile query and an exact or nearest match search 
performed. The number for each locus was entered. Strains 2604.IB and 2604.2B, 
both serotype 3, were matched to strain ID 458 which was isolated from a one month 
old male with bacteraemia from the Oxford region (UK) in 1999. That organism was 
serotype 19F and was sensitive to penicillin, erythromycin, tetracycline, 
chloramphenicol and cefotaxime. The isolates which co-colonised with 2604.IB and 
2604.2B were 2604.1A and 2604.2A respectively, and were both serogroup 19.
MLST Profiles
Table 8.13: Shows MLST allele identities. Isolates labelled “Unknown” are those that 
do not match any in the database. Isolates labelled “No Matches” are those that do not 
match any in the database but have one allele aligning at 99.8% rather than 100%.
Isolate MLST aroE gdh gki recP spi xpt ddl
2604-1A Unknown 1 5 36 3 6 1 9
2604-1B 458 2 32 9 47 6 21 17
2604-2A Unknown 10 13 10 16 15 1 75
2604-2B 458 2 32 9 47 6 21 17
3213-2 No Matches 7 11 4 1 6 14(99.8%) 64
3213-4 No Matches 5 5 4 1 10 1 5(99.8%)
4306-2 No Matches 5 5 4 1 6 1 5(99.8%)
4308-1 No Matches 5 5 4 1 6 1 5(99.8%)
5701-3 Unknown 12 25 9 4 3 20 57
5711-1 Unknown 12 8 9 1 3 20 57
8802-2A No Matches 2 5 36 3 15 14(99.8%) 1
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8.4 Discussion
The lower than expected carriage rates in this community were compared to parallel 
studies using the same swabbing and isolation protocols performed on a different 
population at a nearby sugar plantation. At the sugar plantation the elevation above sea 
level was lower and the humidity higher. Carriage rates o f between 37 and 58% were 
detected (Granerod 2001;Sinclair 2002). Employees o f the sugar plantation community 
are provided with free medical consultation with easy access, and pay only for 
prescriptions. Employee’s families do not get free consultation but since at least one 
member o f every family is in employment they have a reasonably high standard of  
living and are within easy access o f the hospital via a regular bus service. This suggests 
the low carriage rates are a true observation and not a result o f poor ascertainment. The 
elevation and lower humidity possibly play a role in lower than expected carriage rates, 
especially since a community with a lower standard o f living could be expected to have 
higher carriage rates. Carriage was lowest during the hottest o f the three study months, 
February (six month sampling). The baseline and 2 month study months, June and 
October, were during the monsoon months although during the year o f this study the 
rainfall was substantially less than previous years which may contribute to lower 
carriage rates. Rainfall in mm from the weather station at Mkuu was 1 -  5mm for June 
(Baseline), 20 -  25mm for October (2 month) and 25 -  30mm for February ( 6  months).
The ages o f children sampled showed that there was an even sampling with respect to 
age and the higher carriage rate in children below two years agrees with the literature 
(Gray, Converse, III, & Dillon, Jr. 1980;Scott et al. 1996). However, since the ages 
taken were not accurate in all cases no further analysis was done for age distribution.
Antibiotic susceptibilities have been performed for penicillin, co-trimoxazole and 
erythromycin by E-test. Full co-trimoxazole resistance was found to be 26% overall, 
and 46% including intermediate resistant isolates. If disease isolates have the same 
distribution o f antibiotic resistance then up to 26-46% o f pneumococcal infections may 
result in treated failures should co-trimoxazole be the drug o f choice, which given that it 
is the cheapest drug, is a likely scenario.
The mean rate o f penicillin intermediate resistance is 18%. The use o f penicillin in this 
community may promote full resistance in intermediately resistant isolates by affording
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a selective environment in which recombination o f PBP genes may take place, resulting 
in further treatment failures.
Isolates with both intermediate penicillin and full co-trimoxazole resistance were 
frequently observed in the population. This association has been previously reported 
(Adrian & Klugman 1997); the study describes resistance to co-trimoxazole to be 64% 
with co-resistance to penicillin being a major feature. Prudent use o f antibiotics and 
alternative treatment regimes (avoiding co-trimoxazole and penicillin) would be wise, 
however, since self-directed medication is so common, this will be a difficult issue to 
address. The incidence o f HIV is not known in this community, but the use o f low-dose 
co-trimoxazole for prophylaxis in HIV/AIDS patients may have a significant impact on 
the co-trimoxazole resistance in isolates of S. pneumoniae in this and similar 
communities.
Serogroup 19 was the most frequently isolated serotype, which is not surprising since it 
is consistent with global epidemiology (Scott, Hall, Dagan, Dixon, Eykyn, Fenoll, 
Hortal, Jette, Jorgensen, Lamothe, Latorre, Macfarlane, Shlaes, Smart, & Taunay 1996). 
Serotypes 6  and 9 were also commonly isolated. The serotype patterns change slightly 
during the study, however, there is not a significant change. Serotype 14 has very low  
prevalence, which is surprising as it is the most common serotype worldwide, and it is 
known to be poorly immunogenic (Scott, Hall, Dagan, Dixon, Eykyn, Fenoll, Hortal, 
Jette, Jorgensen, Lamothe, Latorre, Macfarlane, Shlaes, Smart, & Taunay 1996). Two 
serotype 14 isolates were recovered demonstrating that they are not absent from the 
population, suggesting they have had the opportunity to spread but have not done so. It 
maybe that serotype 14 has recently been introduced to the population, and repeat 
sampling may find an increase in serotype 14 prevalence. Chapter three demonstrates 
that the low isolation rate o f serotype 14 was not a bias introduced by the choice o f 
transport media chosen.
8 6 % o f isolates were 23-valent polysaccharide vaccine serogroups. If all carriage 
isolates were to have equal opportunity o f invasion then up to 8 6 % o f pneumococcal 
disease may be protected by the use o f the vaccine in this community among children 
older than two years. However, 39% of the carriers were less than two years and would, 
therefore, only be protected by a conjugate vaccine. This would only be available 
through a donation program, but should the 7-valent or 9-valent Wyeth / Lederle
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vaccines be donated then only 47% or 48% of carriers would be protected. The 9-valent 
vaccine would have little advantage over the 7-valent vaccine. Protection against 
carriage would additionally protect non-vaccinated individuals from becoming carriers. 
Since these serotypes included in the two conjugate vaccines are those most frequently 
associated with antibiotic resistance in this study, the protection would be against those 
infections for which treatment failures are more likely.
Siblings are frequently both carriers, however, they rarely carry the same serotype. 
This would suggest that intra-familial spread is not a major feature in this study. This 
differs from observations in studies by Hendley et al in which the family is described as 
being important in the transmission of pneumococci (Hendley et al. 1975). The 
important aspect o f the family is the close contact between family members, which is 
known to accentuate carriage. A possible explanation for the lack o f congruent carriage 
o f the same serotype may be that because the houses are small and very close to each 
other, children may spend much o f their waking hours outside the house playing with 
children from other households, whether or not they are attending school. Additionally 
houses in the Huruma area are generally windowless and therefore well ventilated. If 
this is the case, then although many siblings probably share a sleeping room, the 
reservoir o f pneumococci i.e. other carriers Is to which any individual is frequently 
exposed is greater and includes more than just siblings, reducing the importance o f  
intra-familial spread. Alternatively there may be a high rate o f capsular transformation 
and there may be a higher rate of multiple colonisation than was uncovered. There may 
also be a strong genetic influence, being that siblings may have a genetic predisposition 
to carriage without necessarily exchanging isolates. Children 8715.1 and 8715.2 are 
both carriers; child 8715.1 carried a pneumococci at baseline, two and six months all o f 
serogroup or serotype 18, 11 and 3 respectively. Child 8715.2 carried a pneumococci at 
baseline and six months o f serogroups 6  and 9 respectively, see table 8.7. This any 
suggest a family pre-disposition to carriage as rather than transmission between 
members o f the same family, but there is no further data to directly support this. 
Alternatively it could be that the duration of carriage is very short and that sampling 
only three times over a six month period did not capture the true picture o f intra-familial 
spread. Carriage was reported to last for a duration o f only two weeks in children in a 
comprehensive study involving repeat swabbing of groups o f families either weekly or 
fortnightly over a period o f up to a year for one group (Hendley, Sande, Stewart, & 
Gwaltney, Jr. 1975), hence the sampling in this study may be inadequate to detect intra-
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familial transmission. It may be that multiple carriage was under-detected in this study, 
i f  so then undetected isolates may represent family transmission. If one out o f two co- 
colonising strains is present in lower numbers then it is less likely to be seen on a 
primary isolation plate, hence a molecular method capable of recognising two isolates 
o f different serotypes in a primary sample may offer additional data in colonisation 
studies and in clinical settings.
In tables representing isolates o f congruent carriage, 8.10 -  8.12, red highlighting 
indicates isolates o f the same serotype and antibiotic MIC values (within one doubling 
dilution), which could be the same isolate carried by two individuals and evidence o f  
clonal spread. Blue highlighting indicates the same serotype and different MIC values 
which could indicate either different isolates have acquired the same serotype i.e. 
capsular switching, the same isolate one of which have acquired altered genes for drug 
resistance i.e. horizontal spread or two different isolates which just happen to be the 
same serotype, or a possible discrepancy in the MIC result.
Additional MLST would allow this to be investigated more thoroughly by identifying 
background genotypes o f isolates and provide and insight into the population dynamics 
o f the isolates described by this chapter, see further work discussed in chapter ten.
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Chapter Nine
Population genetics of Penicillin Intermediate 
Resistant Streptococcus pneumoniae
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9.1 Introduction
9.1.1 Studies of penicillin binding proteins
Variation between sensitive and resistant strains in PBP genes has shown that 
recombination and remodelling of these genes has given rise to penicillin resistance in 
S. pneumoniae (Dowson et al. 1989;Dowson, Hutchison, & Spratt 1989;Laible, Spratt, 
& Hakenbeck 1991). Furthermore, variation among penicillin resistant S. pneumoniae 
has shown that these changes have taken place on more than one occasion and 
independently o f other emerging strains (Smith et al. 1993). PBP sequences are 
generally thought to be conserved among sensitive strains (Hakenbeck et al. 1991) 
(O'Neill, Gillespie, & Whiting 1999), although some variation has been found in PBP2x 
(Smith, Klugman, Coffey, & Spratt 1993) which alone is able to confer intermediate 
level resistance to susceptible strains (Grebe & Hakenbeck 1996).
Many studies have been performed to investigate the diversity o f PBPs in intermediate 
and fully resistant isolates but there is an obvious difficulty in comparing studies that 
have been conducted by different research groups using different techniques, sample 
sizes and strain selection criteria. Early studies on PBPs used PCR and RFLP and 
categorised patterns on the basis of their elctrophoretic type using RFLP (Smith, 
Klugman, Coffey, & Spratt 1993). Sequencing is now becoming more accessible and 
increasingly studies are using this approach because it generates more portable data that 
is easily compared between laboratories. Sequence data is also more informative since 
mutations or mosaic rearrangements can be located, rather than simply seeing a 
different restriction pattern. Comparison of sequences can pin point likely donors and 
recipients. Such studies include Overweg et al who used both sequencing and PBP 
RFLPs (Overweg et al. 2000) (Overweg et al. 2001), and found that the discriminatory 
power was the same between sequencing experiments and RFLP experiments for the 
same isolates. Since RFLP based analysis is more rapid and gives the same level of 
discrimination as sequencing it was chosen for this analysis.
9.1.2 Populations of penicillin resistant strains show clonal relationships
A study performed in Portugal showed that 47 clinical isolates of serotypes 9V and 23F 
were highly clonal by pulse field gel electrophoresis (PFGE) analysis, and that clones of 
both serotypes had identical PBP genotypes (Canica et al. 2003). In Korea a study 
using pulsed field gel electrophoresis (PFGE) and ribotyping identified 59 to 82%
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genetic relatedness between multi-drug resistant strains that had relatively uniform 
PBP2b sequences (Song et al. 2000).
A comprehensive study conducted by Sa-Leao et al studied 150 PNSSP (MIC 
>0.5pg/ml) collected in Iceland and found the majority o f clones circulating in the 
country were those whose genetic background had been detected abroad (Sa-Leao et al. 
2002). They found that PBP genotypes were conserved among strains with identical 
PFGE backgrounds and concluded by suggesting that a major mechanism for the 
development of PBP mediated resistance in pneumococci in Iceland was the repeated 
introduction of multiple internationally disseminated lineages, followed by horizontal 
spread and donation of PBP resistant mosaic genes. Thus drug resistant clones have a 
major impact on PBP evolution in populations of pneumococci that include resistant 
and sensitive strains. Studies that include only resistant strains are biased towards 
clonal relationships because they include only strains that have already been selected in 
their natural environment because of their resistant pheno / genotype.
9.1.3 Studies including sensitive and intermediate and resistant strains are not 
selective but may still show clonal populations
Studies that include sensitive and intermediate strains are more representative of 
pneumococcal populations compared to those only including resistant strains, as they 
include strains which may be lost by selection in vivo by antibiotics. However, if  
international clones are dominant in a population, then a clonal distribution will still be 
detected among intermediate and fully resistant strains.
Nichol et al investigated 15 isolates, 5 each for sensitive, intermediate and resistant 
(MIC range <0.03pg/mL - 4pg/mL) which were collected from regions across Canada 
and included sputum, tracheal, eye and lung aspirated isolates (Nichol, Zhanel, & 
Hoban 2002). They sequenced lkbp regions around the penicillin binding domain of 
PBP la, PBP2b and PBP2x genes. For PBP2b and PBP2x they identified a variety of 
mutations, mostly around the active site and demonstrated that in isolates grouped by 
MIC the mutations were common to all strains, furthermore, that isolates with widely 
different MIC (1 - 4pg/ml) had identical mosaic arrangements. Sensitive strains 
displayed homologous genes. For intermediate strains, all PBP2x sequences were 
identical and PBP2b contained a variety of mutations, the majority of which were 
highly conserved. Resistant strains showed highly similar PBP2b sequences. For
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PBP la  a few mutations were observed in sensitive and intermediate strains, but 
extensive remodelling in isolates with MIC >2.0pg/ml strains was observed. A high 
degree of homology within groups with similar MIC values suggests the presence of 
dominant clones, and in fact the PBP sequences were found to be highly homologous to 
those o f isolates from Japan, South Africa and Spain. They then used PFGE to show 
that isolates MIC >lpg/mL were related to the Spanish / USA 23F clone, suggesting the 
homology observed was due to the dominance of this clone in Canada.
O’Neill et al used a larger group of pneumococci collected in the UK (n=106), Denmark 
(n=30) and Papua New Guineua (n = ll) to evaluate the use of PBP2b PCR RFLP for 
prediction o f MIC to penicillin for which they showed sensitivities, specificities and 
positive and negative predictive values to be in the region o f 90 -  100% (O'Neill, 
Gillespie, & Whiting 1999). Using this one PCR and subsequent RFLP they found all 
77 susceptible isolates had the same pattern, 11 intermediately resistant isolates 
exhibited 9 different patterns (one of which was the same as the sensitive pattern) and 
the 18 resistant isolates showed 4 patterns, but was heavily dominated by only one. 
These data suggest that the development of resistance is bi-phasic, phase one being the 
divergence o f sequences from sensitive to intermediate. Recombination than takes 
place in phase two during which important mutations are selected so that strains with 
resistant MICs show more homology, demonstrated in illustration 9.1. Many 
intermediate genotypes are probably lost as strains not carrying high resistance are 
selected out of a population.
pattern pattern
Key: sensitive = S, intermediate resistant = IR and fully resistant = R
Illustration 9.1: Transition from penicillin sensitive to resistant in S. pneumoniae.
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Studies that include intermediate and sensitive strains are therefore more representative 
of populations of pneumococci in the community, either local or international because 
they include genotypes that will be lost in a selected population. Therefore, if  studying 
the evolution of resistance determinants it is important not to study only isolates which 
are fully resistant.
9.1.4 The influence of serotype
The nature of penicillin resistance, being a culmination of single events presumably 
over a period of time, makes the process complicated to study since there is opportunity 
for other influential factors to contribute. The transition from a sensitive phenotype to a 
resistant one may be indirectly interrupted by events such as the immune system 
removing isolates of a particular serotype from their host. Likewise some serotypes 
may thrive in a non-immune host. Co-colonisation may allow capsules to switch and a 
PBP genotype may consequently encounter different host environments as a result, thus 
some intermediate genotypes may be lost or given a free reign to spread and continue to 
evolve. Considering serotype in studying the evolution of PBPs in pneumococci may 
therefore offer a more complete picture.
Such an investigation into the genetic relatedness between serotypes o f penicillin 
susceptible strains was performed on isolates collected in The Netherlands using PBP 
profiling and restriction fragment end labelling (RFEL) techniques and stratifying the 
data according to serotype (Overweg, Bogaert, Sluijter, Yother, Dankert, de Groot, & 
Hermans 2000) (Overweg, Bogaert, Sluijter, de Groot, & Hermans 2001). They found 
that serotypes 7F, 9V and 3 showed a high degree of relatedness, and that strains of 
serotype 6B, 14, and 18C showed more heterogeneity although most o f the strains being 
represented by the same clade. The authors defined a clade as being isolates that differ 
by less than four bands by REEL using EcoRI, which was equivalent to greater or equal 
to 85% genetic relatedness. Serotypes 6A  and 19F were the most heterogenous which 
may reflect recent dissemination of these two serotypes that are known to be poorly 
immunogenic in children. They also investigated 50 serotype 3 isolates from the 
Netherlands (n=8), United States (n=27), Thailand (n=9) and Denmark (n=6) using 
RFEL. There were four distinct clades, one was specific to Thailand and the others 
were represented by isolates from three countries. Further analysis with PBP profiling 
showed that strains of one clade displayed different PBP genotypes. This demonstrated 
the high degree of heterogeneity among S. pneumoniae strains, that representatives of
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certain clades or clones have spread internationally and that PBP genes diverge 
independently of other genes and that there is PBP divergence among otherwise closely 
related strains, suggesting evolution in PBP genes to be recent events.
Having collected the isolates in Tanzania and finding only penicillin intermediate 
resistant isolates it became clear that there was a unique opportunity to study the 
evolution of penicillin resistance among a semi-closed community with low penicillin 
resistance and in the absence of the international resistant clones. Additionally due to 
the local poverty and rural location there is limited influence from people travelling 
from other regions of Tanzania and even less from abroad and hence little introduction 
of novel genotypes. The aim of this chapter was to perform a prospective evaluation of 
the PBP2b and PBP2x for the PNSSP collected for the study detailed in chapter seven. 
Should the baseline, 2 month and 6 month isolates show a non clonal relationship 
suggesting that penicillin intermediate resistance is evolving in this community and is 
not just the spread o f one or a few clones with intermediate resistance, then this might 
provide the foundation of a more long term study to follow the evolution of penicillin 
resistance in the absence of clonal influences.
9.1.5 Aim
To describe the population biology of penicillin non-susceptible carriage strains from 
Tanzania using PCR/RFLP of penicillin binding proteins, serotype and MLST.
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9.2 Materials and Methods
9.2.1 Preparation of DNA
Organisms with intermediate penicillin resistance (MIC 0.1 - lpg/ml) were cultured 
overnight on blood agar 5% blood (Oxoid ready prepared media) in 5% CO2 . Cells 
were harvested using a sterile loop and suspended in lOOpl sterile distilled water, then 
heated to 95°C for 5 minutes. The boil extract was centrifuged at 13,000 rpm for 5 
minutes and lOpl o f the supernatant diluted in 90pl sterile distilled water. The DNA 
was used within 48 hours and kept at 4°C.
9.2.2 Polymerase chain reaction
The PCRs used in this chapter have been described previously (Gillespie et al. 1997). 
The PBP2b gene was amplified using the following HPLC pure primers (Sigma 
Genosys) sequences: 5 ’ -GATCCTCTAAATGATTCTCAGGTGG-3 ’ and 5’-
CAATTAGCTTAGCAATAGGTGTTGG-3’ and the PBP2x gene was amplified using 
the following primers: 5’-CGTGGGACTATTTATGACCGAAATGG-3’ and 5’- 
A ATT C C AGC ACT GAT GG A AT A AAC AT ATT A-3 \  For each PCR reaction the 
master mix consisted of 5jiL NH4 buffer (Bioline, supplied with Taq), 3pL dNTP 
(5mM) (Promega), 3pi MgCh (50mM) (Bioline), 4pL primers (0.1 mM), 0.2pL (5U/pl) 
Taq polymerase (Bioline) and 68.2pL water. The cycling conditions were modified 
from Gillespie et al 1997 and consisted of 95°C for 5 minutes, followed by 30 cycles of 
94°C for 20 seconds, 55°C for 40 seconds and 72°C for one minute, this was followed 
by a final elongation at 72°C for seven minutes using a Techne Progene machine.
9.2.3 Restriction fragment length polymorphism
20pl PCR product was mixed with lpl enzyme (lOU/pl), 5pi buffer and 0.2pl BSA. 
The mixture was incubated at 37°C for 4 hours. 20pl of the digest was loaded onto a 
1.8% agarose gel and electrophoresed following method in section 2.6.6.
9.2.4 Entering patterns into Bionumerics -  Normalisation and band selection
The RFLP digests were photographed according to section 2.6.5 and saved as TIFF files 
and the images were transferred to Bionumerics 3.0 (Applied Maths, Sint-Martins- 
Latem, Belgium) using Microsoft Explore (California, USA). Four experiment types 
were created (all RFLP), for the four digests i.e. PBP2b Hinfi, PBP2b Ddel, PBP2x 
Hinfi and PBP2x Ddel. The images were opened under their respective experiment
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types and the normalization and band selection performed according to Bionumerics 
manual. Using the experiment card, the following information regarding each lane were 
added as information fields: isolate number, collection period e.g. 2 month, serotype 
and MIC value for penicillin.
9.2.6 Serotype as character data
A character type was created called “serotypes” which was used to enter serotype data.
9.2.7 Calculation of degree of clustering
The degree of clustering was calculated using the following equation:-
100 x no. of clustered isolates -  no. of clusters 
total no. of strains
assuming that a cluster was isolates with 100% similarity.
9.2.8 One-way analysis of variance (ANOVA)
Degree o f clustering values for the dendrograms in figures 9.1 -  9.3 were entered into 
Prism 3.0 with the data to be compared arranged in columns. The data was analysed 
using a one-way ANOVA.
9.2.9 Composite dataset
A composite dataset was created for isolates which had all four experiments. 
Comparisons were created for composite datasets for each RFLP experiment, 
combination of Hinfi and Ddel for each gene and both genes for each restriction enzyme 
and all four.
9.2.10 Congruence of experiments test
For the congruence of experiments test all of the strains for which all four tests had been 
performed were selected. The congruence of experiments test was performed to show 
how representative each test(s) were with respect to each other. This is done by 
comparing the degree of clustering (from the cluster analyses already performed) to one 
another and shows the percentage similarity between experiments.
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9.3 Results
9.3.1 PCR/RFLP
23/30 PBP2b and 20/30 PBP2x PCR amplimers were obtained for baseline isolates for 
which 23/30, 23/30, 18/30 and 20/30 RFLP profiles were obtained for Hinfi and Ddel 
enzymes respectively. 23/24 PBP2b and 24/24 PBP2x PCR amplimers were obtained 
for 2 month isolates for which 23/24, 20/24, 24/24 and 18/24 RFLP profiles were 
obtained for Hinfi and Ddel enzymes respectively. 15/15 PBP2b and 14/15 PBP2x 
PCR amplimers were obtained for 6 month isolates, all of which gave RFLP profiles.
9.3.2 Dendrograms of separate experiments
Each digest i.e. 2B Hinfi was treated as a separate experiment. A dendrogram was 
drawn for each experiment for baseline, 2 month and 6 month isolates, this generated 12 
dendrograms seen in figures 9.1 -  9.3.
9.3.3 Degree of clustering
The degree of clustering was calculated for each experiment for baseline, 2 month and 6 
month dendrograms, table 1.
Table 9.1: Degree o f clustering
Experiment Baseline 2 month 6 month Mean SEM
2B Hinfi 78 78 67 74 6.35
2B Ddel 13 35 27 25 11.1
2X Hinfi 33 33 21 29 6.9
2X Ddel 16 29 21 22 6.6
A one-way ANOVA test was performed on the degree of clustering data, as in table 1, 
which showed that there is no significant difference between the clustering o f baseline, 
2 month and 6 month isolates (p = 0.8463) which confirmed that the variation was no 
greater than would be expected by chance.
A one-way ANOVA test was performed on the same data, see methods, to compare the 
degrees o f clustering for the four experiments. Variation between the experiments was 
found to be significantly greater than expected by chance (p = 0.0021).
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9.3.4 Comparison of pooled isolates
It was on this basis that the data from baseline, 2 months and 6 months were pooled. A 
new comparison was created for the four separate experiments and cluster analysis 
performed which included MIC and serotype data as information fields, figures 9.4 -  
9.6. Isolates with the same MIC and serotype did not appear to be clustered together, 
although no statistical test was performed here.
For PBP2b Hinfi for 61 profiles clustering was 82% figure 9.4. For PBP2b Ddel for 58 
profiles clustering was 40%, figure 9.5. For VB?2x Hinfi for 56 isolates clustering was 
34%, figure 9.6. And for PBP2x Ddel for 55 profiles clustering was 37% there were 10 
clusters and 33 un-clustered isolates, see figure 9.7.
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Figure 9.1: Dendrograms of baseline isolates A = PBP2b Hinfi, B = PBP2b Ddel, C 
PBP2x Hinfi and D = PBP2x Ddel. Note the scales for percentage similarity vary.
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Figure 9.2: Dendrograms of 2 month isolates A = PBP2b Hinfi, B = PBP 2b Ddel, C = 
PBP 2x Hinfl and D = PBP 2x Ddel. Note the scales for percentage similarity vary.
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Figure 9.3: Dendrograms of 6 month isolates A = PBP2b Hinfi, B = PBP2b Ddel, C = 
PBP2x Hinfi and D = PBP2x Ddel. Note the scales for percentage similarity vary.
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Figure 9.4: Dendrogram of PBP2b digested with Hinfi. Serotype and MIC data has 
been included as information fields. I = isolate number, C = collection period, ST = 
serotype and MIC = MIC for penicillin.
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0207 1a 6M 15 0.125
8103.2 6M NT 0.19
8602.2 6M 9 038
0210.3 6M NT 0.19
5608.1 OM 23 0.19
8603.2 6M NT 0 38
3213.4 6M 3 025
4308.1 OM 19 0.19
0104.1 6M 18 0 38
4306.2 OM 19 025
8007.1 2M 9 0.19
3018.1 OM NT 0.125
3305.2 OM 9 02 5
Figure 9.5: Dendrogram o f PBP2b digested with Ddel. Serotype and MIC data has
been included as information fields. I = isolate number, C = collection period, ST =
serotype and MIC = MIC for penicillin.
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C ST MIC
1 0 0 3 3 2M 0 Q 19
7 3 0 2 2 6M 19 Q 38
5711.1 CM 19 Q 125
5 7 0 4 2 6M 19 Q 19
3910.1 CM 19 Q 25
8 1 0 3 2 GM NT Q 19
7 2 0 4 2 CM 19 Q125
2604.1a 2M 19 Q 19
5 4 0 5 2 2M 14 Q125
8 1 0 2 3 2M 19 NT
8 0 0 2 2 6M 9 Q 38
0908.1 6M NT Q 125
0912.1 6M 3 Q 19
7 9 0 8 2 2M 3 Q125
2 0 1 3 2 5M 15 Q 19
0509.1 2M 19 Q 125
0 5 0 9 3 2M 19 0 5
2902.1 avi 19 Q125
5 9 0 7 2 CM 0 Q 25
0112.1 94 4 Q 19
5 0 0 7 2 CM 2 3 Q 125
4703.1 2M 8 Q 125
4 9 1 0 2 2M 19 Q 19
7 7 1 2 2 2M 0 Q 38
8 8 0 2 2 avi 2 3 Q 25
8007.1 2M 9 Q 19
3 4 0 3 3 2M 19 Q 125
7 9 0 1 2 2M NT Q 25
0104.1 avi 18 Q 38
1 8 0 3 2 2M NT Q 38
3 2 0 7 3 CM 2 2 Q 25
3213.1 CM 12 Q 38
3 3 1 1 2 CM 19 Q 125
4 0 1 0 2 CM 15 Q 19
3401.1 2M 19 Q 125
8 2 2 2 2 2M NT Q 5
4 0 1 5 3 CM 6 0 3 8
0207 .1a avi 1 5 Q 125
2 4 1 2 3 CM 19 Q 25
3 2 1 3 2 avi 3 Q 19
3213.4 avi 3 Q 25
5 7 0 1 3 CM 19 0 1 9
8 3 0 4 2 2M 19 Q 25
0403.1 2M 9 0 2 5
5 2 0 8 3 2M 19 0 2 5
5 2 0 7 2 2M 3 Q 38
8810.1 2M 3 Q 25
0 9 0 5 2 2M 9 Q 25
2503.1 CM 8 Q 38
3018.1 CM NT Q 125
4 1 1 9 2 CM 15 0 1 9
5807.1 CM 3 Q 19
4 3 0 0 2 avi 19 Q 25
8 2 1 0 2 2M 2 3 Q 125
4308.1 CM 19 Q 19
8 0 0 3 2 avi NT Q 38
Figure 9.6: Dendrogram of PBP2x digested with Hinfi. Serotype and MIC data has
been included as information fields. I = isolate number, C = collection period, ST =
serotype and MIC = MIC for penicillin.
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9 R g 9 B g c ST MIC
6M 19 0.19
6M 19 0.38
0M 12 0.38
2M 6 0.19
2M 1 9 0.19
2M 1 5 0.19
6M NT 0.3B
6M 4 0.19
0M 19 0.25
0M 19 0.25
2M 14 0.125
0M 12 0.38
OM 19 0.19
2M 19 0.25
2M 19 0.25
2M 3 0.25
6M 3 0.19
6M 3 0.25
2M 9 0.19
2M 3 0.38
2M NT 0.25
OM 2 3 0 .125
OM 3 0.19
OM 19 0 .25
OM 19 0 .19
2M 19 NT
6M 9 0.38
OM 19 0 .125
6M 2 3 0.25
2M 9 0.25
OM NT 0 .125
2M 9 0.25
6M 18 0.3B
OM 15 0.19
OM 2 2 0.25
OM 6 0.38
2M 2 3 0 .125
OM NT 0 .125
6M 1 5 0 .125
OM 15 0.19
6M NT 0.19
2M 6 0 .125
2M 6 0.38
2M 19 0 .125
2M 19 0 .125
6M NT 0 .125
OM NT 0 .125
2M 1 9 0 .5
6M 3 0.19
6M 19 0 .125
2M 3 0 .125
OM 19 0 .125
2M NT 0 .5
OM 19 0 .125
OM 6 0.25
Figure 9.7: Dendrogram of PBP2x digested with Ddel. Serotype and MIC data has
been included as information fields. I = isolate number, C = collection period, ST =
serotype and MIC = MIC for penicillin.
I
5 7 0 4 2  
7 5 0 2 2  
3 2 1 2 3  
1 0 0 3 3  
4 9 1 Q 2  
2 0 1 3 2  
8 6 0 3 2  
01121 
3 9 1 0 1  
2 4 1 2 3  
5 4 0 5 2
3 2 1 3 1  
4 3 0 8 1  
8 3 0 4 2  
5 2 0 8 3  
8 8 1 Q1
3 2 1 3 2  
3 2 1 3 4
8007.1
52 07 .2
79 01 .2
50 07 .2
5607.1 
4 3 0 6 2
57 01 .3  
8 1 0 2 3  
8 6 0 2 2
5711.1 
8 8 0 2 2  
0 9 0 5 2
6 3 0 7 .2  
0 4 0 3 1  
0 1 0 4 1  
4 1 1 9 2
3 2 0 7 .3  
2 5 0 3 1  
8 2 1 Q 2  
7 2 0 3 3  
0 2 0 7 .1 a  
4 0 1 Q 2 
8 1 0 3 2  
4 7 0 3 1  
7 7 1 2 2  
0 5 0 9 1  
3 4 0 3 3  
0 9 0 8 1  
3 0 1 8 1  
0 5 0 9 3  
0 9 1 2 1  
2 9 0 2 1  
7 9 0 8 2
3 3 11 .2  
8 2 2 2 2  
7 2 0 4 2
5907 .2
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9.3.5 Composite dataset
A composite dataset was created for all isolates for all four experiments to see the 
overall relatedness o f the isolates with respect to PBP genes. Clustering was seen 
between 47 and 97%. Composite datasets were then created for combinations o f digests 
hence both PBP2b digests (i.e. Hinfi and Ddel), both PBP2x digests, both Hinfi digests 
(i.e. PBP2b and PBP2x), both Ddel digests and all four experiments. This was done in 
order to see which combination of tests showed the most discrimination with respect to 
performing all four.
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8 £
I c ST MIC
3403.3 2M 19 0 .125
2902.1 6M 19 0.125
3311.2 0M 19 0 .125
4703.1 2M 6 0 .125
7712.2 2M 6 0.38
0908.1 6M NT 0.125
0912.1 6M 3 0.19
0509.1 2M 19 0 .125
5907.2 OM 6 0.25
8222.2 2M NT 0.5
3213.1 0M 12 0.38
8304.2 2M 19 0.25
8810.1 2M 3 0.25
5207.2 2M 3 0.38
0403.1 2M 9 0.25
5208.3 2M 19 0.25
3213.2 6M 3 0.19
3213.4 6M 3 0.25
2412.3 OM 19 0.25
0905.2 2M 9 0.25
0104.1 6M 18 0.38
1003.3 2M 6 0.19
7502.2 6M 19 0.38
5704.2 6M 19 0.19
5711.1 0M 19 0 .125
8602.2 6M 9 0.38
8802.2 6M 23 0.25
5405.2 2M 14 0 .125
8102.3 2M 19 NT
8007.1 2M 9 0.19
5007.2 0M 23 0.125
0207 .1a 6M 15 0 .125
4010.2 0M 15 0.19
8103.2 6M NT 0.19
4910.2 2M 19 0.19
0112.1 6M 4 0.19
2013.2 2M 15 0.19
3910.1 0M 19 0.25
8603.2 6M NT 0.38
5607.1 0M 3 0.19
4306.2 0M 19 0.25
4308.1 0M 19 0.19
3018.1 0M NT 0.125
8210.2 2M 23 0.125
4119.2 0M 15 0.19
3207.3 0M 22 0.25
2503.1 0M 6 0.38
7204.2 0M 19 0.125
5701.3 0M 19 0.19
Figure 9.8: Dendrogram representing cluster analysis created for a composite dataset 
that includes all four experiments. Only isolates on which all four experiments had 
been performed were included. Two pairs of isolates chosen for MLST analysis on the 
basis of alignment together (regardless of the percentage) and with the same serotype 
and penicillin MIC are boxed in red. The control pair are boxed in blue. I = isolate 
number, C = collection period, ST = serotype and MIC = MIC for penicillin.
249
Population acnctics o f  penicillin interme d iate resistant Streptococcus pneumoniae
9.3.6 Background genotypic analysis using MLST
Two pairs of isolates thought to be clonal were selected for MLST analysis, with one 
control pair. The clonal pair were selected on the basis that they had aligned together in 
the composite dataset (for all four experiments), albeit not with 100% since no isolates 
were clustered with 100%, and they also had the same serotype and MIC values for 
penicillin and co-trimoxazole. The control pair consisted o f two isolates that had not 
been aligned together by the composite data set but that did have the same serotype and 
MICs to penicillin and co-trimoxazole. Properties of these six strains are detailed in 
table 2, allele specific MLST results are in appendix 5.
Table 9.2: Properties of two pairs of isolates thought to be clonal and one control pair. 
Column labelled MLST shows number of alleles (out of seven) that are identical.
Isolate MLST Serotype Penicillin MIC Co-trimoxazole
MIC
4306.2 7/7 19 0.25 6
4308.1 19 0.19 8
3213.2 2/7 3 0.19 0.5
3213.4 3 0.25 0.5
5701.3 5/7 19 0.19 19
5711.1 19 0.125 19
9.3.7 Inclusion of serotype data as an experiment
A composite data set was created for all four experiments and serotype, all with equal 
weighting, figure 9.9. The degree of clustering is not increased by the inclusion of 
serotype (between 30 and 75%). Figure 10 shows isolates aligned on the basis of 
serotype alone with the images of the digests showing that similar PBP patterns are not 
aligned together.
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I c ST MIC
3213.2 6M 3 0.19
3213.4 6M 3 0.25
3213.1 0M 12 0.38
8304.2 2M 19 0.25
5208.3 2M 19 0.25
881 0.1 2M 3 0.25
0403.1 2M 9 0.25
5207.2 2M 3 0.38
8222.2 2M NT 0.5
0905.2 2M 9 0.25
0104.1 6M 18 0.38
8007.1 2M 9 0.19
5007.2 0M 23 0.125
8602.2 6M 9 0.38
8802.2 6M 23 0.25
5405.2 2M 14 0.125
8102.3 2M 19 NT
5704.2 6M 19 0.19
7502.2 6M 19 0.38
1003.3 2M 6 0.19
4910.2 2M 19 0.19
2013.2 2M 15 0.19
01121 6M 4 0.19
3910.1 0M 19 0.25
2412.3 0M 19 0.25
8603.2 6M NT 0.38
0207.1a 6M 15 0.125
4010.2 0M 15 0.19
8103.2 6M NT 0.19
3207.3 0M 22 0.25
2503.1 0M 6 0.38
0908.1 6M NT 0.125
0912.1 6M 3 0.19
0509.1 2M 19 0.125
3403.3 2M 19 0.125
2902.1 6M 19 0.125
3311.2 0M 19 0.125
4703.1 2M 6 0.125
7712.2 2M 6 0 .38
3018.1 0M NT 0.125
8210.2 2M 23 0.125
4119.2 0M 15 0.19
4308.1 0M 19 0.19
4306.2 0M 19 0.25
5607.1 0M 3 0.19
5907.2 OM 6 0.25
5711.1 OM 19 0.125
5701.3 OM 19 0.19
7204.2 OM 19 0.125
Figure 9.9: Dendrogram of composite data set created after serotype had been added as 
a separate experiment. All four PBP experiments and serotype where given equal 
weighting. I = isolate number, C = collection period, ST = serotype and MIC = MIC for 
penicillin.
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5 9 0 7  2
2503 .1
8 1 0 2 . 3
8 6 0 3  2
0 9 0 8  1
3 0 1 8 .1
0 4 0 3 .1
0 5 0 9  1
2 9 0 2  1
7 2 0 4  2
3 9 1 0  1
5 7 0 1 .3
8 2 1 0  2
8 1 0 3  2
2M 3 0.3 8
2M 3 02 5
6M 3 0 .1 9
6M 3  0 .1 9
6M 3  0 .2 5
OM 3 0 .1 9
6M 4 0 .1 9
2M 6 0 .125
2M 6 0 .1 9
2M 6  0 .3 8
OM 6 0 .2 5
OM 6 0 .3 8
2M 19 NT
2M NT 0  5
6M NT 0 3 8
6M NT 0 .1 2 5
OM NT 0 1 2 5
2M 9 0 .1 9
2M 9 0  2 5
2M 9  0 .2 5
6M 9  0 .3 8
2M 19 0 .2 5
2M 19 0 2 5
2M 19 0 .1 9
2M 19 0 .1 2 5
2M 19 0 .125
6M 19 0 1 2 5
6M 19 0 .1 9
6M 19 0 3 8
OM 19 0 .125
OM 19 0 .2 5
OM 12 0 3 8
OM 19 0 .125
OM 19 0 2 5
OM 19 0 1 2 5
OM 19 0 .1 9
OM 19 0 1 9
OM 19 0 2 5
6M 18 0 3 8
2M 23 0 1 2 5
6M 23 0 .2 5
OM 23 0 .125
OM 22 0 .2 5
2M 15 0 .1 9
6M 15 0 .125
OM 15 0 .1 9
OM 15 0 1 9
2M 14 0 .125
6M NT 0 1 9
IOC 10D
Figure 9.10: Dendrogram of isolates for which a comparison has been made on the basis of serotype alone. Images of experiments are 
shown; 10A 2B Hinjl, 10B 2B DdeI, IOC 2X HinfI and 10D 2X Dde\.
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9.3.8 Congruence of experiments test
The congruence of experiments test was performed to see which single experiments or 
two experiments most represented the diversity of PNSSP in this study, assuming that 
the PBP comparison is the most representative of all experiments. To avoid doing all 
four PCRs, the most representative pair of experiments would be PBP2b comparison 
which is 70.1% similar to all four, and the most representative single test is PBP2b DdeI 
experiment which is 52% similar, figure 9.11.
j   PBP comparison jjjjj^ J
1------  Ddel Comparison
—  --------  2X Comparison
  PBP2XDdel
______ i— PBP2BDdel
'—  2B Comparison
________i— PBP2XHinfl
'—  Hinfl Comparison
-------------------- PBP2B Hinfl
Figure 9.11: Congruence of experiments test performed on all experiments and 
composite datasets.
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9.4 Discussion
The overall conclusion from this chapter is that the population of pneumococci are 
polymictic with regard to their PBP genes, with the exception of PBP2b Hinfl digests. 
The study would benefit from complete MLST data to give a degree o f background 
genetic relationship of the strains, such approaches have been used before (Overweg, 
Bogaert, Sluijter, de Groot, & Hermans 2001).
Dendrograms in figures 9.1 -  9.3 show different levels of clustering of the same strains 
in the different experiments, i.e. that the same isolates were not clustered together by 
Hinfl. and Ddel digests for either PBP. This suggests that PBPs are evolving 
independently to each other and that isolates are not clonal. The same band tolerance 
and optimization was used for all comparisons, and the composite data set comparisons 
were made using settings taken from the previous experiments. The tolerance settings 
used show a lower degree of clustering for PBP2b Hinfl experiments than would be 
expected by eye, however, it was felt that keeping the settings the same was important 
since comparisons could not be made between strains on the basis of clustering if the 
tolerance settings were not consistent. The degree o f clustering was calculated 
assuming 100% agreement to be a cluster so that a change in molecular weight of a 
single band gives a different pattern and hence a new cluster (for more than one isolate). 
A one-way analysis of variance was then used to show that there was no significant 
difference between the isolates at baseline, 2 month and 6 month so that these isolates 
could be considered a single population. Since there had been an intervention, the 
azithromycin distribution, it was not considered appropriate to regard these as a single 
population without statistical confirmation that they were not significantly different by 
this genotype. Although it did not appear that the azithromycin had affected the 
population this conclusion had only been made on the basis of serotype distribution and 
erythromycin resistance data (see chapter seven). The one-way analysis o f variance 
demonstrated that there is significant difference between the four tests and that the tests 
should be considered separately.
Dendrograms were then created for pooled isolates, figures 9.4 -  9.7, and it was clear 
that baseline, 2 month and 6 month isolates were not distinct populations as they were 
evenly clustered, i.e. not all of the baseline isolates were together. Serotype and MIC 
(penicillin) data were included as information fields so that they did not affect the 
clustering. This was done to see whether isolates o f either the same serotype or MIC
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were clustered together, that is to see whether MIC was associated with a certain RFLP 
pattern or if a serotype was associated with a pattern, the latter being an indication of 
clonality and evolutionary time scale. Although there were a few clusters of isolates 
with the same MIC and serotype, overall they were evenly dispersed, with the exception 
of PBP2b Hinfl. which shows the most homogeniety. Since all o f the strains have 
intermediate penicillin resistance, it was not expected that there would be clustering of 
MIC, since there is only a small variation of MIC values (0.1 -  0.5pg/ml). Clustering 
with MIC would be more likely if there had been a wider range of MIC values, as in the 
O’Neill study (O’Neill et al. 1999). They described how sensitive, intermediate and 
resistance strains could be identified on the basis of the PBP patterns. Conservation of 
patterns within MIC groups had previously been reported (Smith, Klugman, Coffey, & 
Spratt 1993). The patterns obtained from PBP2b Hinfl digestion in this study are 
identical to the pattern that was shown to represent sensitive in the O’Neill study, 
suggesting that PBP patterns do not reliably represent MIC. This may reflect 
geographical differences, however, since genotypes are known to be internationally 
disseminated this has important implications for resistance determination using PBP 
RFLP. However, it is likely that MIC and PBP restriction patterns are not associated 
since the restriction enzymes do not target key known mutation sites in the PBP. This is 
also supported by the evidence that other factors are contributing to penicillin 
resistance, such as other PBPs (Grebe & Hakenbeck 1996) and others. Since only a 
relatively small variation in the MICs o f PNSSP was found in this study stratification 
was not done on the basis of MIC, since one doubling dilution differences could be a 
result of experimental variation.
The fact that serotypes are not clustered with together when PBP patterns are used for 
cluster analysis, suggests that PBP recombinations have taken place more recently than 
the serotypes were distributed throughout the population and possibly since serotypes 
diverged from one another, thus supporting the theory that PBP genes are sites of 
frequent recombination. This observation of diversity differs from another published 
study investigating PBP through RFLP and sequencing techniques. Overweg et al 
studied 153 PSSP isolated from patients with meningitis in the Netherlands in 1994. 
The strains were analyzed by PBP PCR and RFLP, RFEL and serotyping. They showed 
that some PBP genotypes were associated only with serotypes 8, 5, 32A and 19F 
suggesting that these serotypes emerged after the divergence o f these PBP genotypes. 
They also found RFEL types that matched those of internationally spread clones,
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therefore the populations dynamics are likely to be quite different between the this and 
the Overweg study (Overweg, Bogaert, Sluijter, Yother, Dankert, de Groot, & Hermans 
2000).
To test the theory that strains are highly divergent in this study and using the limited 
MLST available, three pairs o f isolates were chosen for analysis. Two pairs were 
chosen that were thought to be clonal on the basis of identical PBP composite data set 
analysis, serotype and MIC. One control pair was included that had the same MIC and 
serotype, but that were not clustered together in the composite dataset. One test pair 
was confirmed to be clonal as they were identical at 7/7 loci, the other was not clonal 
having only 2 identical loci and the control pair was on the borderline with 5/7 loci 
identical. This lends further weight to the suggestion that this population is not clonal, 
if  only one of two pairs thought to be highly clonal was in fact identical. That the 
control pair was possibly clonal supported the suggestion that PBP divergence is recent 
in this population, that isolates chosen to be identical on the basis o f serotype and MIC 
were in fact clonal by MLST analysis, but unrelated by PBP analysis.
Due to the high levels of penicillin resistance globally, many studies include strains 
with full penicillin resistance which have a clear selective advantage within their niche; 
an environment which more often than not is being studied for its high penicillin or 
multi-drug use. With a selective advantage a resistant strain, especially if  multi 
resistant, will have a dominant effect on the population via dissemination or donating 
resistant genes, and hence clonal relationships are unveiled. Clonality can be seen on 
the basis of genetice background of isolates by using MLST or PFGE. Alternatively on 
the basis o f certain loci by sequencing of PBP genes show that genotypes have spread 
from one donor to recipient -  an event that is likely to be facilitated by the selective 
advantage conferred. Sa-Leao et al found that multi-drug resistant international clones 
had dominated the pneumococcal population in Iceland. Iceland had enjoyed relatively 
low penicillin resistance until 1989 (Sa-Leao, Vilhelmsson, de Lencastre, Kristinsson, 
& Tomasz 2002). The first penicillin resistant isolate was recorded in 1988, then 
between 1989 and 1993 a rise in penicillin resistance from 2.3% to 19.8% recorded 
(which then declined to 15% in 1995). This coincided with a reduction in the use of 
antibiotics in children, see section 1.5.7.3.a. The group showed that the majority of 
PNSSP shared the same mosaic PBP structure with the Spain6B-2 clone (pandemic in 
Spain). This clone was isolated repeatedly and isolates were soon reported with MIC
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0.1 - ljj.g/ml. They demonstrated using PFGE that this clone has probably acted as a 
donor o f mosaic PBP genes and has had a very dominant affect on the population. The 
population described in this chapter is different as there does not appear to be a 
dominant PBP pattern, and may be as a result of the absence o f isolates with high 
penicillin MIC so there are no strains with a strong selective advantage, which could act 
as a donor. Should a strain evolve, or be introduced to the population, the population 
dynamics may be altered. In this study penicillin use was not monitored, so there is no 
data regarding the usage in the region. If the price of drugs and resistance recorded 
reflects use, then penicillin is probably used much less than co-trimoxazole (Stronge 
2002). If a strain with only penicillin resistance was introduced into the community 
then it may have less selective advantage than one with penicillin and co-trimoxazole 
resistance which may become dominated and alter the population dynamics. Should a 
similar study be performed for co-trimoxazole, a different pattern of diversity versus 
clonality may be seen. However, many strains were found to be co-resistant to 
penicillin and co-trimoxazole so a selective advantage would be offered to the same 
strains by use o f either of these antibiotics.
This chapter describes a polymictic population of pneumococci isolated from a semi­
closed community with access to medical treatment and known use o f self-administered 
medication (Stronge 2002). With respect to penicillin binding proteins there appears to 
be recent evolution or recombination among this population of strains that has not been 
affected by a dominant clone. Passage from intermediate resistance to resistance has 
not yet occurred and it may be possible to monitor the transition with follow up studies. 
This study suggests a unique opportunity to study the evolution and dynamics o f 
emerging penicillin resistance in an area without resistance.
The strains in this population are the penicillin non-susceptible portion o f a completely 
unselected strain collection from a cross sectional study. This is different from studies 
that select strains from geographically unrelated locations and included only because 
they are either invasive, collected from a patient with a particular disease or harbour full 
penicillin resistance regardless of their origin. Such studies often report either clonal 
strains with divergent PBP patterns / sequences, diverse backgrounds with clonal PBP 
patterns / sequences (Sa-Leao et al. 2000) or clonal with respect to both PBP and 
genetic background (Canica, Dias, Vaz-Pato, & Carvalho 2003). This makes the strains
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in this study representative of the population dynamics of the given location, rather than 
just or a collection of random isolates collected with a bias towards resistance.
Returning to the area and performing a follow-up study would allow comparison of 
PBPs over a longer time scale which would show how time is influencing the 
population structure that has been partially described by this chapter, whether there are 
any penicillin resistant isolates, or if the PBP profiles bear any resemblance to those in 
seen in this chapter. It would also be of interest to investigate PBP la, which is thought 
to recombine to give fully resistant strains and to investigate PBP2b and PBP2x for 
sensitive strains. A more complete analysis should include MLST on all strains in order 
to compare genetic background with serotype and PBP genotypes, much like the 
Overweg et al studies but in a different setting. So far no such long-term study has been 
performed in an area that compares pre- full penicillin resistance data with post full 
penicillin resistance data.
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The population biology of S. pneumoniae is poorly understood (Enright & Spratt 1998). 
With respiratory disease having overtaken diarrheal disease as the most frequent cause 
of death for children in developing countries (World Health Organisation 1993) the 
need has never been greater for improving our understanding of the dynamics of 
pneumococcal epidemiology and evolution.
To improve our understanding of pneumococcal disease it is necessary to optimise the 
tools for collecting and typing isolates. Should there be a selective advantage at the 
sample collection point so that some serotypes to survive better than others, then data 
collected would be inaccurate. The STGG media has been described previously 
(Ghema R.L. 1981) (O'Brien et al. 2001) (Leach et al. 1997), however, evaluation of 
serotype survival at different temperatures is essential and has not been previously 
reported. When epidemiological studies are performed in developed countries, hospital 
settings allow the time between specimen collection and plating onto enriched media to 
be relatively short or alternatively to provide the appropriate storage and transport 
conditions to support the organisms. Field studies have the disadvantage of being 
undertaken some distance from the laboratory, and may involve house visits that are 
lengthy and time consuming. Transport and storage media in these settings are 
important since inaccurate data could be reflected in inappropriate vaccine selection. In 
this work SGG and STGG have been shown to give no significant selective advantage 
to any serotype over the time periods covered. By far the best advantage o f SGG and 
STGG media is the versatility, that they can be used for transport and storage o f both 
specimens and pure organisms. When working away from the laboratory it is a major 
advantage to be able to directly freeze samples until the samples can be processed fully. 
The data in chapter three demonstrates that freezing and then thawing, even on multiple 
occasions, does not reduce the viability of the S. pneumoniae and thus will not alter the 
outcome of a study. The results from this work enabled large numbers of throat swabs 
to be taken during the study of the impact of azithromycin detailed in chapter seven, 
with confidence that they could be collected and stored before processing, and later 
transported to the UK under optimal conditions for survival. Having tested the survival 
rates of four serotypes, then performing the azithromycin study, the decision was made 
to include more serotypes, such as serotype 14 since it was so surprising that, despite 
being the most prevalent serotype worldwide, only two serotype 14 strains were 
isolated. No reduction in viability was seen for serotype 14 and thus confirms the 
accuracy of the data collected. SGG may be useful for routine use in developing
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countries as a cost effective alternative to pre-prepared swabs in routine testing, and 
may be one less barrier to routine culture in resource-poor countries.
A major advantage of a PCR method for serotyping is that it would obviate the 
requirement of culture, therefore allowing data to be collected more quickly, and 
importantly from culture negative specimens, such as those taken from patients taking 
antibiotics. Methods for applying the CpsAB PCR directly to clinical specimens were 
explored in chapter four but focus was turned to the long range PCR based RFLP as it 
provided serotype specific data. The requirement for fresh genomic DNA preparations 
in the long range PCR and the lengthy elongation time of the PCR cycle means that it is 
not a quick alternative to serological typing. There is no point in reducing the PCR 
cycle time unless the extraction time can be shortened since the RFLP will still need to 
be performed on a consecutive day. Despite this, the Promega extraction kit and the 
PCR method should be easy to follow for any laboratory that has the equipment 
available, and should therefore be widely applicable. However, it will not have many 
advantages for laboratories processing large and continuous numbers of strains, such as 
reference laboratories, where sufficient resources make the complete set o f antisera 
available and where there is a dedicated investigator that can become an expert at the 
serology. Even in reference laboratories the long range PCR may still be of use for 
recognising new capsular types, and in countries such as Tanzania and among 
indigenous populations, where types rarely seen in the developed world are common 
(Leach, Shelby-James, Mayo, Gratten, Laming, Currie, & Mathews 1997). The 
database generated from the work in this chapter is not yet complete for all serotypes. It 
contains patterns for isolates that have not been sub-typed and only 24 different 
patterns. However, the data suggests that there are enough patterns to demonstrate that 
a PCR RFLP based serotyping technique focusing on the whole capsulation locus is 
feasible by this method and requires only completion for all serotypes. The next step 
would be to acquire a complete set of strains, including multiple isolates for each type 
and compile a database.
Recently a paper describing amplification of serotype specific genes in a multiplex PCR 
system was described (Lawrence et al. 2003). The fragments are sized using an 
automated capillary sequencer and is well suited to high throughput environments such 
as public health laboratories. This system will need updating as prevalent serotypes 
change, which can be done by including additional primers. A major advantage of this
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system is the ability to recognise more than one serotype. However, this PCR is not 
applicable for the developing world where access to capillary sequencer technology is 
unlikely and the technique would be barely feasible without. Both this multiplex PCR 
strategy and the long range PCR RFLP method may be useful, and complement one 
another, in routine diagnostic work in developed countries.
The impact of resistance of antibiotics in primary pathogens is clinically important and 
the threat o f some primary pathogens with resistance is increasing. The association 
between the use of antibiotics and the risk of acquiring resistant pathogens has been 
clearly demonstrated (Gould & MacKenzie 2002). It has also been demonstrated that 
prudent use and reducing consumption o f antibiotics has been correlated with a fall in 
the incidence of resistance in some countries (Kristinsson K 1999). It is therefore very 
important to assess the use of one antibiotic against one organism on resistance of the 
same antibiotic or class of antibiotics on other organisms, to prevent the solution to one 
problem directly exacerbating another. In this instance the use of azithromycin for 
treating trachoma on a community basis has been assessed for any impact o f macrolide 
resistance in S. pneumoniae. Leach’s group performed a similar study among 
Aboriginal children and found that azithromycin use selected for already resistant 
organisms (Leach, Shelby-James, Mayo, Gratten, Laming, Currie, & Mathews 1997). 
Six months afterwards the levels of macrolide resistance had fallen, but not below pre­
treatments figures. The data in this study suggests that a community o f individuals 
carrying fully macrolide sensitive organisms is not affected by azithromycin use. 
Carriage rates may well have fallen immediately after drug distribution, this was not 
assessed, but two months afterwards the carriage rate had not changed (11% at baseline 
and 12% at two months) and there was no significant change in the distribution of 
serotypes. Since there were no resistant organisms pre-treatment, no selective 
advantage was offered to any pneumococci. It is important to assess if the single dose 
regimen of azithromycin used in this context will offer the opportunity for such 
mutations to arise and be selected. Given this outcome, azithromycin will be 
appropriate in communities like Huruma. Assessing the access to macrolides, which in 
this case limited or non-existent (Stronge 2002), may be an easy and effective method 
of predicting resistance in rural communities with limited access to medical facilities. 
The Leach study described macrolide use in among the population under study, and so 
in both cases macrolide use correlated with the outcome.
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The availability of co-trimoxazole and the worldwide levels o f penicillin resistance 
prompted the testing of resistance to these two antibiotics in this study. Co-trimoxazole 
resistance levels are high in Africa and are likely to increase since the WHO has 
recommended it for prophylaxis in HIV patients (Badri et al. 2001). It is therefore 
important that co-trimoxazole resistance levels are measured in Africa, especially in 
poor regions such as Huruma where the hospitals are not able to perform testing or 
record this data. Co-trimoxazole resistance levels in this population are comparable 
with studies in similar areas (Feikin et al. 2003). Co-trimoxazole and penicillin 
resistance levels are significantly associated in this population, which is in accordance 
with other data (Adrian & Klugman 1997). The use of co-trimoxazole, either for 
treatment of infections or prophylaxis, is likely to select for isolates resistant to co- 
trimoxazole and penicillin, thereby altering the ratio of resistant to sensitive carriage 
isolates. This is likely to increase the proportion of infections by resistant organisms, 
which will impact on therapy, and have serious consequences on mortality to 
pneumococcal infection, especially in regions where sensitivity testing is not routine.
Examination o f the genotypes of PBP o f PNSSP suggests that the evolution o f penicillin 
resistance in this community has not arisen by the donation o f resistance genes from 
fully resistant strains. It appears the penicillin resistance is evolving in this community 
independently from areas where resistant isolates are already circulating. It is important 
that the isolates used in the PBP evaluation were an un-selected population and that no 
bias was introduced at this stage. Studies that are conducted over wide geographic 
regions by collecting resistant organisms from multiple centres are important for 
monitoring the development and spread of multi resistant clones. However, population 
biology cannot be investigated unless unselected populations are used. The lack of 
clonality among PBPs and the lack o f association between serotype and PBP profile 
suggests recent recombination of PBP genes. The lack of association between serotype 
and PBP patterns suggests that PBP recombination has taken place more recently than 
the spread of the observed serotypes throughout the community, otherwise there would 
be isolates with the same serotype displaying the same PBP patterns.
Understanding of the evolution of antibiotic resistance in the context of other circulating 
organisms in a population for pathogens such as S. pneumoniae and S. aureus is 
important as they are known to acquire mutations by multiple gene rearrangements as 
apposed to point mutations which frequently account for resistance in M. tuberculosis
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(Ayliffe 1997;Dowson et al. 1989;Gillespie 2002;Sibold et al. 1994). This means that 
the population dynamics o f circulating pneumococci, carriage and invasive organisms, 
becomes more important as it is the interaction of many organisms in the presence of 
selective pressure and not the mutation of a single organism in a host undergoing 
antibiotic therapy. The lack of full resistance in this community, for which there is an 
established collaboration for research, suggests that this is a rare opportunity to study 
the evolution of penicillin resistance by recombination.
The lack of familial transmission observed in this community is surprising, given that 
many o f the families sampled are very poor and therefore live in small houses, which 
would suggest close familial contact. As the rate of carriage rate was low it is possible 
that isolates were missed thus familial transmission missed. Alternatively that familial 
transmission is a less important mechanism for transmission of pneumococci than has 
been previously reported (Hendley et al. 1975). It may be that assumptions made in 
certain types of populations not necessarily applicable to others.
Further work
There are likely to be two major aspects to work that may continue from this thesis. 
Isolates representing serotypes not already included in the database will be subjected to 
long range PCR and RFLP and entered into the database. This will be done to expand 
the typing capability o f the database and to further test the technique. More non- 
typeable strains will be included, especially for isolates collected from continuing 
studies in Tanzania, which may add to serotype prevalence data for types that have not 
been recognised in this study.
Multi locus sequence typing will be used to identify background genotypes of more of 
the isolates collected in Tanzania. PBP la PCR and RFLP analysis o f the penicillin non- 
susceptible strains and PBP2b and PBP2x PCR and RFLP of some sensitive strains and 
sequencing o f PBP genes from isolates representing different PBP genotypes will be 
performed. If funding becomes available repeat sampling may be undertaken in the 
Huruma villages for a longer-term evaluation of the evolution of penicillin resistance in 
this population. With the inclusion of MLST data and further PBP analysis, along with 
the serotype and MIC data already generated, a detailed description of the population 
genetics and evolution of PBP mediated antibiotic resistance can be performed for the 
Huruma population.
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Baseline
Pen Eryth Cotri Serogroup
1101.2 0.016 S 0.094 S 12 R 11
1104.1 0.016 S 0.064 S 12 R 1
1104.2 0.006 S 0.094 S 0.125 S 4
1105.1 0.016 S 0.064 S 3 1 NR
1108.1 0.016 S 0.064 S 32 R 4
1804.1 0.016 S 0.094 S 0.125 S 18
2412.3 0.25 I 0.094 S 0.75 I 19
2503.1 0.38 I 0.125 S >32 R 6
2503.2 0.19 I 0.125 S 32 R 23
2701.2 0.016 s 0.125 s 0.38 S 19
2710.1 0.016 s 0.19 s 0.25 S 19
2711.3 0.016 s 0.125 s 0.125 S 23
2804.5 0.016 s 0.094 s 0.125 S 8
2810.1 0.016 s 0.094 s 6 R 15
2810.2 0.016 s 0.064 s 0.125 S 11
2902.1 0.016 s 0.125 s 0.38 S 9
2906.3 0.016 s 0.047 s 0.25 s 19
2907.1 0.004 s 0.094 s 0.19 s 9
3005.1 0.032 s 0.064 s 0.38 s 19
3005.2 0.016 s 0.094 s 0.19 s 11
3018.1 0.125 I 0.064 s 0.25 s NR
3111.2 0.032 s 0.047 s 1 I 6
3205.1 0.016 s 0.064 s 0.19 s 23
3205.5 0.25 I 0.094 s 0.75 I NR
3207.3 0.25 I 0.064 s >32 R 22
3208.2 0.032 s 0.094 s 0.38 S 9
3208.3 0.047 s 0.094 s 0.19 s All
3212.2 0.016 s 0.094 s 0.19 s 18
3212.3 0.38 I 0.094 s 0.125 s 12
3213.1 0.25 I 0.125 s 1 I 19
3213.3 0.016 s 0.094 s 0.75 I 3
3305.2 0.25 I 0.125 s 0.25 s 9
3305.3 0.047 s 0.064 s 0.25 s 23
3311.1 0.016 s 0.094 s 0.38 s 15
3311.2 0.125 I 0.094 s 0.38 s 19
3401.3 0.094 s 0.064 s 0.38 s 6
3412.2 0.016 s 0.125 s 0.25 s 23
3601.1 0.023 s 0.064 s 0.19 s 9
3601.2 0.032 s 0.094 s 0.19 s NR
3602.1 0.016 s 0.094 s 0.25 s 9
3606.1 0.016 s 0.094 s 0.25 s 9
3612.2 0.016 s 0.094 s 0.19 s 9
3612.3 0.016 s 0.094 s 0.125 s 15
3682.2 0.016 s 0.125 s 0.25 s 4
3703.1 0.023 s 0.125 s 0.75 I 19
3904.1 0.064 s 0.064 s 0.38 s 6
3910.1 0.25 1 0.094 s 0.75 I 19
3911.1 0.094 s 0.064 s 8 R 7
3912.1 0.016 s 0.094 s >32 R 11
3912.2 0.023 s 0.047 s 0.25 S 3
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3915.2 0.016 S 0.094 S 0.25 S 19
4002.1 0.25 I 0.094 S 12 R 6
4010.2 0.19 I 0.094 s 0.25 S 15
4014.1 0.016 S 0.094 s >32 R 23
4015.3 0.38 1 0.094 s 0.25 S 6
4110.1 0.023 s 0.064 s 0.25 s 3
4113.1 0.016 s 0.047 s 0.25 s 6
4114.2 0.047 s 0.032 s 0.19 s 9
4119.1 0.016 s 0.064 s 0.094 s G
4119.2 0.19 I 0.064 s 0.25 s 15
4201.1 0.016 s 0.064 s 0.19 s 7
4304.1 0.016 s 0.064 s 0.125 s G
4306.2 0.25 1 0.125 s 6 R 19
4307.1 0.016 s 0.047 s 0.25 S All
4307.3 0.012 s 0.094 s 0.125 S G
4307.3 0.016 s 0.064 s 0.125 S 14
4308.1 0.25 I 0.064 s 8 R 19
4407.1 0.032 s 0.064 s 8 R 23
4806.1 0.016 s 0.064 s 0.38 S 7
5007.2 0.125 I 0.064 s 0.25 S 23
5111.1 0.016 s 0.125 s 0.19 S 9
5302.1 0.016 s 0.064 s 6 R 19
5303.2 0.016 s 0.094 s 4 R 23
5310.3 0.032 s 0.064 s 0.125 S 7
5402.2 0.032 s 0.047 s 1 I 6
5412.2 0.016 s 0.094 s 0.125 s 19
5602.3 0.016 s 0.064 s 6 R 15
5605.1 0.38 1 0.094 s 0.5 I 19
5605.2 0.016 s 0.094 s 0.25 S 6
5607.1 0.19 I 0.064 s 0.75 I 3
5608.1 0.19 I 0.064 s 0.094 s 23
5608.2 0.016 s 0.064 s 12 R 23
5609.1 0.032 s 0.064 s 0.19 S 9
5609.2 0.016 s 0.094 s 0.19 s 6
5609.3 0.016 s 0.064 s 0.19 s 6
5701.3 0.19 1 0.094 s 0.19 s 19
5701.4 0.016 s 0.094 s 6 R 23
5701.5 0.016 s 0.094 s 0.25 S 9
5702.1 0.016 s 0.064 s 0.19 S 1
5704.3 0.016 s 0.064 s 0.19 S 3
5706.3 0.047 s 0.094 s 0.25 S All
5709.5 0.064 s 0.064 s 0.38 S 19
5711.1 0.125 I 0.047 s 0.75 I 19
5802.1 0.016 s 0.064 s 0.19 s 7
5803.1 0.016 s 0.094 s >32 R 23
5803.3 0.016 s 0.094 s 4 R 23
5804.1 0.016 s 0.094 s 16 R 23
5805.1 0.016 s 0.094 s 6 R 23
5805.2 0.016 s 0.094 s 6 R 23
5807.2 0.047 s 0.064 s 0.19 S 9
5808.1 0.016 s 0.047 s 0.19 S 18
5809.2 0.064 s 0.094 s 0.125 S 3
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5907.2 0.25 1 0.094 S 0.75 I 6
5907.3 0.023 S 0.047 S >32 R 9
6101.3 0.016 S 0.064 s 0.25 S 7
6109.3 0.016 s 0.064 s 0.19 s 4
6303.2 0.016 s 0.094 s 6 R 6
6305.1 0.016 s 0.094 s 0.125 S 3
6307.2 0.125 I 0.094 s 1 1 NR
6611.1 0.023 s 0.032 s 0.38 s 6
6614.2 0.25 I 0.094 s 4 R 19
6802.1 0.047 s 0.19 s 0.125 S 19
6901.2 0.047 s 0.094 s 12 R 19
6903.2a 0.094 s 0.094 s 4 R 19
6903.2b 0.047 s 0.094 s 24 R 19
6903.2c 0.016 s 0.094 s 0.75 I 19
7007.2 0.23 I 0.094 s >32 R all
7107.1 0.008 s 0.064 s 0.19 S 23
7204.2 0.125 I 0.094 s >32 R 19
7305.1 0.016 s 0.125 s 2 I 19
7305.2 0.008 s 0.047 s 0.5 I 6
8605.1 0.25 I 0.064 s >32 R 19
8715.1 0.032 s 0.125 s 0.19 S 18
8715.2 0.016 s 0.064 s 0.19 S 6
0205.3 0.032 s 0.125 s 16 R 19
0505.2 0.047 s 0.064 s 12 R 19
0508.1 0.094 s 0.125 s 16 R NR
0602.1 0.016 s 0.094 s 0.25 S 17
0606.1a 0.016 s 0.094 s 24 R 6
0606.1b 0.016 s 0.064 s 3 I all
0607.3 0.012 s 0.064 s 6 R 6
0609.1 0.008 s 0.064 s 0.125 S 9
0803.1 0.023 s 0.094 s 0.19 S 3
0912.3 0.016 s 0.094 s 0.25 S NR
2712.3a 0.016 s 0.094 s 0.094 S 15
2712.3b 0.016 s 0.094 s 0.19 S 15
54??.5 0.047 s 0.094 s 0.19 S 18
7203.3 0.125 I 0.094 s >32 R NR
7305.2b 0.064 s 0.094 s 3 I 6
7310.1a 0.094 s 0.064 s 0.19 S 6
7310.1b 0.016 s 0.094 s 1.5 I 5
S 111 S 141 S 82
1 30 I 0 I 20
R 0 R 0 R 39
Total 141 141 141
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2 Month
1003.20
Pen
0.38 I
Eryth
0.125 S
Cotri
>32 R
Serotype
6
1003.30 0.19 I 0.047 s >32 R 6
1008.10 0.016 S 0.094 S 0.125 S 18
1009.20 0.016 s 0.047 S 0.125 S 9
1102.10 0.016 s 0.064 s 6 R 11
1102.10 0.016 s 0.064 s 6 R 11
1103.20 0.016 s 0.094 s 0.25 S 19
1104.10 0.016 s 0.094 s 4 R 6
1106.10 0.016 s 0.125 s 4 R 6
1204.10 0.016 s 0.094 s >32 R 23
1308.10 0.023 s 0.064 s >32 R 15
1402.30 0.016 s 0.094 s 0.25 S 6
1701.30 0.016 s 0.094 s 0.25 S 19
1710.20 0.016 s 0.094 s 0.125 S NR
1801.10 0.016 s 0.016 s 0.19 S NR
1803.20 0.38 I 0.032 s >32 R NR
1804.10 0.016 s 0.094 s 0.38 S 19
1806.10 0.016 s 0.094 s 0.19 S 6
1810.20 0.016 s 0.064 s 0.19 S 6
1813.10 0.016 s 0.094 s 0.19 S 9
1910.20 0.016 s 0.094 s 4 R 11
2013.20 0.19 I 0.016 s 8 R 15
2103.20 0.016 s 0.032 s 0.25 S NR
2204.10 0.023 s 0.047 s 0.19 s 18
2208.10 0.016 s 0.094 s 0.25 s 6
2401.20 0.016 s 0.125 s 0.5 s 19
2505.10 0.064 s 0.125 s >32 R NR
2506.10 0.016 s 0.125 s 0.19 S NR
2514.10 0.012 s 0.125 s 0.38 S 7
2601.10 0.023 s 0.064 s 0.19 S 6
2604.20 0.016 s 0.125 s 0.25 S 19
2703.20 0.023 s 0.094 s 0.19 s NR
2703.30 0.032 s 0.016 s 0.75 I All
2705.20 0.032 s 0.032 s 0.19 s NR
2706.10 0.016 s 0.094 s 0.25 s 4
2711.10 0.012 s 0.125 s 0.38 s 19
3043.30 0.094 s 0.032 s 8 R 19
3207.20 0.016 s 0.047 s 0.19 s 18
3208.30 0.016 s 0.094 s 0.75 I NR
3401.10 0.125 I 0.032 s 0.75 1 19
3401.20 0.023 s 0.064 s 0.25 s NR
3403.30 0.125 I 0.094 s >32 R 19
3601.40 0.023 s 0.047 s 0.125 s All
3708.20 0.008 s 0.125 s 0.19 s 17
3711.30 0.016 s 0.064 s 0.25 s 19
3805.40 0.016 s 0.094 s 6 R 19
3806.10 0.023 s 0.047 s 0.125 s NR
4202.10 0.016 s 0.094 s 6 R 6
4203.20 0.016 s 0.094 s 0.25 S 6
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4204.10 0.094 S 0.094 S 0.38 S 15
4207.10 0.016 S 0.047 S 0.25 s 6
4210.10 0.064 S 0.19 S 0.25 s 19
4316.30 0.016. S 0.094 S 0.5 I 6
4506.10 0.008 s 0.125 S 0.19 s 7
4509.10 0.016 s 0.047 S 0.19 s 3
4514.10 0.016 s 0.064 s 0.25 s NR
4517.20 0.094 s 0.125 s 0.75 I 19
4605.30 0.016 s 0.094 s 0.38 s 11
4608.30 0.016 s 0.125 s 0.38 s 8
4703.10 0.125 I 0.094 s 1 I 6
4711.20 0.016 s 0.125 s 0.25 s 7
4801.20 0.016 s 0.047 s 0.125 s H
4808.20 0.012 s 0.125 s 0.19 s 9
4903.40 0.016 s 0.125 s 0.19 s 9
4910.20 0.19 1 0.125 s 0.75 I 19
4915.10 0.016 s 0.125 s 0.75 I 4
4916.10 0.023 s 0.094 s 0.19 s NR
4921.10 0.012 s 0.094 s 6 R 23
5001.20 0.016 s 0.125 s 0.25 s 19
5013.10 0.38 I 0.125 s 0.5 s 19
5016.20 0.016 s 0.094 s 8 R 23
5102.10 0.016 s 0.094 s 0.25 s 18
5102.20 0.016 s 0.047 s 0.19 s All
5111.20 0.016 s 0.125 s 0.125 s 7
5207.20 0.38 I 0.125 s 0.38 s 3
5208.30 0.25 I 0.094 s 0.75 I 19
5303.20 0.016 s 0.125 s 0.125 s NR
5305.20 0.016 s 0.125 s 12 R All
5405.20 0.125 I 0.094 s 4 R 14
5712.10 0.016 s 0.064 s 0.19 S 9
5712.20 0.016 s 0.094 s 0.38 S 6
5801.20 0.016 s 0.094 s 0.38 S 18
5805.10 0.016 s 0.125 s 12 R 23
5805.20 0.016 s 0.094 s >32 R 1
5807.10 0.016 s 0.094 s 0.25 S 9
5905.10 0.032 s 0.125 s 6 R 23
5907.10 0.016 s 0.064 s 8 R 11
5907.20 0.016 s 0.125 s 12 R NR
6010.10 0.016 s 0.125 s 1 I NR
6101.20 0.016 s 0.19 s 1.5 I 6
6607.30 0.016 s 0.094 s 0.75 I 6
6608.20 0.047 s 0.032 s 0.38 S 23
6610.20 0.016 s 0.125 s 0.38 S 19
6612.10 0.032 s 0.032 s 6 R 3
6614.10 0.016 s 0.094 s 0.19 S 17
6614.30 0.016 s 0.094 s 4 R 6
6901.20 0.094 s 0.125 s >32 R 19
7008.20 0.016 s 0.094 s 0.19 S 19
7201.20 0.016 s 0.094 s 0.125 S 6
7201.40 0.016 s 0.094 s >32 R NR
7712.20 0.38 I 0.19 s 1 I 6
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7901.20 0.25 I 0.064 S 0.75 I NR
7905.10 0.023 S 0.094 S 0.19 S 19
7908.10 0.094 S 0.094 s >32 R 19
7908.20 0.125 I 0.125 s >32 R 3
7910.10 0.016 s 0.094 s 1 I 19
7911.20 0.064 s 0.125 s 0.75 I 19
7916.10 0.016 s 0.125 s 1 I 19
7916.20 0.016 s 0.125 s 1.5 I 19
8007.10 0.19 I 0.047 s 1 I 9
8010.20 0.016 s 0.094 s 0.19 S 4
8102.30 0.19 I 0.094 s 0.38 S NR
8109.20 0.016 s 0.094 s 12 R 23
8210.20 0.125 I 0.125 s >32 R 23
8215.30 0.016 s 0.125 s 0.125 S NR
8222.20 0.5 I 0.094 s 1 I 3 OR 9
8304.20 0.25 I 0.094 s 0.75 1 19
8509.20 0.094 s 0.125 s 0.38 s 6
8603.20 0.016 s 0.094 s 0.19 s D
8715.10 0.016 s 0.094 s 8 R 11
8810.10 0.25 I 0.094 s 0.75 I 3
8903.20 0.032 s 0.094 s 0.19 S 6
8909.10 0.016 s 0.125 s 0.25 S 6
9007.10 0.016 s 0.094 s 0.25 S 18
9008.10 0.016 s 0.094 s > 32 R NR
0403.1 0.25 1 0.094 s 0.75 1 9
0404.2 0.016 s 0.064 s 0.19 s NR
0406.4 0.016 s 0.125 s 0.25 s 19
0407.3 0.047 s 0.094 s 2 I 6
0502.3 0.016 s 0.125 s 0.38 s 6
0505.2 0.016 s 0.047 s 8 R 11
0508.2 0.047 s 0.094 s 0.125 S 23
0509.1 0.125 I 0.094 s >32 R 19
0509.3 0.5 I 0.094 s 24 R 19
0604.2 0.016 s 0.125 s 0.25 S 9
0606.2 0.047 s 0.094 s 0.38 S 9
0708.3 0.016 s 0.125 s 0.5 S 6
0710.1 0.047 s 0.064 s 0.125 S 9
0901.1 0.016 s 0.094 s 0.19 S 19
0905.2 0.23 I 0.094 s 3 I 9
0907.1 0.032 s 0.064 s 0.19 s NR
0909.1 0.012 s 0.125 s 0.19 s 18
1108.3a 0.023 s 0.19 s 16 R 23
1108.3b 0.016 s 0.064 s 0.19 S 3
2604.1a 0.19 I 0.094 s 0.5 S 19
2604.1b 0.023 s 0.094 s 0.25 S 3
2604.2a 0.023 s 0.094 s 0.19 S 19
2604.2b 0.032 s 0.094 s 0.125 S 3
4915.1b 0.016 s 0.064 s 0.5 S 3
S 123 S 149 S 85
I 26 I 0 I 25
R 0 R 0 R 39
Total 149 149 149
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6 month
0101.1
Pen
0.016 S
Ery
0.125 S
Co-tri
0.25 S
Serotype
NR
0104.1 0.38 I 0.19 S 1 I 18
0106.1 0.016 S 0.064 S 0.25 S 4
0107.2 0.016 S 0.094 S 0.19 s 9
0112.1 0.19 1 0.064 S 0.094 s 4
0207.1a 0.125 I 0.047 s 0.19 s 15
0207.1b 0.016 s 0.064 s 0.25 s 15
0210.1 0.016 s 0.094 s 6 R 23
0210.2 0.016 s 0.125 s 16 R 23
0210.3 0.19 I 0.125 s 24 R NR
0301.1 0.016 s 0.19 s 16 R 23
0302.2 0.016 s 0.094 s >32 R NR
0305.2 0.016 s 0.125 s >32 R 23
0307.1 0.023 s 0.064 s 0.25 S 3
0309.1 0.016 s 0.094 s 0.25 S 18
0705.3 0.016 s 0.125 s 0.5 I 6
0708.1 0.016 s 0.094 s 0.19 S NR
0801.1a 0.047 s 0.064 s 0.25 s 15
0801.1b 0.016 s 0.094 s 0.75 I 19
0805.2 0.016 s 0.125 s 16 R NR
0806.1 0.016 s 0.125 s 0.25 S 23
0908.1 0.125 I 0.125 s 0.19 s All
0912.1 0.19 I 0.064 s 0.19 s 3
1003.2 0.016 s 0.064 s 4 R 11
1103.1 0.016 s 0.094 s 0.5 I 20
1103.2 0.016 s 0.064 s 0.5 I 6
1209.2 0.016 s 0.032 s 0.25 S 6
1305.1 0.016 s 0.064 s 6 R 23
1311.1 0.032 s 0.047 s 0.125 S 15
1402.1 0.032 s 0.064 s 0.125 S 19
1603.1 0.023 s 0.064 s 0.25 S 6
1603.2 0.016 s 0.064 s 3 1 11
1606.1 0.094 s 0.094 s 6 R 18
1803.2 0.019 s 0.032 s 32 R 7
1810.1 0.032 s 0.047 s 0.19 S 12
1811.1 0.016 s 0.094 s 0.19 s NR
1811.2 0.016 s 0.125 s 0.75 I All
1906.1 0.016 s 0.064 s >32 R NR
1907.2 0.016 s 0.064 s 0.125 S 9
2401.2 0.016 s 0.094 s 1.5 I 3
2604.1 0.016 s 0.094 s 0.125 S NR
2702.1 0.016 s 0.064 s 0.25 S 19
2902.1 0.125 I 0.064 s 0.75 I 19
2905.1 0.016 s 0.094 s 0.19 s NR
2905.2 0.023 s 0.064 s 0.25 s NR
2908.3 0.016 s 0.064 s 0.25 s 6
3111.1 0.016 s 0.064 s 0.25 s 15
3208.1 0.023 s 0.064 s 0.25 s 18
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3207.1 0.016 S 0.047 S 0.19 S 6
3213.2 0.19 I 0.047 S 0.5 I 3
3213.4 0.25 I 0.064 S 0.5 1 3
3302.1 0.016 S 0.094 s 0.19 s all
3313.1 0.016 S 0.047 s 0.125 s 9
3407.1 0.023 s 0.094 s 0.19 s 12
3603.1 0.094 s 4 R 8 R 7
4209.1 0.016 s 0.023 S 0.19 S 6
4212.3a 0.047 s 0.094 s 1.5 I 9
4212.3b 0.016 s 0.094 s 0.25 S 6
4500.2 0.016 s 0.047 s 3 I 23
4510.2 0.016 s 0.094 s 6 R 23
4603.1 0.023 s 0.125 s 6 R 23
4705.2 0.023 s 0.094 s 0.19 S 19
4801.2 0.064 s 0.047 s 0.25 S 23
4913.1 0.016 s 0.064 s 0.38 S 19
4916.1 0.016 s 0.064 s 0.25 S 19
5003.1 0.012 s 0.094 s 0.19 s 3
5205.1 0.016 s 0.094 s 0.75 I G
5512.3 0.016 s 0.125 s 6 R 23
5704.2 0.19 I 0.125 s 8 R 19
5709.2 0.016 s 0.125 s 6 R 18
5807.1 0.016 s 0.023 s 0.19 S 15
6001.1 0.023 s 0.047 s 0.125 S 18
6006.1 0.016 s 0.047 s 0.19 S 4
6010.1 0.016 s 0.19 s 0.75 I 5
6604.1 0.023 s 0.064 s 32 R 11
6608.1 0.064 s 0.19 s >32 R 4
7502.2 0.38 I 0.064 s 6 R 19
7905.2 0.016 s 0.125 s 0.25 S NR
7906.1 0.016 s 0.125 s 0.5 I NR
7908.1 0.016 s 0.047 s 0.19 S 11
8009.1 0.016 s 0.125 s 0.25 s 18
8015.3 0.016 s 0.125 s 0.25 s NR
8103.2 0.19 I 0.19 s 8 R 12
8602.2 0.38 I 0.125 s 1.5 I 9
8603.1 0.016 s 0.19 s 0.38 s 18
0806.1 0.047 s 0.094 s 0.25 s NR
8610.1 0.016 s 0.023 s 0.25 s NR
8603.2 0.38 I 0.016 s 0.75 I NR
8715.1 0.016 s 0.023 s 0.75 I 3
8715.2 0.016 s 0.023 s 1 I 9
8802.2a 0.25 1 8 R 16 R 23
8802.2b 0.023 s 0.125 s 0.25 S 15
S 77 S 90 S 49
I 15 I 0 I 20
R 0 R 2 R 23
Total 92 92 92
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